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ABSTRACT 
 
In this work, an attempt was made to study the hepatoprotective effects of ethanol 
extracts of Curcuma xanthorrhiza and Ipomoea aquatica which are traditionally used 
for liver complications.  
The preliminary work involved an in vitro screening of free radical scavenging of both 
plants together with silymarin as an agent known to have prevention effect on cirrhosis. 
In order to study the hepatoprotective and possible mechanism of actions, thioacetamide 
was used to induce liver cirrhosis in rat model. For each plant extract experiment, 5 
groups of rats were assigned as normal control, cirrhotic control, silymarin control, low 
dose and high dose plant extract. After two months of the experiment, the animals were 
sacrified and blood and tissues samples were collected for biochemical and histological 
studies. The parameters included serum liver biomarkers, ALP, AST, ALT, total 
protein, albumin and bilirubin; liver tissue histological examination; liver tissue 
Masson’s trichome staining and  immunohistochemical staining of α-SMA; liver tissue 
antioxidant, CAT, SOD; liver tissue lipid peroxidation maker, MDA; serum 
proinflammatory and profibrotic cytokines TNF-α, TG-Fβ1; liver tissue NF-κB. Then, 
both plant extracts were subjected to fractionation using column chromatography and 
the obtained fractions were screened for hepatoprotective in thioacetamide-induced 
hepatotoxicity normal liver cell line (WRL-68). From each plant extract, the fraction 
which was most effective in WRL-68 was subjected to LCMS to identify the available 
compounds. From the LCMS results of the fractions which exhibited best 
hepatoprotective results, violaxanthin from Ipomoea aquatica and xanthorrhizol from 
Curcuma xanthorrhiza were selected for further study. The selection of these 
compounds was based on the available information from the previous studies which 
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could be used to infer that these compounds may be the main contributor in the 
hepatoprotective activity of the fraction and plant extract as whole.  
The results demonstrated that ethanol crude extracts of Curcuma xanthorrhiza and 
Ipomoea aquatica possess hepatoprotective activities in vivo against thioacetamide-
induced liver cirrhosis which was proven in biochemical and histopathological findings. 
In the in vitro screening, Curcuma xanthorrhiza showed higher free radical scavenging 
than silymarin, however, the free radical scavenging of Ipomoea aquatica was less than 
silymarin. Nevertheless, both plant extracts significantly increased antioxidant enzymes 
and reducing lipid peroxidation, which suggest that both plants exhibit hepatoprotective 
activity, at least in part, by improving endogenous antioxidant status. In addition to that, 
both extracts exhibited antinflammatory properties to which might have inhibited 
fibrosis progression through the down regulation of proinflammatory and profibrotic 
cytokines which lead to the decrease in HSC activation and therefore decreased ECM 
deposition. This was proven by liver tissue α-SMA and Masson’s trichome staining. 
The hepatoprotective activities of both plant crude extracts were confirmed in vitro 
against thioacetamide induced cell damage in WRL-68. Furthermore, separated fraction 
5 from Curcuma xanthorrhiza and fraction 11 from Ipomoea aquatica exhibited the 
highest hepatoprotective activities against thioacetamide induced cell damage in WRL-
68. Similar to the animal study, both crude extracts, their fractions and selected 
compounds improved antioxidant enzymes and inhibited lipid peroxidation. The 
selected compounds were more effective than their crude extracts in protecting cell 
damage and improving antioxidant status. In fact, violaxanthin was more effective than 
silymarin.  
These results suggest that both plant extracts are hepatoprotective and the possible 
mechanism of action is likely to be through improving endogenous antioxidant status, 
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decreasing proinflammatory and profibrotic cytokines, to which xanthorrhizol and 
violaxanthin may be the main contributors.   
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ABSTRAK 
 
Dalam ujikaji ini, percubaan telah dibuat untuk mengkaji kesan hepatoprotektif bagi 
ekstrak etanol temu lawak dan kangkung yang secara tradisinya digunakan untuk 
komplikasi hati. Kerja-kerja awal yang terlibat dalam ujian in vitro menunjukan kadar 
pemerangakapan radikal bebas bagi kedua-dua tumbuhan ini bersama-sama dengan 
silymarin sebagai agen, telah diketahui mempunyai kesan pencegahan pada sirosis. 
Dalam usaha untuk mengkaji mekanisme hepatoprotektif dan tindakbalas mungkin, 
thioacetamide telah digunakan untuk mendorong sirosis hati dalam model tikus. Bagi 
setiap eksperimen ekstrak tumbuhan, 5 kumpulan tikus telah diketogorikan sebagai 
kawalan normal, kawalan cirrhotic, kawalan silymarin, ujian dos rendah dan ujian dos 
tinggi extrak tumbuhan. Selepas dua bulan eksperimen, haiwan tersebut dibunuh dan 
sampel darah dan tisu dikumpul untuk kajian. Parameter termasuk biomarkers hati 
serum, ALP, AST, ALT, jumlah protein, albumin dan bilirubin; pemeriksaan histologi 
tisu hati; pewarnanan Masson trichome tisu hati itu dan pewarnaan 
immunohistochemical terhadap SMA α-; antioksidan tisu hati, CAT, SOD; agen 
peroksidaan pembuat lipid tisu hati, MDA; serum proinflamasi dan sitokin profibrotik 
TNF-α, TG-Fβ1; tisu hati NF-κB. Kemudian, kedua-dua ekstrak tumbuhan telah 
mejalani langkah farksinasi dengan menggunakan kromatografi turus dan fraksi-fraksi 
yang diperoleh telah manjalani ujian hepatoprotective dengan thioacetamid-penyebab 
hepatoksisiti bagi sel hati normal (WRL-68). Bagi setiap ekstrak tumbuhan, fraksi yang 
paling berkesan terhadap sel WRL-68 akan menjalani ujian LCMS untuk mengenal 
pasti sebatian yang tersedia. Daripada keputusan LCMS fracksi-fraksi yang mempunyai 
aktiviti hepatoprotektif berpunca kehadiran sebatian dikenali violaxanthin dari 
kangkung dan xanthorizol dari temu lawak, yang seterusnya telah dipilih untuk kajian 
lanjut. Pemilihan sebatian ini adalah berdasarkan maklumat yang didapati daripada 
kajian sebelumnya yang boleh digunakan untuk membuat kesimpulan bahawa sebatian 
vi 
 
ini mungkin menjadi penyumbang utama dalam aktiviti hepatoprotif bagi fraksi-fraksi 
dan ekstrak tumbuhan secara keseluruhan. Keputusan bagi ekstrak etanol mentah 
temulawak dan kangkung menunjukan ianya mempunyai aktiviti hepatoprotektif dalam 
ujian in vivo terhadap thioacetamide penyebab sirosis hati yang telah dibuktikan dalam 
penemuan biokimia dan histopathologi. Di dalam ujian in-vitro, temu lawak 
menunjukkan kadar pemerangkapan radikal bebas yang lebih berbanding silymarin. 
Walaubagaimanapun, kadar pemerangkapan radikal bebas oleh kangkung adalah kurang 
daripada silymarin. Kedua-dua ekstrak menunjukan  peningkatan enzim antioksidan dan 
pada masa yang sama mengurangkan peroksidaan lipid, yang mencadangkan bahawa 
kedua-dua tumbuhan mempamerkan aktiviti hepatoprotetif, dengan meningkatkan tahap 
antioksidan endogen. Di samping itu, kedua-dua ekstrak menujukan sifat antinflammasi 
yang mungkin telah menghalang perkembangan  fibrisis melalui down-regulation 
proinflamasi dan profibrotik sitokin yang membawa kepada penurunan kadar 
pengaktifan HSC dan seterusnya menurun pemendapan ECM. Ini telah dibuktikan oleh 
keadaan tisu hati α-SMA oleh pewarnaan Masson trichome. Aktiviti hepatoprotetif bagi 
kedua-dua ekstrak mentah tumbuhan telah disahkan dalam  ujian in-vitro terhadap 
kerosakan sel thioacetamide teraruh dalam WRL-68. Tambahan pula,  fraksi 5 daripada 
temu lawak dan fraksi 11 dari kangkung mempamerkan aktiviti hepatoprotektif tertinggi 
terhadap kerosakan sel thioacetamide teraruh dalam WRL-68. Serupa dengan kajian 
haiwan, kedua-dua ekstrak mentah, pecahan fraksi dan sebatian terpilih boleh 
meningkatkan enzim antioksidan dan menghalang peroksidaan lipid. Sebatian tulen 
yang dipilih adalah lebih berkesan daripada ekstrak mentah tumbuhan dalam 
memainkan peranan  untuk melindungi daripada kerosakan sel dan meningkatkan tahap 
antioksidan. Malah, violaxanthin adalah lebih berkesan daripada silymarin. 
Kesimpulannya, bahawa kedua-dua ekstrak tumbuhan ini mempunyai kesan 
hepatoprotektif dan faktor kemungkinan mekanisma tindakabalas adalah mungkin 
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melalui penigkatan tahap antioksidan endogen, pengurangan proinflamasi dan 
profibrotik sitokin, dimana xanthorrhizol dan violaxanthin adalah penyumbang utama. 
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CHAPTER I 
INTRODUCTION 
1.1 Introduction  
Liver is the largest organ in the human body that performs various interrelated 
functions. In an adult of 70 kg, liver weighs approximately 1.7 kg (Arias, et al., 1988) 
Liver located at the right side of the abdominal cavity just below the diaphragm and 
divided into two unequal lobes by the falciform ligament. These lobes made up of 
numerous lobules that include plates of liver parenchymal cells (hepatocytes), hepatic 
venules, branches of hepatic artery and sinusoids (Cunningham & Van Horn, 2003). 
Apart from parenchymal cells and hepatocytes, liver also include stellate cells, 
endothelial cells, kupffer cells and bile duct epithelial cells. Hepatocytes get the blood 
containing absorbed, digested or secreted substances by the gastrointestinal tract, 
pancreas, and spleen from the portal vein. Oxygenated blood, on the other hand, 
delivered through the hepatic artery (Cunningham & Van Horn, 2003). Liver is the 
essential prerequisite of the human body without the normal function of which one 
might not survive. Liver carryout several critical functions such as:  
 Metabolism of proteins, carbohydrate and lipids.  
 Production of clotting factors.  
 Storage of vitamins (vitamin A, D and B12) and iron and glycogen.   
 Secretion of bile (Heidelbaugh & Bruderly, 2006).  
Liver also protects the body against the foreign substances by detoxifying, neutralizing 
and eliminating the drugs and other xenobiotics (Samuel, et al., 2012).   
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Since liver is the critical organ of the body for maintaining overall health and 
detoxification, disorders to this organ remain one of the serious health problems 
(Samuel, et al., 2012). The main causes of the liver diseases in the developed countries 
include viral-induced and excessive alcohol consumption. Whereas the primary causes 
in the developing countries are  hepatitis B and C viruses, parasitic disease, 
environmental toxins, and hepatotoxic drugs (chemotherapeutic agents, certain 
antibiotics, high doses of paracetamol, carbon tetrachloride (CCl4) and thioacetamide 
(TAA) (Schuppan & Afdhal, 2008). In the Western countries liver cirrhosis is the ninth 
leading cause of death (Kim, et al., 2002). 
Liver cirrhosis regarded as the ending stage of chronic liver disease in which chronic 
inflammation of liver results in a substantial accumulation of scar tissue in the liver. 
Regardless of the cause of liver diseases, most of the chronic liver diseases carry the 
potentiality to develop to this stage, and it tends to be stable or unstable, with varied 
presentations (Al-Attar, 2011). Progression to cirrhosis results in the liver structural and 
functional alteration as a results that normal tissue replaced with scar tissue, obstructing 
the flow of blood all through the organ and thus accumulation of toxins within the body. 
Accumulation of harmful toxins can initiate various other complications, making it a 
critical stage of chronic liver diseases which can results in liver failure accompanied 
with an impaired metabolic function, bleeding tendency, hepatic encephalopathy, portal 
hypertension and hepatocarcinoma. Chronic liver damage initiates specific cellular 
response, which regulated by a number of cytokines leading to increased deposition of 
extracellular matrix proteins (Li & Friedman, 1999). Imbalance between formation and 
degradation of extracellular matrix proteins result in alteration of the liver architecture 
of the liver which brings about serious pathological and physiological effects. Cirrhosis, 
histologically, known as a widespread hepatic process characterized by the 
transformation of normal liver structural design into abnormal fibrosis and nodules. 
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Several research studies have revealed that oxidative stress play a primary role in the 
etiopathogenesis of fibrosis, an important component of cirrhosis in chronic liver 
diseases (Poli, 2000; Shimizu, et al., 1999). Reactive oxygen species (ROS) have a 
primary role in the initiating as well as in the progression of disease of the liver. In 
response to toxic injury, increased production of ROS results in cellular membranes 
lipid peroxidation, and DNA and protein oxidation, which causes cellular injury 
(Bremer, et al., 1994; Loguercio & Federico, 2003). Lipid peroxidation, which means 
the oxidative degradation of lipids, is a multifarious and natural destructive process 
(Tribble, et al., 1987). The biological systems incorporate protective arrangements that 
protect them from the harmful effects of ROS. This includes superoxide dismutase 
(SOD) and catalase (CAT) (Zhao, et al., 2011). However, enhanced lipid peroxidation 
leads into tissue injury and failure of the antioxidant defence mechanisms to prevent the 
formation of excess free radicals. These ROS mainly generated from the mitochondria 
of hepatocytes, the activated Kupffer cells (macrophages), and also the infiltrating 
neutrophils (Bremer, et al., 1994; Loguercio & Federico, 2003). They exaggerate the 
condition by initiation of the activation of nuclear factor-kappa B (NF-κB) and thus the 
activation of inflammatory cytokines, adhesion molecules and chemokines  which 
further promote the  production of ROS (Bremer, et al., 1994; Loguercio & Federico, 
2003). Inflammation  lead to the release of the cytokine transforming growth factor β 
(TGFβ) which stimulate extracellular matrix (ECM) production by activation of 
quiescent hepatic stellate cells (HSCs) (Bataller & Brenner, 2005b; Friedman, 2008). 
During the fibrogenic process, HSCs along with inflammatory cells release and also 
respond to TGFβ  (Gressner, et al., 2002). TGFβ steadily upregulates the synthesis and 
accumulation of the primary ECM (Arthur, 2000; Gressner, et al., 2002). 
Although liver cirrhosis is a global health issue and one of the most frequent occurring 
diseases with high mortality and high morbidity, currently, the medicinal management 
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is inadequate and often have side effects (Rao, et al., 2006). Moreover, most of the 
available therapies tackle the symptoms and not preventing the progression of fibrosis 
process, which eventually develop into cirrhosis (Franklin, 1995). On account of the 
absence of effective therapy, a great number of scientific studies searching for 
hepatoprotective constituents from natural sources continued to be conducted (Adnyana, 
et al., 2001; Huang, et al., 2010).  
The application of medicinal plants for the treatment of different disorders extended 
ancient civilizations (Wadud, et al., 2007). The usage of traditional medicinal plants in 
treating various disorders is in practice even when modern healthcare are readily 
available. According to the World Health Organization (WHO) estimation, in the 
developing countries about 80% of individuals in general use traditional medicine 
(Rahim & Khan, 2006). In developing countries, in which communicable diseases are 
endemic, and hygiene and healthcare services are insufficient, medicinal plant used as 
antibacterial, antiviral, antioxidant, ant inflammatory, antiulcer, antidiabetic and 
anticancer. In view of serious side effects as a results of synthetic agents and absence 
effective therapy in the modern medicine, a good number of medicinal plants 
increasingly used to treat liver disorders (Dhiman, et al., 2012). These recommended 
medicinal plants for the treatment of liver disorder have been in use for long time and 
claimed to produce significant results (Sanmugapriya & Venkataraman, 2006). Some of 
those which have scientifically studied for various liver disorders have exhibited 
promising results. For example, for the treatment of chronic viral hepatitis glycyrrhizin 
exhibited promising results whereas Silymarin demonstrated potential in the prevention 
of cirrhosis (Stickel & Schuppan, 2007). Silymarin, which derived from Silybum 
marianum, is a well known hepatoprotective agent. It exhibits considerable protection in 
laboratory animal models of different liver cirrhosis inducer agents, including 
thioacetamide (TAA).    
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Several chemicals such as chloroform, iodoform, carbon tetrachloride and 
acetaminophen has been used to induce liver cirrhosis in experimental animals (Weber, 
et al., 2003; Weiler-Normann, et al., 2007). However, TAA has an advantage over other 
liver damage chemicals. It induces  hepatic fibrosis resembling the human hepatic 
fibrosis (Wong, et al., 2012). Hence, TAA widely employed to induce liver cirrhosis in 
the experimental animals. 
From prospective reliable drug viewpoint, it is obviously beneficial to conduct studies 
in medicinal plants using laboratory model systems searching for safe and reliable liver-
protective therapy. Hepatoprotective studies, particularly, of the medicinal plants 
possess antioxidants and antinflammatory properties may lead to a discovery of new 
drug, which can prevent or even treat the cirrhosis by blocking the progression of 
fibrosis process. In this study, an attempt was made to scientifically study the 
hepatoprotective effects of Curcuma xanthorrhiza and Ipomoea aquatic in 
thioacetamide-induced liver cirrhosis in rats.  
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1.2 Objectives  
1.2.1 General  
To evaluate hepatoprotective and antioxidant activities of Curcuma xanthorrhiza and 
Ipomoea aquatica then identify their possible mechanisms of action and active 
constituents. 
1.2.2 Specific  
1)  To prepare ethanol extracts of Curcuma xanthorrhiza and Ipomoea aquatica, and 
conduct acute toxicity study for both extracts. 
2) To evaluate hepatoprotective activities of Curcuma xanthorrhiza and Ipomoea 
aquatica ethanol crude extracts against thioacetamide-induced liver cirrhosis in rats (in 
vivo).  
3) To evaluate the antioxidant activities of the ethanol crude extracts of the two plants 
(in vitro) and in rats liver homogenate samples (in vivo).  
4) To fractionate both crude extracts and screen the fractions for hepatoprotective 
against thioacetamide-induced WRL-68 normal liver cell line (in vitro).  
5) To identify the possible mechanism of action of both two plants  
 6) To identify the active constituents of the plant extracts proven to have 
hepatoprotective activities.  
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CHAPTER II 
LITERATURE REVIEW 
2.1 Liver 
Liver is the largest glandular organ in human body which performs various interrelated 
functions. It is on the right hand side of the abdominal cavity, just below the diaphragm 
and covered by visceral peritoneum as well as dense irregular connective tissue layer. It 
is reddish brown in color and weighs around 1.7 kg in an adult of around 70 kg (Arias, 
et al., 1988). Liver is divided into four lobes, right, left, caudate and quadrate. The large 
right lobe and a small left lobe are separated by the falciform ligament and located 
superiorly. The unique nature of liver is the ability of regenerating its own tissue within 
few weeks to its original size (Highleyman & Franciscus, 2012).  
Each liver lobe is made up of numerous lobules which is about the size of sesame and 
contains plates of liver cells or also known as hepatocytes which are organized in 
irregular, branching, connected plates around the central vein. The large space in the 
liver lobule through which the liver receives the blood is known as sinusoid. The small 
space between the sinusoids and the hepatocytes are known as space of Disse. These 
sinusoids are partly present along with stellate endothelial cells also known as Kupffer’s 
cells. Bile is partially a digestive secretion and partially an excretory product of 
hepatocytes present in liver. The bile secreted by liver cells passes through the bile 
capillaries to the small bile ducts which are merged together to form left and right 
hepatic ducts (Cunningham & Van Horn, 2003). 
Hepatocytes or the liver cells occupy around 78% of the tissue volume and non-
hepatocytes such as stellate cells, endothelial cells and kupffer cells accounts for 6.3% 
of the total tissue volume (Gumucio, et al., 1996). Hepatocytes arranged in plates of 
single cell thick are responsible for most of liver’s synthetic and metabolic activities. 
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Since both surface areas of hepatocyte are exposed to the blood flowing towards the 
hepatic vein within the space of Disse, they extract the toxins and nutrients. Kupffer’s 
cells are macrophages that phagocytes bacteria, worm, worn out red as well as white 
blood cells and toxic substances. It also breakdown heme into bilirubin which is the 
principle bile pigments. Hepatic stellate cells (HSC) are found in space of Disse and 
during the liver injury they transform into cells that produce collagen leading to liver 
fibrosis (Cunningham & Van Horn, 2003).  
The total blood flow to the liver is around 1300 mL per minute. Hepatic artery and 
portal vein supply the oxygenated and deoxygenated blood into to the liver sinusoids, 
respectively. Portal vein supply the blood containing enterally absorbed digested or 
secreted substances by gastrointestinal tract, pancreas, and spleen to the liver. Whereas 
hepatic arteries supply oxygenated blood to the liver (Cunningham & Van Horn, 2003). 
2.1.1 Functions of liver 
Liver is an essential and a vital organ of human body, which carryout around 500 bodily 
essential functions required for the survival of human. It plays a key role in the 
metabolic process of carbohydrates, proteins and lipids, digestion, secretion of bile and 
also in the body’s immune defense. It synthesizes blood proteins, stores body nutrients, 
and generates energy remove toxins from the blood.  
2.1.1.1 Metabolism of carbohydrate, proteins and lipids  
Liver carries out several metabolic functions to generate the energy required by the 
body and regulates the production, storage as well as release of carbohydrates, proteins 
and fats. In case of carbohydrates, the consumed carbohydrates are partly converted into 
energy by liver and partly converted into glycogen and stored. During fasting or stress 
liver converts glycogen to energy by the process known as glycogenolysis or 
gluconeogenesis. Liver is responsible for the oxidative deamination and transamination 
in order to generate substrates for both amino acid synthesis and carbohydrate 
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metabolism. Through the urea cycle liver excretes the nitrogen in the form of urea. 
Liver synthesizes around 80% of the cholesterol in the body from acetyl-CoA and 
remove it from circulation. Liver also helps in synthesis, storage and export of 
triglycerides. Liver also converts excess of amino acids from the digested food into fatty 
acids which is later converted to ketones to generate energy by liver (Highleyman & 
Franciscus, 2012).  
2.1.1.2 Secretion of bile juice 
Bile is a reddish yellow or brownish liquid secreted (800-1000 mL/day) by liver cells 
everyday and bilirubin is the principle pigment present in bile. Bile behaves like a 
detergent to emulsify and breakdown of lipid globules into suspension of droplets 
followed by their digestion and absorption. Liver removes bilirubin, cholesterol, toxins 
and other wastes through the bile (Heidelbaugh & Bruderly, 2006). 
2.1.1.3 Synthesis and storage  
Liver synthesize and store several binding proteins which bind and transport vitamins, 
minerals, hormones and fats. Several clotting factors such as fibrinogen, prothrombin 
and other clotting factors such as VII and VII were also synthesized and stored in liver. 
Liver also stores various nutrients such as vitamin A, D, B9 and B12 (Highleyman & 
Franciscus, 2012).  
2.1.1.4 Detoxification and removal of toxic substances 
Liver plays a vital role in the detoxification of pleasant substances such as alcohol, 
organic solvents, pesticides, heavy metals and more importantly various consumed 
drugs. These substances were delivered to the sinusoids and then area of Disse of liver 
through the portal vein where in the enzymes present in hepatocytes (cytochrome P-450 
enzymes) metabolize them and excreted in the bile. Liver is responsible for the 
destruction and removal of worn out erythrocytes. Moreover, liver also process and 
10 
 
excretes the toxic byproduct such as ammonia and some excess sex hormones (Saleem, 
et al., 2010).  
2.1.2 Liver diseases 
Since the liver is the important organ of our body, for maintaining overall health and 
detoxification, any disorder to this organ remain one of the serious health issues 
(Samuel, et al., 2012). Around hundred liver diseases are developed due to liver 
damage, and it is extremely difficult to early warning symptoms of liver disorders. If it 
is not treated in the early stages it will leads to liver fibrosis, cirrhosis and finally liver 
damage and death (Ao, et al., 2009).  Liver diseases such as hepatocellular carcinoma, 
viral hepatitis, alcoholic and non-alcoholic steatosis are the most common liver 
associated and prevalent diseases in the world that are all closely associated with 
jaundice (Akanitapichat, et al., 2010). Also, liver cirrhosis is the ninth top rated cause of 
mortality in Western countries (Kim, et al., 2002). 
2.1.2.1 Viral hepatitis  
Hepatitis refers to the inflammation of the liver. Viral hepatitis is caused by the virus 
which are known as hepatitis A, B. C, D and E. consumption of food and fluids 
contaminated with hepatitis A and E virus causes hepatitis A and E, but it is not life 
threatening (Sembulingam & Sembulingam, 2004). However, hepatitis B, C and D are 
serious diseases, which may lead to cirrhosis and liver cancer (Kobayashi, et al., 2002; 
Loguercio & Federico, 2003). These are caused by blood transfusion from infected 
donors, sharing infected person needles, inheritance from mother during parturition and 
also unprotected sexual activity with an infected individual.  During the early stage of 
viral hepatitis, liver have the ability to tolerate and resists damage caused to liver cells 
by regenerating liver cells and hence compensates the liver damage caused by a virus. 
This phase is called as compensated liver disease during which liver is still able to 
continue all functions normally. However, as the time elapse liver lose its ability to 
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regenerate liver tissues and hence its normal functions are altered and this phase is 
called as decompensated liver disease (Chen, et al., 2006).  
2.1.2.2 Jaundice   
Jaundice is represented by the yellow pigmentation of the skin, mucous membrane as 
well as deeper tissues due to the increased amount of bilirubin in the blood circulation. 
Jaundice are of hemolytic jaundice caused due to the destruction of red blood cells, 
hepatocellular jaundice caused due to the damage of liver cells and obstructive jaundice 
caused due to the obstruction of bile flow from biliary system (Chen, et al., 1994; 
Sembulingam & Sembulingam, 2004).  
2.1.2.3 Alcoholic liver diseases 
Alcoholic liver diseases include alcoholic fatty liver, alcoholic hepatitis and alcoholic 
cirrhosis which may occur alone or together in the same patient. Chronic consuming 
alcohol results in the development of scar tissue in the lobules of liver followed by 
cirrhosis and finally leads to the development of alcoholic liver diseases (Cunningham 
& Van Horn, 2003; Ishak, et al., 2006). Fatty liver is the very common and least 
harmful alcoholic liver disease which occurs within few days of heavy consumption of 
alcohol. During this liver swells slight to large proportions due to the accumulation of in 
the cytoplasm of liver cells. Heavy consumption of alcohol also lead to acute hepatitis, 
chronic hepatitis, which may leads to cirrhosis followed by death. Alcoholic cirrhosis is 
always life threatening and characterized by the development of nodules of hepatic 
tissues followed by the growth of scar tissues, which finally ends with liver cirrhosis 
(Hoek, 1994; Ishak, et al., 2006).  
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2.1.2.4 Hemochromatosis  
It is the most common genetic disease in United States of America, characterized by the 
presence of the higher level of iron in the body. High amount of iron accumulated in the 
body enhances oxidative stress by increasing the level of free radicals in the body. 
During hemochromatosis, the excess amount of iron present in the body is absorbed by 
various organs mainly by the liver. Hemochromatosis also co-exists along with other 
liver disorders making the matters much worse in those patients (Bassett, et al., 1986; 
Cogswell, et al., 1998). 
2.1.2.5 Hepatocellular carcinoma 
Hepatocellular carcinoma is the most common liver malignant caner in the world (90% 
of all tumors). Viral hepatitis often leads to cirrhosis which further ends with liver 
cancer. Liver cancers can be detected by combinations of serologic tests, imaging 
studies and biopsies. If liver tumors are formed it can be removed by surgery as the liver 
has the ability regenerate itself to its full size but it is not possible in patients with liver 
cirrhosis. In these patients liver transplantation is conducted (Beasley, 1988; Chen, et 
al., 2006; El-Serag, et al., 2003). 
2.2 Cirrhosis 
Liver cirrhosis regarded as the end stage of chronic liver disease in which scar tissue 
replaces the normal tissue and thus alters the liver structure and function. Regardless of 
the cause of liver damage, most chronic liver diseases progress from mild inflammation, 
to more severe inflammation, to fibrosis, and finally to cirrhosis. Hepatic fibrosis during 
which healthy liver tissue is replaced by the scar tissue is the wound healing process 
which leads to the accumulation of extracellular matrix (ECM) due to chronic liver 
injury (Schuppan, et al., 2001). Hepatic fibrosis is associated with the oxidative stress, 
chronic inflammation, increased inflammatory cytokines and transforming growth 
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factors (Brenner, 2009). Liver cirrhosis is commonly preceded by hepatitis coupled with 
fatty liver. If diagnosed and the underlying cause is eliminated at this stage, the changes 
are still completely reversible (Detlef & Nezam, 2008). Continue to form scar tissue is a 
potentially life-threatening condition as it alters the structure of the liver and 
consequently obstruct the flow of blood. As the liver continue to loss the normal liver 
tissue, the processing and handling of nutrients, drugs, hormones and toxins declines. At 
the same time, the synthesis of proteins together with other substances produced by the 
liver is reduced (Schuppan & Afdhal, 2008). Because of the fact that liver function 
declines, water might accumulate in the abdomen and legs. Reduction in proteins 
necessary for blood clotting results in easy bruising and bleeding. The detoxification 
process of drugs and toxins is also slowed down by cirrhosis which leads to the 
accumulation toxins in the blood. Jaundice develop and present itself in the later stages 
of cirrhosis as a result of the accumulation of bile pigment which is passed by the liver 
into the intestines.  Liver cirrhosis is mainly classified into three different major forms. 
The most common form is called Laennec’s cirrhosis and also known as alcohol-
induced cirrhosis. Laennec’s cirrhosis caused by chronic alcoholism together with 
malnutrition. It is the most commonly encountered form which is characterized by 
forming fibrosis predominantly around central veins as well as portal areas. 
Postnecrotic is another form of cirrhosis which is also known as micronodular cirrhosis. 
Postnecrotic cirrhosis is caused by acute viral hepatitis especially hepatitis C which 
leads to broad bands of scar tissue or as a results of drug-induced massive hepatic 
necrosis. Biliary cirrhosis is a rarer form of cirrhosis than the preceding forms. Biliary 
cirrhosis occurs as a result of scarring damage of bile ducts and lobes of the liver which 
results from chronic biliary blocking and infection (cholangitis).  
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2.2.1 Pathology 
Liver cirrhosis regarded as the ending stage of chronic liver disease in which chronic 
fibrosis leads to the accumulation of scar tissue and therefore structural and functional 
alteration. Fibrosis is a reversible wound healing process which takes place virtually in 
all chronic liver damage. Despite the fact that the wound healing response generally 
starts when hepatocyte damaged, the total response may considerably extends (Baldo, et 
al., 2008). Fibrosis, thereby, is a physiologic mechanism, which happens to be 
beneficial in the beginning, but then develops into pathological in the event that chronic 
hepatocellular injury persist (Jarnagin, et al., 1994; Meyer, et al., 2005; Minagawa, et 
al., 2004).  The damage to the hepatocytes generates a cascade of events (Holstege, et 
al., 2005; Svegliati Baroni, et al., 2003). These particular events bring in onset and 
mobilization of several inflammatory cells that launch cytokines that not only result in 
expansion of the totally response, but at the same time may bring in indirectly or even 
directly activation of HSC (Friedman, et al., 1985). Among the events that take place 
when liver is injured include alteration in cellular response and ECM deposition in the 
space of Disse and sinusoid subendothelial. These alteration results in losing sinusoidal 
endothelial fenestrae, hepatocyte microvilli and activation of Kuppfer cell which further 
activate HSC (Figure 2.1). The main source of  extracellular matrix deposition is HSC, 
regardless of whether other cell types as an example portal fibroblasts are likely 
involved  (Bataller & Brenner, 2005a).  Hepatic stellate cells  lie within the 
perisinusoidal space (or simply space of Disse) between the endothelial wall surface of 
the sinusoid and the vascular face of the hepatocytes (Geerts, 2001). The HSC’s 
generally activated by cytokines that includes tumor necrosis factor alpha (TNFα),  
tumor growth factor beta (TGFβ)  and platelet derived growth factor (PDGF) which can 
be released in response to liver damage. At the same time, other cytokines such as 
interleukin-10 (IL-10) are release and have the opposite action of HSC which 
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degradation of ECM. Once activated, HSC’s secrete cytokines which includes tumor 
growth factor beta (TGFβ1), platelet derived growth factor PDGF, endothelin (ET-1) 
and monocyte chemotactic protein 1(MCP-1). These cytokines are directly involved in 
fibrogenesis and each of the play different roles. For instances, MCP-1 involved in 
chemotaxis, PDGF and ET-1 in proliferaton of HSC whereas TGFβ1 is a growth factor 
for the connective tissue (Realdon, et al., 2004). In addition to being caused by 
increased synthesis of ECM, liver fibrosis also caused from imbalance between 
production and degradation of matrix proteins. Activated HSCs also increase release of 
tissue inhibitors of metalloproteinases (TIMPs) which prevent matrix metaloproteinases 
(MMPs) to degrade excessive matrix collagen. The process is driven by signalling 
pathways mediated by proinflammatory cytokines mainly involves including TNFα  and 
also TGFβ1 (Wang, et al., 2006). The most accumulated ECM involved in fibrosis are 
the interstitial collagens, types I, and III (Schuppan, 1990). In all different chronic liver 
disease, the progression of fibrosis is a step by step and gradually process starting from 
minimal fibrosis limited to in and within the portal tracts causing periportal stellate 
fibrous accumulates and extension (periportal or zone one fibrosis) (Marcellin, et al., 
2006). As the process gets progressively worse over time, fibrous tissues increase to the 
nearby mesenchymal arrangements with the development of fibrous septa. Then it 
progressively grows into the lobules towards the central veins (zone three) with septa 
development. Finally, when almost all of the central veins or portal tracts 
interconnected, bridge fibrosis generated, and annular fibrosis surrounding nodules of 
the liver cells, cirrhosis occur ((Z.D. Goodman & K.G. Ishak, 1995; Zachary D 
Goodman & Kamal G Ishak, 1995; Scheuer, et al., 2005).  
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Figure 2.1: Diagram shows normal and damaged liver with four major cells 
(hepatocytes, endothelial cells, Kupffer cells and stellate cells) (Adapted from  
(Moreira, 2007)). 
 
2.2.2 Etiologies of liver cirrhosis  
Normally any chronic insult or damage to the liver will leads to inflammation, fibrosis 
and cirrhosis. Etiologies of liver cirrhosis are as follows: 
Most common causes 
 Excessive consumption of alcohol (60 to 70 %) 
 Chronic hepatitis B and C (10 %) 
 Hemochromatosis (5 to 10 %) 
 Nonalcoholic fatty liver disease (10 %t) – commonly resulting from obesity 
 Biliary obstruction (5-10 percent) 
Less common causes 
 Toxins and drugs such as amiodarone, alpha methyldopa, paracetamol,. 
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 Genetic metabolic diseases such as amino acid disorder (tyrosinemia), bile acid 
disorder, lipid disorder (abetalipoproteinemia), porphyria and Wilson’s disease. 
 Infections such as brucellosis, congenital syphilis, schistosomiasis, 
echinococcosis etc. 
 Idiopathic and miscellaneous such as granulomatous liver disease and portal 
fibrosis. 
(Friedman & Schiano, 2004; Heidelbaugh & Bruderly, 2006) 
2.2.3 Symptoms of liver cirrhosis 
More or less forty percent of individuals with liver cirrhosis have no symptoms, and the 
diseases revealed during routine laboratory tests or during the course of radiographic 
studies. Hence liver cirrhosis is considered as a asymptomatic disease mostly until 
decompensation of liver take place. Following are the symptoms of liver cirrhosis:  
 Jaundice (observed in skin and/or eyes) 
 Bleeding of gastrointestinal  
 Osteoporosis  
 Oagulopathy 
 Pruritus  
 Anorexia and weight loss 
 Fatigue,  
 Increased abdominal girth 
 Changes in mental status  
 Weakness  
Each one of these clinical findings is the consequence of deteriorated hepatocellular 
function with or even without physical obstruction secondary to cirrhosis (Heidelbaugh 
& Bruderly, 2006). 
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2.2.4 Complications of cirrhosis 
The major complications of liver cirrhosis includes ascites, hepatic encephalopathy, 
portal hypertension, variceal bleeding, bacterial peritonitis and hepatorenal syndrome 
(Friedman & Schiano, 2004; Jalan & Hayes, 2000; Runyon, 2004). Ascites is referred to 
as the pathological increased accumulation of fluid in the peritoneal cavity and around 
85% patients with ascites have cirrhosis (Runyon, 2002). Hepatic encephalopathy is 
caused due to acute or chronic liver diseases, and it is characterized by slight and 
sometimes intermittent changes in memory, concentration, personality and reaction 
times (Heidelbaugh & Bruderly, 2006). Development of portal hypertension is very 
common in patients with liver cirrhosis irrespective of the etiology of cirrhosis. It 
occurs as a result of increased resistance to portal blood flow as a result of narrowing, 
scarring and compression of liver sinusoids (Heidelbaugh & Bruderly, 2006). Around 
50% of patients with liver cirrhosis develop varices and variceal bleeding and it occurs 
around 10-30 percent per year (Cales, et al., 1990). Variceal bleeding is defined as 
bleeding from an esophageal varix during the time of endoscopy or the presence of 
substantial esophageal varices with blood in the stomach (Jalan & Hayes, 2000). 
Hepatorenal syndrome is defined as functional renal failure in liver cirrhotic patients in 
the absence of intrinsic renal disease. Patients with this syndrome exhibit higher sodium 
and water retention, renal vasoconstriction leading to reduced} renal blood flow, 
glomerular filtration rate and also urinary output (Heidelbaugh & Bruderly, 2006). 
Hepatorenal syndrome occurs in patients with severe hepatic disorders, however, 
patients with biliary cirrhosis are relatively protected.  
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2.2.5 Diagnosis of liver cirrhosis  
2.2.5.1 Physical examination of liver cirrhosis 
Various physical examinations provide the useful information regarding liver cirrhosis 
and its treatment (Heidelbaugh & Bruderly, 2006) which are as follows: 
 Asterixis 
 Ascites 
 Abdominal wall vascular collaterals 
 Clubbing and hypertrophic osteoarthropathy 
 Anorexia, fatigue, weakness and weight loss 
 Jaundice 
 Palmar erythema 
 Splenomegaly 
 Hepatomegaly 
 Gynecomastia  
 Testicular atrophy 
 Spider angiomata 
 Dupuytren’s contracture 
 Terry’s nails and Muehrcke’s nails 
 Fetor hepaticus- a sweet, pungent breath odor 
 Kayser Fleischer ring-brown-green ring of copper deposition within the cornea 
 Cruveilhier-Baumgarten murmur - a venous hum in the patient developed  portal 
hypertension 
2.2.5.2 Laboratory evaluation of liver cirrhosis 
Liver function tests were conducted routinely to diagnose cirrhosis. Though these tests 
may not reflect exactly with hepatic function, interpreting these biochemical parameters 
along with physical examination studies and radiographic studies provides the clinical 
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picture of various liver disorders (Heidelbaugh & Bruderly, 2006). Liver function is 
generally assessed by static tests and dynamic tests. Common tests, which were 
included in the standard liver panels, are serum enzyme aspartate transaminase (AST), 
alanine transaminase (ALT), alkaline phosphatase (AP), gamma glutamyl transferase, 
serum bilirubin, serum albumin, complete blood count with platelets and prothrombin 
time tests  (Dufour, et al., 2000; Heidelbaugh & Bruderly, 2006). Estimation of ALT is 
the most cost effective test conduct to identify metabolic and drug induced 
hepatotoxicity nevertheless its use is confined since it is unable to predict the degree of 
inflammation and severity of fibrosis (Dufour, et al., 2000). Dynamic tests such as 
clearance of indocyanine green, bromosulfopthalein, caffeine test and aminopyrine tests 
provide hidden hepatocellular dysfunction (Paxian, et al., 2003). Dynamic tests are 
related to the ability of the liver to eliminate or metabolize particular substances (Sakka, 
2007). 
Liver enzymes  
When hepatocellular plasma membrane is damaged by hepatotoxins, various serum 
enzymes located in the cytosol are released into the blood stream these enzymes reveal 
the extent of hepatocellular necrosis (AST and ALT) or cholestasis (AP). In the animal 
experimental models the liver damage induced by carbon tetrachloride, paracetamol, 
thioacetamide and other hepatotoxicin were assessed by the determination of levels of 
liver enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) (Dobbs, et al., 2003; Xu, et al., 2002). AST is a cytosolic enzyme present mainly 
in the liver where as ALT is a mitochondrial enzyme released from heart, liver, skeletal 
muscles and kidney hence; both these enzymes are sensitive markers of hepatocellular 
damage. These two enzymes play a major role in the metabolic process of amino acid 
by catalysing reversible transfer of the alpha amino group. The elevated level of these 
liver enzymes in serum represents the hepatocellular leakage together with the losing 
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functional integrity of liver cell membrane (Zimmerman & Seeff, 1970). Estimation of 
these serum marker enzymes provide the useful information about the extent and type of 
hepatocellular damage (Mitra, et al., 1998). Normally ALT levels are high in patients 
who are suffering from viral hepatitis, alcoholic hepatitis, hepatic necrosis, cirrhosis and 
intrahepatic cholestasis. AST levels are also elevated by 10 to 200 fold in patients with 
viral hepatitis and hepatic necrosis. 
Alkaline phosphatase (AP) is one more important enzyme normally determined to 
evaluate the liver function test. It is produced by tissues like liver, bone, intestine, bile 
ducts, kidneys and placenta and excreted through the bile and responsible for the 
hydrolysis of organic phosphate esters (Sakka, 2007). Increased production of AP by 
hepatic parenchymal cell and defective hepatic excretion lead to an elevated level of 
serum alkaline phosphatase which indicates the hepatobiliary disease. Determination of 
the amount of this enzyme provides the clinical information regarding the disease 
occurring in the liver or in the bile duct (Sakka, 2007).   
 
Serum protein 
Liver possess the ability to synthesize various proteins such as albumin, fibrinogen, 
transferrin, haptoglobin and prothrombin out of this albumin is the major protein 
synthesised and secreted into the blood (Kind & King, 1954). Total protein was 
measured to diagnose and treat various diseases of liver, kidney and also other 
metabolic disorders. A significant decrease in the level of protein such as albumin can 
be caused by factors, including deterioration of liver function, sever necrosis of the liver 
and hepatic resistance to insulin (Ezzat, et al., 1989; Rao, 1995). Similarly, hepatotoxins 
also causes the reduction levels of both total protein as well as albumin. This decrease is 
caused by the injury caused to the endoplasmic reticulum of liver (Recknagel, et al., 
1989). Drugs with hepatoprotective activity generally increase the protein and also 
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albumin levels indicating the stabilisation of the endoplasmic reticulum, resulting in 
protein production (Mondal, et al., 2005).  
 
Serum bilirubin 
Measurement of total bilirubin amount in the blood stream also provides information 
related to status and function of hepatic cells. Bilirubin is a metabolic product of the 
breakdown of haemoglobin and it is conjugated by the liver and excreted in bile. 
Normally serum bilirubin level is elevated due to the over production or decreased 
conjugation or decreased uptake by the liver or due to the bile ducts blockage (Mondal, 
et al., 2005). However, if drugs under screening possess hepatoprotective activity, it 
will have a tendency to bring down serum bilirubin level in the liver damage model 
indicating the effectiveness of the drug in the normal functional status of the liver 
(Singh, et al., 2003).  
 
Liver biopsy 
Liver biopsy was considered only when serologic and radiological evaluation failed to 
confirm the diagnosis. Liver biopsy is carried out through laparoscopic, transjugular, 
percutaneous, open operative or CT guided fine needle approaches. Liver biopsy 
provides 80-100 percent of accuracy of liver cirrhosis diagnosis and this method is very 
sensitive and specific. The accuracy of this method mainly depends on the sampling 
method employed and number and size of the histology samples collected. It also helps 
in the treatment of liver diseases (Abdi, et al., 1979; Heidelbaugh & Bruderly, 2006).   
 
Indocyanine green and bromosulfophthalein clearance 
It is an infrared absorbing fluorescent agent that is completely removed by the liver into 
the bile without going through enterohepatic recirculation (P Faybik & H Hetz, 2006; P. 
Faybik & H. Hetz, 2006). Indocyanine green (ICG) clearance from the blood depends 
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on the live blood flow, parenchymal cellular function and biliary excretion. The normal 
value of ICG plasma disappearance rate (PDR) is over 18%/min and mortality related to 
liver dysfunction is higher in patients with ICG-PDR under 8%/min. Moreover, ICG 
elimination kinetics was commonly considered before setting of liver surgery (P. Faybik 
& H. Hetz, 2006; Sakka, 2007). Similarly, bromosulfophthalein (BSP) is also extracted 
and cleared by the liver. Less than 10% of BSP is retained in healthy individuals in 
comparison with patients with liver disorders (Chopra & Griffin, 1985). 
 
Caffeine test 
Caffeine physiologically metabolised by the liver to various metabolites such as 
theobromine, theophylline and parxanthine. Hepatic dysfunction was evaluated on the 
basis of metabolite/caffeine ratio. In patients with liver dysfunction elimination of 
caffeine takes longer time than the healthy volunteers (Jodynis-Liebert, et al., 2004).  
2.2.5.3 Radiographic evaluation 
Radiographic studies were conducted to detect ascites, hepatocellular carcinoma, 
hepatosplenomegaly, hepatic vein thromboses and portal vein thromboses (Heidelbaugh 
& Bruderly, 2006). Abdominal ultrasonography provides useful information regarding 
gross appearance of the liver and blood in portal and hepatic veins. The presence of 
hepatic multinodulars, irregularities and ascites are easily diagnosed by 
ultrasonography. Magnetic resonance imaging (MRI) and computed tomography (CT) 
accurately demonstrates about nodularity, lobular atrophy and hypertrophy, ascites, 
varices, hepatocellular carcinoma and hence helps in determining the severity of 
cirrhosis (Heidelbaugh & Bruderly, 2006).  
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2.2.6 Cirrhosis treatment 
Medical treatments for chronic liver diseases which include cirrhosis are in general 
problematic. In spite of the fact that liver cirrhosis is a global health issue and one of the 
most frequent occurring diseases with high mortality and high morbidity, currently, the 
medicinal management is inadequate and often have side effects (Rao, et al., 2006). In 
addition to serious side effects, for instance, corticosteroids, colchicines, penicillamine 
and interferon are associated with possibly risk of relapse. Moreover, the available 
therapies tackle the symptoms and not preventing the progression of fibrosis process, 
which eventually develop into cirrhosis  (Franklin, 1995). Some of these treatments, for 
instance, corticosteroids, colchicines, penicillamine and interferon are associated with 
possibly risk of relapse. Eventually, when the complications can no longer be managed 
by the available treatment and the liver is severely damage then liver transplant become 
the only option. Due to the reason that there is no effective and safe therapy, a great 
number of scientific studies searching for hepatoprotective constituents from natural 
sources continued to be conducted (Adnyana, et al., 2001; Huang, et al., 2010). In many 
cases the research on medicinal plant is guided from a traditional use or from 
undocumented treatment modalities.  
2.2.7 Liver cirrhosis and medicinal plants 
Medicinal plants for the treatment of different disorders extended ancient civilizations 
(Wadud, et al., 2007). The usage of traditional medicinal plants in treating various 
disorders is in practice even when modern healthcare are readily available. According to 
the World Health Organization (WHO) estimation, in the developing countries about 
80% of individuals in general use traditional medicine (Rahim & Khan, 2006). In 
developing countries in which communicable diseases are endemic, and hygiene and 
healthcare services are insufficient, medicinal plant used as antibacterial, antiviral, 
antioxidant, antinflammatory, antiulcer, antidiabetic and anticancer. In view of serious 
25 
 
side effects as a results of synthetic agents and absence effective therapy in the modern 
medicine, a good number of medicinal plants increasingly used to treat liver disorders 
(Dhiman, et al., 2012). These recommended medicinal plants for the treatment of liver 
disorder have been in use for long time and claimed to produce significant results 
(Sanmugapriya & Venkataraman, 2006). Only a few of these have been adequately 
studied. These include Silybum marianum (milk thistle), Camellia sinensis (green tea), 
Curcuma longa (turmeric), , Chelidonium majus (greater celandine), and Allium sativa 
(garlic) (Luper, 1998). In general the constituents of the medicinal plant extract posse 
anti-inflammatory, liver protective and immune stimulating activities. The plant extracts 
exhibit ability to stimulate the production of hepatocyte for the repairing of liver. There 
are evidence that plant derived antioxidant is effective against fibrosis process. 
Silymarin derived from Silybum marianum is the most effective hepatoprotective 
natural product. It has been found to have potential in the prevention of cirrhosis 
(Stickel & Schuppan, 2007) Silymarin reduce the accumulation of hepatic collagen and 
exhibits considerable protection in laboratory animal models of different liver cirrhosis 
induced agents, including thioacetamide (TAA). Medicinal plant regarded as important 
source of antioxidant to which its secondary metabolites has potent free radical 
scavengers. Silymarin as well as its constituent silibinin possess important antioxidant 
activity (Pietrangelo, et al., 1995). 
2.3 Thioacetamide induced hepatotoxicity model 
Thioacetamide (figure 2.2) was initially used to control the decay of oranges and further 
used as a fungicide (Childs & Siegler, 1945). It is a selective hepatotoxin and widely 
used to induce acute and chronic liver injury in rats and other experimental animals 
depending on the dose and duration of administration (Hung, et al., 2005; Wang, et al., 
2004). Thioacetamide induces rat liver cirrhosis with biochemical and morphological 
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observations, resemble that of human liver cirrhosis and therefore serves as a suitable 
animal model for studying human liver fibrosis and cirrhosis (Fan & Weng, 
2005).Oxidative stress and inflammation have been reported to contribute to the 
pathogenesis of TAA liver damage in animal model (Lin, et al., 2009). The appropriate 
dose of TAA to induce liver damage in experimetal animals through intraperitoneal 
route of administration is reported to be 200 mg/kg (Chen, et al., 2012). Its long-term 
administration induces hepatic fibrosis in rats, and causes the development of cirrhosis 
associated with an increased extent of lipid peroxidation (Kadir, et al., 2011). Following 
administration, TAA is metabolised by the mixed function of oxidase system to 
acetamide and TAA-S-oxide ((Ahmed, et al., 2008; Bastway Ahmed, et al., 2010). Then 
TAA-S-oxide is metabolised, at least in part, by cytochrome P-450 monoxygenases to, a 
very highly reactive compound, TAA-S-dioxide (Wang, et al., 2006). The binding of 
TAA-S-dioxide to tissue macromolecules induce hepatic necrosis and oxidative stress 
(Túnez, et al., 2005). Besides, TAA produces oxidative stress, equally by both increased 
generation of ROS and also by reduction of cellular oxidative defences system. Studies 
have also revealed that liver cells intoxicated with TAA tend to be more susceptible to 
the cytotoxic effects of TNF-α along with other cytokines. It is well established that 
mitochondria has an essential role in the apoptotic response, therefore functional 
alteration in mitochondrial following TAA treatment lead to cell death through necrosis 
or apoptosis (Hoek & Pastorino, 2002). 
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Figure 2.2 Chemical structures of thioacetamide (adapted from (Muñoz, et al., 1991)). 
2.4 In vivo and in vitro model used for hepatoprotective  
2.4.1 In vivo models  
In hepatoprotective studies, in vivo experiments are the most important applications 
employed to study liver damage and the response to the treatment. The animal model is 
prepared by chemical-inducing liver damage along with the plant extract treatment or 
after the plant treatment has started for a period of time. The liver damage animal model 
(rat or mice) produced by using toxic chemical dosage or prolonged dosage of 
hepatotoxin mimic any type natural liver damage occur in liver diseases. In 
hepatoprotective studies, the effectiveness of the plant extracts are studied against 
hepatotoxin which include thioacetamide (TAA), rifampicin, beta galactosamine, 
carbon tetrachloride (CCl4), paracetamol and alcohol. Among these, the most used 
chemicals to induce liver cirrhosis are CCl4, paracetamol and TAA, and each of them 
has different mechanism of inducing liver damage. Thioacetamide liver cirrhosis animal 
model is found to be more reliable and convenient to perform (Kreft, et al., 1999). 
Generally, the plant extract studied for its effectiveness in hepatoprotective is 
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administrated in advance or alongside the toxin, and if possess hepatoprotective activity 
it should be able to prevent or reduce the damage on the liver. The assessment of liver 
damage is carried out by means of biochemical parameters which include serum levels 
of AST, ALT, AP, LDH, GGT, total protein, albumin and bilirubin (Rahman, et al., 
2001; Schuppan, et al., 2003). In addition to that, histological parameters which include 
apparent necrosis signs and cirrhosis, and also the ration of liver size to the body weight 
confirm the biochemical findings.  
2.4.2 In vitro model  
In vitro experiments working with liver cell line may be more advantageous in terms of 
processing large number of samples, providing more reproducible results and also less 
costly as compared to the animals experiments. For the purposes of identification of 
active constituents separated from a known hepaprotective plant crude extract, a large 
number of the fractions need to be screened. Using animal model for the purpose of 
screening large number of sample may not be convenient when considering the time 
involved together with expenses. Cell lines can be applied to study cellular functions 
and provide important interactions information within it, for instance, metabolism 
(Gebhardt, 2000). The cell lines used in researches are mainly obtained from the cell 
banks that maintain the cell conditions which include American Type Culture 
Collection (ATCC). Generally, these cell lines preserve most of the features that can be 
found in the primary cell lines and are documented and identified for particular 
experimental applications. For the hepatoprotective studies, liver cell damage is induced 
by the use of hepatotoxin to which the effectiveness of the treatment (for example, plant 
extract) can be evaluated. The effectiveness of the treatment can be evaluated by means 
of parameters which include cell viability and oxidative stress (Bladier, et al., 1997; 
Huang, et al., 1999).  
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2.5 Silymarin  
Silymarin, derived from Silybum marianum (milk thistle), is a well known 
hepatoprotective agent. Silymarin comprise three flavonolignan isomers, silybin, 
silychristine and silydianin. The mixture exhibits considerable protection in laboratory 
animal models of different liver cirrhosis inducing agents.  Silybin appear to be the 
primary active constituents that deliver the effectiveness of silymarin (Kshirsagar, et al., 
2009). Silymarin continues to be used to tackle toxic liver condition and as a supporting 
therapy for persistent active hepatitis and also liver cirrhosis (Flora, et al., 1998).  
It has been reported that silymarin suppress the deposition of collagen in fibrotic-
induced animal models. Silymarin is a free radical scavenger with properties including 
antioxidant, antinflammatory and antifibrotic. It prevents the binding of the hepatotoxin 
to the hepatocyte receptor and reduction of glutathione oxidation levels in the liver. It 
enhances the generation of hepatocyte by stimulating ribosomal RNA polymerase and 
therefore synthesis of protein. Silymarin exhibits considerable protection in laboratory 
animal models of different liver cirrhosis inducing agents, including thioacetamide 
(TAA) (Dixit, et al., 2007; Ghosh, et al., 2010; Pradhan & Girish, 2006). 
2.6 Antioxidant activity  
2.6.1 Free radicals and reactive oxygen species 
Free radicals are highly unstable chemical substances that have unpaired electrons in the 
external electron orbit. They continually try to find electrons to pair with the intention 
achieve stability, hence they grab the electrons from macromolecules particularly   
DNA, proteins, carbohydrates and lipids.  The molecules from which the electron is 
stolen become free radical and therefore steal electron from another molecule and 
therefore result in an uncontrolled chain reaction which alter and damage the function 
leading various diseases (Valko, et al., 2006). The free radicals are categerised into 
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reactive nitrogen species and reactive oxygen species (ROS). The most important free 
radicals in the human body is ROS which represent any free radical associated with 
oxygen-centered free radical with two unpaired electrons in external shell. The free 
radicals may arise exogenously or endogenously. The generation of free radicals 
endogenously takes place during the generation of energy in the mitochondria, and in 
the course of nutrient metabolism. Reactive oxygen species (ROS), particularly, in the 
liver cells also produced by a group of enzymes collectively known as cytochrome P450 
mixed–function oxidases. Small amount of ROS is generated during the cytochrome 
P450 enzyme catalyzing process for the reason that oxygen is involved in reaction. The 
amount of ROS produced remarkably depending on the compound undergoing 
degradation and the cytochrome P450 molecule involved. The most known active 
cytochrome molecule in the production of ROS is called P450 2E1 (CYP2E1) (Lieber, 
1996). The exogenous source free radicals are the environmental contaminants which 
include toxic chemicals, smoking, radiation, pesticides, air pollution and organic 
solvents (Gülçİn & Küfrevİoğlu, 2001). Free radicals take part in a number of 
physiological processes and also human diseases that include arteriosclerosis, cancer, 
alcoholism and liver injury, ischaemia, Parkinson syndrome, arthritis, aging and toxin 
induced reaction (Willcox, et al., 2004). The increase in the amount of free radical 
amounts found during liver injury is caused by enhanced generation of free radicals 
together with reduced scavenging capability of the cells. 
2.6.2 Oxidative stress in liver cirrhosis 
Oxidative stress is regarded as imbalance between the increased generation of ROS and 
antioxidant (endogenous) defense system that might result in cell damage. This 
imbalance oxidation of biomolecules results in dysregulation of signal transduction and 
gene expression and thereafter cell necrotic and/or apoptotic (Dröge, 2002). In the liver 
oxidative stress contributes to the development and pathological findings of cirrhosis 
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and ultimately hepatocellular carcinoma irrespective of the cause and acts as a link 
between liver damage and fibrosis (Halliwell, 1999; Zhu, et al., 2012). Fibrosis of the 
liver as a result of long-term ethanol intoxication is usually with indices of increased 
oxidation of polyunsaturated membrane lipids. Oxidative stress is responsible in the 
initiation and progression of the activation of TGF-β, HSC and collagen accumulation 
in the fibrogenesis induced by chemical (Kim, et al., 2000). During oxidative stress the 
aldehydes produced from membrane lipid peroxidation assault extracellular and even 
cellular proteins in the hepatocytes and promote the accumulation of collagen in the 
inflamed cells (Albano, 2006). 
2.6.3 Antioxidant and liver cirrhosis 
Antioxidants are compounds which have the ability to scavenge, dispose and prevent 
the generation of free radicals, or challenge their actions. Antioxidants offer protection 
to body against free radical assaults which may result in diseases which include liver 
cirrhosis (Hasani-Ranjbar, et al., 2009). They adopt four mechanisms of scavenging free 
radical. The mechanisms of scavenging include reducing the potency of ROS, donating 
electron to the free radical, removing the ROS initiator or by chelating the free radical. 
Plant derived antioxidants have demonstrated to possess potent hepatoprotective and 
antifibrotic agents. At the same time, in patients with alcoholic liver disease lipid 
peroxidation has been found be considerably high which is coupled with decline in 
antioxidant (Shinde & Ganu, 2009). There is growing interest nowadays to plant 
materials which have bioactive properties, particularly, antioxidant properties.  There is 
a wide range of compounds in the plant materials that possess antioxidant properties and 
these include polyphenolic, terpenoids and tocopherols. Recently, a number of 
hepatoprotective, antinecrotic and antinflammatory drugs have revealed, as a part of 
their mechanism, to possess antioxidant properties. In order to maintain redox 
homeostasis, all cells are armed with different types of cellular antioxidant enzymes 
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together with substances that can potentially battle against ROS. Antioxidant enzymes, 
take for instance, catalase (CAT), superoxide dismutase (SOD) and glutathione 
peroxidase (GPx) each perform a specific role in scavenging free radicals and therefore 
as a whole protecting against cell damage. Along the line of the antioxidant enzymes, 
vitamin C and E protect the cells by preventing lipid peroxidation.  In cases where the 
antioxidant defense is overwhelmed by oxidant, antioxidant supplement can be used to 
assist in reducing oxidative damage (Bergendi, et al., 1999). 
2.6.4 Evaluation of antioxidant activity 
There are number of in vitro and in vivo assays employed to determine antioxidant 
capacity of plant based extract. The in vitro methods, ABTS and DPPH, can be used to 
measure the activity of the antioxidant of plant extract or pure isolated compound. 
These methods are known to be highly sensitive. Never the less, it is recommended to 
use more than one assay to determine the antioxidant activity of plant extract due to the 
complex nature of phytochemicals (Chanda & Dave, 2009). Together with the in vitro 
assays conducted on plant extracts, there are several in vivo cellular enzymes and 
substances that might be accomplished on tissue homogenate of the experimental 
animal model which include CAT, SOD and MDA, which determine the lipid 
peroxidation levels (Pietrangelo, et al., 1995) 
2.7 Curcuma xanthorrhiza  
2.7.1 Botanical description of C. xanthorrhiza 
C. xanthorrhiza (figure 2.3) is a medicinal herb belongs to the family Zingiberaceae of 
genus Curcuma with a synonym of Curcuma javanica found in various tropical regions 
of the world. C. xanthorrhiza is one of the extensively studied with various vernacular 
names such as temo labak (Indonesia), temu lawas (Malaysia), wan chakmotluk 
(Thailand) and temu lawak (Javanese). This medicinally valued rhizome is commonly 
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found wild as well as cultivated in Java, Malaysia, Thailand, and Philippines, and 
occasionally in India also. Several species of Zingiberaceae family are commonly found 
in damp, shaded parts of hill slopes and lowlands in Peninsular Malaysia. Curcuma 
xanthorrhiza rhizome is one of the important herb belongs to this family. Outer region 
of C. xanthorrhiza rhizomes are dark to reddish brown and interior have orange-red in 
colour. C. xanthorrhiza is commonly found in thick, moist, fertile and humus rich soils 
(Wardini & Prakoso, 1999) and possesses an aromatic, pungent odour with bitter taste 
(Devaraj, et al., 2010). 
 
 
Figure 2.3 Curcuma xanthorrhiza rhizoma   
 
2.7.2 Traditional uses of C. Xanthorrhiza 
Traditionally, temu lawak has been used as food and medicinal purposes. Young stems, 
rhizomes and inflorescences of C. xanthorrhiza are consumed either raw or after 
cooking as food. Rhizomes were cooked to prepare juice and used as soft drink (Husein, 
et al., 2009; Lin, et al., 1996). The juice is also used to treat indigestion and rheumatism 
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(Ruslay, et al., 2007). Curcuma xanthorrhiza as a traditional folk medicine ‘Jamu’ in 
Indonesia used to treat malaria, dysentery, cancer (Yamada, et al., 2009), to relieve 
uterus pain and to relieve abnormal menstruation symptoms. C. xanthorrhiza rhizomes 
are traditionally used for the treatment of various conditions which include liver 
disorders, abdominal complaints, fever, constipation, bloody diarrhea, haemorrhoids, 
skin infection, acne vulgaris and smallpox. It is also used as a galactogogue and to 
reduce the uterine inflammation after the child birth (Wardini & Prakoso, 1999). 
2.7.3 Phytochemistry of C. xanthorrhiza 
Rhizome of C. xanthorrhiza contains several phytoconstituents such as terpenoids, 
monoterpenoids, sesquiterpenoids and curcuminoids. The important sesquiterpenoids 
present are α and β-curcumene, xanthorrhizol, α and β-turmerone, arturmerone, 
germacrone, β-sesquiphellandrene, and curzerenone (Uehara, et al., 1992). Essential oils 
present in C. xanthorrhiza rhizome constitute around 65% of the total bioactive 
components (Yasni, et al., 1994). Xanthorrhizol is the main sesquiterpenoid which 
make up 51% of the total essential oils (Chean, et al., 2006; Chen, et al., 2006)). It has 
been reported that ar-curcumene, xanthorrhizol, α- and β-curcumene, curzerenone, and 
germacrone are the main constituents in the essential oil obtained by hydrodistillation of 
C. xanthorrhiza Roxb (Zwaving & Bos, 1992). Several non phenolic diarylheptanoids 
such as trans, trans-1,7-diphenyl-2,3-heptadien-4-one, 1,7-diphenyl-5-hydroxy-(lE)-
1.heptene and 1,7-diphenyl-5-hydroxy-(lE,3E)-1,3-heptadiene was isolated from the 
hexane extract of C. xanthorrhiza rhizomes cultivated in Thailand (Claeson, et al., 
2007). Even some phenolic diaryheptanoids such as demethoxycurcumin, 
bisdemethoxycurcumin, 1-(4-hydroxy-3,5-dimethoxyphenyl)-7-(4-hydroxy-3-
methoxyphenyl)-(1E,6E)-1,6-heptadien3,5dione (Masuda et al, 1992), 5-hydroxy-7-(4-
hydroxyphenylt1-phenyl-(lE)-l-heptene, 7-(3,4-dihydroxy phenyl)-5-hydroxy-l-phenyl-
(1E)-l-heptene were also isolated from C. xanthorrhiza rhizomes.  
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Curcumin and its analogues such as hexahydrocurcumin, octahydrocurcumin, 
dihydrocurcumin, l-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-6-hepten-3,5-dione 
(Uehara, et al., 1992) and 3’-demethoxycyclocurcumin were also reported from C. 
Xanthorrhiza (Yamada, et al., 2009). C. xanthorrhiza rhizome also contains saponins, 
flavonoids and tannins..  
A new LC-MS method was developed to analyse and identify the bioactive compounds 
from the aqueous extracts of C. xanthorrhiza (Ruslay, et al., 2007). These researchers 
then reported that curcuminoids such as bis-demethoxycurcumin, demethoxycurcumin 
and curcumin are the potent antioxidant components present in the ethyl acetate fraction 
of aqueous extracts of C. xanthorrhiza. Earlier, a rapid capillary zone electrophoresis 
method for the separation as well as identification of three main curcuminoids, 
demethoxycurcumin,  and  bis-demethoxycurcumin,  from  C. xanthorrhiza Roxb was 
also developed (Lechtenberg, et al., 2004). 
2.7.4 Previous scientific studies of C. xanthorrhiza 
C. xanthorrhiza rhizome has been extensively studied to evaluate its therapeutic 
efficacy. C. xanthorrhiza extract as well as xanthorrhizol showed significant and dose 
dependent decrease in the expression of matrix metalloproteinase-1, and increased the 
type-1 procollagen levels in UV-irradiated human skin fibroblasts suggesting it as a 
potential skin anti-aging candidate. An anti-inflammatory study revealed the potent anti-
inflammatory potency of methanolic extract of C. xanthorrhiza in 12-O-
tetradecanolyphorbol-13-acetate (TPA) induced inflammation as well as 7,12-
dimethylbenz[a]anthracene (DMBA induced number of tumors in mouse explaining its 
anticancer potency (Park, et al., 2008).  
Hepatoprotective activity of aqueous extract of C. xanthorrhiza prepared by decoction 
method in male Wistar albino rats intoxicated with β-D-galactosamine was evaluated 
(Lin, et al., 1996). The results of this study revealed that C. xanthorrhiza extract at a 
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dose of 100 mg/kg could significantly reduce the elevated serum transaminases and 
reduced the severity of liver damage induced by β-D-galactosamine. Another study of 
hepatoprotective was conducted using ethanolic extract of C. xanthorrhiza against 
ethanol induced liver toxicity in Sprague-Dawley rats (Devaraj, et al., 2010). The 
results of the study demonstrated that oral administration of 500 mg/kg extract could 
significantly reduce the elevated serum transaminases and protein emphasizing that the 
plant could be an important source of hepatoprotective agent. 
Oral acute toxicity of C. xanthorrhiza showed no any toxic symptoms even at the 
maximum dose used (5 g/kg) (Devaraj, et al., 2010). The plant extract also 
demonstrated peripheral and central analgesic activity at the dosage of 200 and 400 
mg/kg in both phases of formalin induced pain model (Devaraj, et al., 2010). An in vitro 
antioxidant study of acetone extract revealed the potent antioxidant activity of C. 
xanthorrhiza in both thiobarbituric acid and thiocyanate assay methods (Jitoe, et al., 
1992).  
Oral administration of C. xanthorrhiza at the dose of 2, 3 and 4g/kg in male rabbits 
resulted in significant increase in fat excretion through the lipid metabolism by liver 
also decreased cholesterol, triglyceride and LDL concentrations. In addition, C. 
xanthorrhiza sample also significantly increased the HMG-CoA reductase activity 
(Wientarsih, et al., 2002). Contrary to this a recent study revealed that ethanolic extract 
of C. xanthorrhiza only decreased LDL concentration when given orally at a dose of 25 
mg/kg in male Wistar rats (Sukandar & Nurdewi, 2012). However in combination with 
aqueous extract of Guazuma ulmifolia at a dose of 12.5 mg/kg significantly decreased 
total cholesterol and LDL level (Sukandar & Nurdewi, 2012).  
Earlier, study reported the significant decrease in the concentration of serum 
triglycerides and phospholipids as well as liver cholesterol and also increased the serum 
HDL cholesterol in rats treated with C. xanthorrhiza extract (Yasni, et al., 1993). The 
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study also reported that curcuminoids of C. xanthorrhiza does not have role in the 
obtained hypolipidemic effect and hence concluded that active constituents other than 
curcuminoids are responsible for the found activity. Another study reported the 
significant hypolipidemic activity through the inhibition of hepatic triglyceride secretion 
by two phenolic diarylheptanoids isolated from C. xanthorrhiza. 
Potent antimicrobial activity of ethanolic as well as ethyl acetate extract of C. 
xanthorrhiza rhizome against Staphylococcus aureus, Bacillus cereus and Escherichia 
coli have been reported (Husein, et al., 2009). C. xanthorrhiza extract antibacterial 
effects on Streptococcus mutans bioflims revealed the strong bactericidal activity and 
inhibition of acidogenesis rendering it has a new source for the prevention of dental 
caries (Kim, et al., 2008). A study reported two fold increase in the estrogenic activity 
of C. xanthorrhiza aqueous ethanolic extract in yeast two hybrid system (Siri & 
Incamnoi, 2008).   
2.7.5 Important pharmacological studies of xanthorrhizol  
Xanthorrhizol is the main and bioactive sesquiterpenoid found only in C. xanthorrhiza 
Roxb but not in any other species of Curcuma (Husein, et al., 2009). Several positive 
findings regarding its therapeutical potency have been investigated. Xanthorrhizol 
exhibited the hepatoprotective activity on cisplatin-induced hepatotoxicity through its 
ability to regulate the DNA-binding action of nuclear factor-kB (NF-kB) (Kim, et al., 
2005) and by the phosphorylation of c-Jun N-terminal Kinases (JNKs) in a dose-
dependent manner (Hong, et al., 2005). Topical application of xanthorrhizol possess the 
ability to inhibit the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced acute 
inﬂammation in mouse ear by the inhibiting the expression of ornithine decarboxylase, 
cyclooxygenase-2 and inducible nitric oxide synthase through the NF-kB and mitogen-
activated protein kinases.  
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Protective effect of xanthorrhizol on cisplatin-induced nephrotoxicity in ICR male mice 
was carried out (Kim, et al., 2005). In this study, it was reported that xanthorrhizol at a 
dose of 200 mg/kg significantly reduced the elevated levels of blood urea nitrogen, 
serum creatinine and kidney weight. Moreover, the same study also revealed that the 
nephroprotective effect of xanthorrhizol is more efficacious than curcumin at the same 
tested dose (200 mg/kg). 
A study was carried out to evaluate the antioxidant and anti-inflammatory activity of 
xanthorrhizol in hippocampal neurons and cultured microglial cells. The results of this 
study showed that xanthorrhizol could reduce the expression of cyclooxygenase-2 as 
well as inducible nitric oxide synthase and the release of proinflammatory cytokines 
like TNF-α and, interleukin-6 in microglial cells activated by lipopolysaccharide (Lim, 
et al., 2005). The same team of researchers also reported the potent neuroprotective 
activity of xanthorrhizol on glutamate induced neurotoxicity in murine hippocampal 
HT22 cells through the inhibition of lipid peroxidation (Lim, et al., 2005).  
In a study conducted to evaluate the growth inhibitory effect of xanthorrhizol in 
HCT116 human colon cancer cells, it was reported that xanthorrhizol dose dependently 
exerted antiproliferative effect and apoptosis by triggaring DNA fragmentation, release 
of cytochrome c and by activation of caspases (Kang, et al., 2009). Xanthorrhizol show 
antiproliferative effect on human hepatoma cells HepG2 through the activation of 
suppressor p53 and down regulation of antiapoptic Bcl-2 and Bcl-XL protein expression. 
(Handayani, et al., 2007; Tee, et al., 2012). In addition, xanthorrhizol also induces 
apoptosis of cervical cancer cell line HeLa cells via the up-regulation of tumour 
suppressor protein p53 and the pro-apoptic protein Bax (Ismail, et al., 2005). 
Xanthorrhizol in combination with curcumin exhibited synergistic growth inhibitory 
effect on MDA-MB-231 human breast cancer cells through apoptosis induction (Cheah, 
et al., 2009).  
39 
 
Xanthorrhizol also found to inhibit the formation of tumour nodules in the mouse lung 
tissue and intra-abdominal tumour mass formation through the attenuation of expression 
of cyclooxygenase-2, matrix metalloproteinase-9 and phosphorylated extracellular 
signal regulated kinase.  
With regards to anticandidal activity of xanthorrhizol, a compound isolated from 
methanolic extract of C. xanthorrhiza was studied against six Candida species and 
reported to have potent anticandidal activity against all the species with MIC 
concentration of 1.0-25 mg/L (Rukayadi, et al., 2006). Further study conducted revealed 
that the found anticandidal activity is through the modification of external morphology, 
deformation and protrusions on the surface of the Candida cells (Rukayadi & Hwang, 
2007). Xanthorrizol isolated from C. xanthorrhiza also exhibited potent anti-Malassezia 
activity expressed in terms of minimum inhibitory concentration (MIC) against two 
Malassezia species with the MIC value of 0.25 to 1.25 µg/mL (Rukayadi & Hwang, 
2007). A study regarding the antibacterial effects of C. xanthorrhiza extract on 
Streptococcus mutans bioflims revealed the strong bactericidal activity and inhibition of 
acidogenesis rendering it has a new source for the prevention of dental caries (Kim, et 
al., 2008). Other researchers revealed the potent antibacterial activity of xanthorrhizol 
against Streptococcus species which cause dental caries. Xanthorrhizol and its 
methylation derivative exhibited strong inhibition of platelet activating factor receptor 
binding (Jantan, et al., 2004). It has been reported that two fold increases in the 
estrogenic activity of C. xanthorrhiza aqueous ethanolic extract in yeast two hybrid 
systems.   
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2.8 Ipomoea aquatica 
2.8.1 Botanical description of Ipomoea aquatica  
Ipomoea aquatic (figure 2.3) is one of the 400 species under the genus Ipomoea L. 
belongs to the family Convolvulaceae and distributed throughout tropical climatic 
countries. It is indigenous to China but also distributed throughout India, Sri Lanka, 
Africa, Australia and Tropical Asia. It is also well-known by different names  including 
aquatic morning glory, kangkong, water spinach, water convolvulus, swamp cabbage 
(Prasad, et al., 2008). It grows wildly in India but cultivated commercially in Malaysia, 
Singapore, Indonesia Taiwan, China and Hong Kong where it is consumed as an edible 
leafy vegetable (Prasad, et al., 2008; Wills, et al., 1984). 
Ipomoea aquatica is an annual or perennial aquatic plant normally found floating or 
trailing in fresh water ponds, marshes, and in ditches also found in muddy stream banks 
as creepers (Rao & Vijay, 2002). Leaves, petiole and stems of this plant are green in 
color with white or pale purple color flowers. Leaves are ovate to elliptic in form with 
an acute tip and sagittae base having a length of 6-15 cm. Leaves are present on long, 
fleshy petiole arising from the nodes of the lateral branches. Flowers are of 2-2.5 cm, 
axillary in shape present either singly or in group of 3-7 on the lateral branches and fruit 
is in the capsule form (Edie & Ho, 1969).  
Leaves of this plant possess high nutritive value for human, fish and grazing animals 
and also reported to have medicinal value (Hu, et al., 2010). Since the amount of 
essential amino acids present in I. aquatica is comparable to that of soyabean or egg it 
can be utilized as a source of food supplement. Currently, Ipomoea aquatic leaves were 
extensively used to purify waste water (Hu, et al., 2008) 
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Figure 2.3 Ipomoea aquatica plants (adapted from (Prasad, et al., 2008)) 
 
2.8.2 Traditional uses of I. aquatica  
Though I. aquatica is extensively used as leafy vegetable due to its high nutritive value 
its traditional uses will not be neglected. In Ayurveda and homeopathic medicine it is 
used to various disorders including the disorders of liver, oxidative stress, nose bleed 
and high blood pressure (Prasad, et al., 2005). Traditionally, juice of this plant is used in 
liver disorders, eye disease (Jain & Verma, 1981), gastric and intestinal disorders 
(Westphal, 1993) and in constipation (Samuelsson, et al., 1992) and, buds are used in 
the treatment of leprosy, leucoderma and fever (Mamun, et al., 2003).  
In traditional medicine, Ipomoea aquatica have also been used to treat certain nervous 
conditions with sleeplessness as well as head-ache and also the plant has a anxiolytic 
effect (Prasad, et al., 2008). According to the Sri Lankan indigenous medicine it 
possesses insulin like activity (Jayaweera, 1980). In particular juice of this vegetable is 
commonly used as an emetic to treat opium and arsenic poisoning (Kapoor & Kapoor, 
1980). 
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2.8.3 Phytochemistry of I. aquatica 
Preliminary phytochemical analysis of I. aquatica plant extract has shown the presence 
of phenols, flavonoids, tannins, saponins, steroids and alkaloids (Vasu, et al., 2009; 
Yadav & Agarwala, 2011). Ipomoea aquatica is a rich source of vitamin C, soluble 
proteins and sugars (Hu, et al., 2010), essential amino acids such as aspartic acid, 
glycine, alanine, leucine, organic acids like citric acid, oxalic acid, malic acid (Wills, et 
al., 1984).  
Several carotenes and pigments from I. aquatica were separated using thin layer 
chromatography, column chromatography and high performance liquid chromatography 
and to identify β-carotene, β-cryptoxanthin, lutein, lutein epoxide, violaxanthin and 
neoxanthin by comparing the absorption spectra and retention time with reference 
standards (Chen, et al., 1991). Later , a new HPLC method developed to separate and 
identify these carotenes and pigments along with cis-lutein and, cis-β-carotene from I. 
aquatica (Chen & Chen, 1992). Several other carotenes such as zeaxanthin, 
anthraxanthin and luteoxanthin were also identified from this plant (Wills & Rangga, 
1996). Further down the line the provitamin A carotenoid content was determined using 
a validated HPLC method and the variation in the carotenoid content of I. aquatica was 
reported according to its maturity and origin (Hulshof, et al., 1997).  
The separation of essential oils from the leaves and stems of I. aquatica was carried out 
using Likens Nikerson apparatus that identified 58 volatile components some important 
components are phytol, palmitic acid, alpha humulene, n-hexacosane and bis(2-ethyl-
hexyl) subacetate (Kameoka, et al., 1992). I. aquatica found to posses several phenolic 
compounds such as procatechuic acid, p-hydroxybenzoic acid, vanillic acid and salicylic 
acid (Leela & Rao, 1994) and flavonoids such as 7-O-β-D-glucopyranosyl-
dihydroquercetin-3-O-α-D-glucopyranoside (Prasad, et al., 2005). Other study reported 
the presence of quercetin (205 mg/kg of dry weight) in the acid hydrolysed aqueous 
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ethanolic extract of I. aquatica (Miean & Mohamed, 2001). Several other flavonoids 
such as quercetin, luteolin, apigenin, myricetin, quercetin-3’-methyl ether, quercetin-4’-
methyl ether and anthocyanins were also reported from I. aquatica (Chu, et al., 2000; 
Daniel, 1989). 
2.8.4 Previous scientific studies 
The wide distribution and easy availability attracted the attention of various researchers 
to evaluate its therapeutic efficacy. A study evaluated antioxidant activity of Ipomoea 
aquatica leaf and stem ethanolic and waters extract using DPPH assay, reducing power 
method and ferric thiocyanate method, and antiproliferative activity in human 
lymphoma NB4 cells (Huang, et al., 2005). The results of this study revealed the 
highest DPPH radical scavenging activity, reducing power and significant total phenolic 
content in the ethanolic stem extract whereas highest antiproliferative activity was 
observed with water extract of stem with an EC50 value of 661.4 ± 3.36 µg dry 
matter/mL (Huang, et al., 2005). Using Soxhlet extraction method, serial extraction of I. 
aquatica leaf was extracted and followed by the determination of antioxidant activity in 
which both methanolic as well as aqueous extract showed significant antioxidant 
activity.  Recently, three carotenoids namely violaxanthin, lutein and β-carotene were 
separated by HPLC-MS and then evaluated for their antioxidant potency (Fu, et al., 
2011).  The result revealed that β-carotene possess highest DPPH radical scavenging 
activity whereas, violaxanthin significantly prevented the lipid peroxidation.  
A study reported the potent antioxidant activity of I. aquatica in DPPH, trolox 
equivalent antioxidant capacity as well as oxygen radical absorbance capacity assays 
and also mentioned that this plant extract also possess antitumor activity on mouse 
myeloma cell line P388 (Shekhar, et al., 2011). Further in the study conducted by the 
same team of researchers the plant extract revealed the antimutagenic activity in 
Salmonella Typhimurium TA98 and antimicrobial activity against Pseudomonas 
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aeroginosa and Escherichia coli bacteria. Crude methanolic extract of I. aquatica 
possess moderate cytotoxic activity against Hep-2 (human larynx epithelial carcinoma) 
and A-549 (human small cell lung carcinoma) cell lines followed by the column fraction 
and the isolated bioactive compound 7-O-β-D-glucopyranosyl-dihydroquercetin-3-O-α-
D-glucopyranoside (Prasad, et al., 2005).  
Ipomoea aquatica is also known to posse hypoglycemic activity and study was 
conducted using boiled whole extract of I. aquatica in normal male Wistar rats. In this 
study it was reported that single dose of the extract (3.4g/kg) significantly reduced the 
serum glucose level (33%) in comparison with the multiple dose of the extract (25%) 
(Malalavidhane, et al., 2000). Based on this result, the same authors conducted an oral 
hypoglycemic activity of finely shredded leaves and stem of I. aquatica in 
streptozotocin-induced male Wistar diabetic rats and boiled whole extract in human 
diabetic patients. The result of this study revealed the significant decreased fasting 
blood glucose levels in diabetic rats and also in type 2 diabetic patients with a 29.4% 
decrease in the serum glucose concentration (Malalavidhane, et al., 2003). The 
hypoglycemic efficacy of I. aquatica extract was reported to be comparable with that of 
tolbutamide in lowering blood glucose level (Malalavidhane, et al., 2001). In the same 
line, another study evaluated the effect of I. aquatica aqueous as well as 
dichloromethane/methanolic extracts on the glucose absorption in rat intestinal 
preparation and reported that aqueous extract significantly decreased the intestinal 
glucose absorption (Sokeng, et al., 2007). 
In the evaluation of antimicrobial and anti-inflammatory activities of  methanolic and 
aqueous extracts of I. aquatica leaf has been  reported that methanolic extract possess 
potent antimicrobial activity against Bacillus subtilis Staphylococcus aureus, 
Pseudomonas aeruginosa, Escherichia coli and Proteus vulgaris compared to aqueous 
extract. In addition they also reported that, the anti-inflammatory activity exhibited by 
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both extracts at a dose of 200 mg/kg was almost equal to the activity shown by 
indomethacin. It is also reported to inhibit prostaglandin synthesis (Tseng, et al., 1992) 
and moderate antinematocidal activity against pine wood nematode (Mackeen, et al., 
1997).  
Methanolic extract of I. aquatica at dose of 200 and 400 mg/kg significantly decreased 
the concentration of total cholesterol, total lipid, free fatty acids, phospholipids and 
triglycerides in plasma as well as in liver and, kidney in hyperlipidemic Swiss albino 
rats (Sivaraman, 2010). Ethanolic extract of I. aquatica leaf at a dose of 200 and 
400mg/kg body weight effectively reduced the free and total acidity in aspirin induced 
gastric ulcer model in Swiss albino rats through the its cytoprotective effect (Sivaraman, 
2010).    
Diuretic activity of this plant has also been reported in a study in which Swiss albino 
mice treated with methanolic extract of I. aquatica at a dose of 250 and 500 mg/kg body 
weight. The result proved that I. aquatica possess potent and dose dependent diuretic 
activity, and the found activity was higher than the reference drug furosemide (Mamun, 
et al., 2003). Positive findings regarding the anxiolytic activity of I. aquatica extracts in 
elevated pus maze, light dark apparatus and hole board apparatus has also been reported 
(Khan, et al., 2011). 
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CHAPTER III 
MATERIALS AND METHODS 
3.1 Chemicals 
All chemicals used in the study were of analytical grade and purchased from Sigma-
Aldrich. Thioacetamide (TAA, Sigma-Aldrich, Switzerland) was used as an inducer for 
liver cirrhosis and silymarin (International Laboratory, USA) was used as a standard 
drug in the experiment. 2,2-diphenyl-1-picrylhydrazyl (DPPH), potassium persulphate, 
2,2-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS), 
Vitamin-C, gallic acid, silymarin were purchased from Sigma Chemicals, Germany.  
3.2 Plant materials 
Fresh plant materials of C. xanthorrhiza (vulture No. KLU 11022) and I. aquatica 
(vulture No. KLU 041845) were purchased from the Ethno Sdn Bhd, Selangor 
Malaysia, and identified by comparison with the Voucher specimen deposited at the 
Herbarium of Rimba Ilmu. Separately, C. xanthorrhiza rhizome (cut into small pieces) 
and I. aquatic leaves were first washed with tap water and followed   rinsing with 
distilled water. The plant materials were then air dried for 7 days.  
3.3 Extraction of Curcuma xanthorrhiza  rhizome and Ipomoea aquatica leaves 
The dried C. xanthorrhiza rhizome and the dried leaves of I. aquatica were powdered 
using electrical blander.  100 grams of each powdered plant material then was extracted 
in 900 ml of 95% ethanol at 25°C for 72 hours. The suspensions were gently mixed, 
from time to time, to allow the powdered materials fully dissolved in the ethanol.  The 
ethanol extract was filtered through cheese cloth and then by filter paper (Whatman No. 
1) and evaporated under reduced air pressure using Buchi rotary evaporator to obtain 
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the percentage yield crude-dried extract of 5.4  and 18.4%,  (w/w) for C. xanthorrhiza 
and I. aquatica samples, respectively. 
3.4 In vitro antioxidant of plant extracts  
In vitro antioxidant of crude extracts of C. xanthorrhiza and I. aquatica were 
determined using DPPH radical scavenging assay and ABTS radical scavenging assay. 
3.4.1 DPPH radical scavenging assay 
The method described by Brand-Williams with slight modification was employed to 
determine DPPH radical scavenging activity of I. aquatica and C. xanthorrhiza extracts 
as well as standards (Brand-Williams, et al., 1995). Ascorbic acid was diluted in five 
concentrations of 25, 12.5, 6.25, 3.125 and 1.56 μg/ml and used as standards in the 
assay to create standard curve. Then in order to compare the scavenging power of the 
samples, Ascorbic acid BHT, together with silymarin, C. xanthorrhiza and I. aquatica 
each was diluted to into two dilutions 25 and 6.25 μg/ml. Each of the prepared dilution 
was mixed with 195 μl of DPPH (40 X dilution) in triplicate.  The decrease in the 
absorbance due to free radical scavenging activity was recorded at 515 nm for 2 hr with 
20 min intervals. The percentage inhibition of DPPH radicals by tested samples was 
calculated using the following formula and the results were expressed as Mean ± 
Standard Error Mean (S.E.M.): % of radical scavenging activity = (Abs Blank – Abs 
Sample) /Abs Blank X100 
3.4.2 ABTS radical scavenging assay 
ABTS radical scavenging activity of I. aquatica and C. xanthorrhiza extracts and 
standards were determined according to the procedure described by Re (Re, et al., 
1999). Trolox was used as standard in the assay to create standard curve. Then in order 
to compare the scavenging power of the samples, Ascorbic acid, BHT, together with 
silymarin, C. xanthorrhiza and I. aquatica each was diluted to into two dilutions 100 
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and 25 μg/ml. The generation of 2, 2'-azino-bis-(3-ethylbenzothiazoline-6-sulphonic 
acid (ABTS) radical cation take place when is reacted with 7 mM ABTS and 2.45 mM 
potassium persulfate incubated in the dark for 12–16 hours at room temperature. Fresh 
ABTS was prepared and diluted with methanol to yield an absorbance of 0.700 ± 0.02 at 
734 nm, and the same solution was used for this assay. Then 10 μl of prepared dilutions 
of sample and standards were mixed with 1 ml ABTS and mixed thoroughly. The 
reactive mixture was kept at room temperature for 15 min and the absorbance was 
recorded at 734 nm and the percentage inhibition of ABTS radicals was calculated. 
3.5 Cell culture medium 
Normal human liver embryo cells WRL-68 obtained from American Type Culture 
Collection (ATCC, USA) were cultured in RPMI 1640 (Sigma, Aldrich-USA), 
supplemented with 10% Fetal Bovine Serum (Sigma, Aldrich-USA), 1% 
Penicillin/Streptomycin (Sigma, Aldrich-USA) and incubated at 37°C in a humidified 
atmosphere of 5 % CO2.  
3.6 Selection of TAA dose for hepatotoxicity induction in WRL-68 cells 
Thioacetamide (TAA) was used to induce oxidative stress and therefore cell damage in 
the normal human liver embryo cells (WRL-68). The cells were seeded in 200 µl of 
RPMI containing 10% FBS with density 3000 cells/ well. After 24 hours, cells were 
treated with 10 µl of different concentrations (0.01, 0.02, 0.04, 0.06, 08 and 0.10g/ml) 
of freshly prepared TAA (Merck, Darmstadt, Germany) and then again incubated at 
37°C in humidified 5 % CO2 incubator for 2 hours. The WRL-68 growth inhibition as 
results of TAA toxicity were determined by applying MTT assay described (Mosmann, 
1983; Scudiero, et al., 1988). The assay was carried out in three separate experiments. 
The TAA concentration which demonstrated the cell growth inhibition of approximately 
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50% was chosen for in vitro hepatoprotective activity of the plant extracts and the 
fractions. 
3.7 Hepatoprotective effect of crude extracts against TAA cytotoxicity 
Thiacetamide at the concentration of 0.04g/ml was selected to induce approximately 
50% cell growth inhibition of normal human liver embryo cells (WRL-68). The cells 
were seeded in 200 µl of RPMI containing 10% FBS with density 3000 cells/ well and 
incubated at 37
o
C and 5% CO2 for a day. After 24 hours, using 2.5% DMSO, 10 µg/ml 
media of both plant crude extracts were prepared. The prepared crude extracts were 
added to the cells as per the designed experiment (Table 3.1) and incubated for 2 hours. 
The cells were then treated with 10 µl of 0.04g/ml TAA. Normal control cells was kept 
with media only, toxin control was kept with 0.04 g.ml TAA only and standard drug 
control (silymarin) was kept with TAA then silymarin at the concentrations 10 µg/ml 
(Sarkar & Sil, 2007). The cells were incubated for 2 hours and the hepatoprotective 
effect of plant extracts were determined by cell viability using MTT assay as described 
by (Mosmann, 1983; Scudiero, et al., 1988). The assay was carried out in three separate 
experiments.   
Table 3.1: The design of in vitro hepatoprotective screening of C. xanthorrhiza and I. 
aquatica crude extracts 
Group Name TAA 0.04g/ml  Treatment 10µl/ml 
 
Normal control No TAA (10µl medium) DMSO 10µl 
TAA control 10µl  DMSO 10µl 
Silymarin control 10µl  Silymarin 10µl 
C. xanthorrhiza crude 10µl  Crude extract 10µl 
I. aquatica crude 10µl  Crude extract 10µl 
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3.8 Antioxidants of the cell line treated with crude extracts  
The crude extracts of both plants were tested for their antioxidant activities. The 
antioxidant activity was measured using the following kits: superoxide dismutase 
(SOD) assay kit (Cayman Chemical Company, USA), catalase (CAT) assay kit 
(Cayman Chemical Company, USA) and molandialdehyde (MDA) assay kit (Cayman 
Chemical Company according to the manufacturer’s instructions. Briefly, to determine 
the activity of SOD, CAT and lipid peroxidation (MDA), WRL-68 cells were seeded in 
200 µl of RPMI containing 10% FBS with density 3000 cells/ well and incubated at 
37
o
C and 5% CO2 for a day. After 24 hours, using 2.5% DMSO, 10 and 100 µg/ml 
media of both plant crude extracts were prepared and added to the cells as per the 
designed experiment (Table 3.2) and incubated for 2 hours. The cells were then treated 
with 10 µl of 0.04g/ml TAA and reincubated for 2 hours. Normal control cells was kept 
with media only, toxin control was kept with 0.04 g/ml TAA only and standard drug 
control (silymarin) was kept with TAA then silymarin at the concentrations 10 and 100 
µg/ml. The cells were then washed three times with PBS pH 7.4 and sonicated on ice 
and the solution was then centrifuged at 13,000 x g for 15 minutes at 4°C. The obtained 
supernatants were used to determine intracellular antioxidants in a microplate reader at 
440 nm for SOD, 540 nm for CAT and 540 nm for MAD. The assay was carried out in 
three separate experiments.   
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Table 3.2: The antioxidant and lipid peroxidation experimental design for cell line 
treated with crude extracts.  
 
Group Name TAA 0.04g/ml  Treatment 10µl/ml and 
100µl/ml 
Normal control No TAA (10µl medium) DMSO 10µl 
TAA control 10µl  DMSO 10µl 
Silymarin control 10µl  Silymarin 10µl 
Silymarin control 10µl  Silymarin 100µl 
C. xanthorrhiza crude 10µl  Crude extract 10µl 
C. xanthorrhiza crude 10µl  Crude extract 100µl 
I. aquatica crude 10µl  Crude extract 10µl 
I. aquatica crude 10µl  Crude extract 100µl 
3.9 Acute toxicity test 
The procedure for this animal study was reviewed and then approved by Animal Ethics 
Committee (Ethic No. PM/27/07/2010/MAA). Thirty six Sprague-Dawley rats aged 7-8 
weeks (eighteen male and eighteen female) were used for each plant extract in which 
they were divided into three groups of each gender with six rats each. For C. 
xanthorrhiza the animal groups marked as vehicle, low dose and high dose were orally 
administered with 5ml/kg of 10% tween 20, 2g/kg and 5g/kg of prepared dose of C. 
xanthorrhiza extract, respectively. In case of acute toxicity study of I. aquatic, the 
animal groups marked as vehicle, low dose and high dose were orally administered with 
5ml/kg sterile distilled, 2g/kg and 5g/kg of prepared I. aquatica extract, respectively. 
Prior dosing the rats were kept fasting for overnight and after the dose for another 4 
hours. Following the dose the rats were carefully observed for the development of any 
clinical or toxicological symptoms at 30 minutes and then 2, 4, 8, 24 and 48 hours. On 
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the 15th day, all the rats were sacrificed and samples for biochemical and histological 
studies were collected and analyzed as per (Lorke, 1983). 
3.10 Hepatoprotective study of the crude extracts   
3.10.1 Experimental animals  
The study was carried out using male Sprague-Dawley rats (195 - 215 g) obtained from 
the Animal House Unit, Faculty of Medicine, University of Malaya, Malaysia. The 
chosen animals were housed in bottomed cages at 25 ± 3°C temperature, 50–60% 
humidity, and under a 12 hours light-dark cycle for a week before the experiment. The 
animals were maintained at standard housing conditions and free access to a standard 
diet and water ad libitum during the experiment. The experiment was performed in 
accordance to the guideline of taking care of animals prepared by the National Academy 
of Sciences.    
3.10.2 Preparation of doses  
Thioacetamide (cirrhosis inducer) was dissolved in sterile distilled water and then 
injected intraperitoneally to the experimental rats at a dosage of 200 mg/kg body weight 
(Aydın, et al., 2010). Silymarin (a standard drug) was dissolved in sterile distilled water 
and orally administered to rats in concentrations of 50 mg/kg body weight (Aydin, et 
al., 2010). Crude dried ethanol extract of C. xanthorrhiza rhizome was dissolved in 
tween 20 (10% w/v) and orally administered to the experimental animals at a dosage of 
250 and 500 mg/kg body weight. Crude dried ethanol extract of I. aquatica leaves was 
dissolved in sterile distilled water and orally administered to the experimental animals 
at a dosage of 250 and 500 mg/kg body weight. For each plant, normal control group of 
animals received distilled water and 10 % tween 20 for I. aquatica and C. xanthorrhiza 
extracts, respectively. 
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3.10.3 Study design for Curcuma xanthorrhiza  
Thirty rats were randomly divided into five groups of six animals each. Group 1 
(normal control) received intraperitoneal injection of sterile distilled water (1 ml/kg) 
three times a week for eight weeks and oral administration of tween 20 (10%, 5 ml/kg) 
daily for eight weeks. Group 2 (cirrhosis control) received intraperitoneal injection of 
TAA (200 mg/kg) three times a week for eight weeks and oral administration of  tween 
20 (10%, 5 ml/kg) daily for eight weeks. Group 3 (standard drug control) received 
intraperitoneal injection of TAA (200 mg/kg) three times a week for eight weeks and 
oral administration of Silymarin (50 mg/kg) daily for eight weeks. Group 4 (low dose 
ethanolic extract treated group) received intraperitoneal injection of TAA (200 mg/kg) 
three times a week for eight weeks and oral administration of C. xanthorrhiza (250 
mg/kg) daily for eight weeks. Group 5 (high dose ethanol extract treated group) 
received intraperitoneal injection of TAA (200 mg/kg) three times a week for a period 
of eight weeks and oral administration of C. xanthorrhiza  (500 mg/kg) daily for eight 
weeks. 
3.10.4 Study design for Ipomoea aquatica  
The procedure described for C. xanthorrhiza was followed to determine the 
hepatoprotective activity of I. aquatica. Except the group 1 (normal control) received 
intraperitoneal injection of sterile distilled water (1 ml/kg) three times a week for eight 
weeks and oral administration of  sterile distilled water (5 ml/kg) instead of  10% tween 
20 daily for eight weeks.  
3.10.5 Analysis of serum biochemical parameters of the liver 
Biochemical parameters were analyzed by standard biochemistry automated analyzer at 
the Central Diagnostic Laboratory of the medical Centre of University Malaya. Blood 
samples collected from the rats were centrifuged at 3000 rpm for 10 minutes. Then the 
separated serum samples were used to analyze liver biochemical parameters including 
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alanine aminotransferase (ALT), alkaline phosphatase (AP), aspartate aminotransferase 
(AST), total protein, bilirubin and albumin.   
3.10.6 Histopathological examination 
Histopathological examination of the liver was carried out by means of light 
microscope. Liver was fixed in 10 % buffered formaldehyde subsequently processed by 
programmed tissue processing machine and after that embedded in paraffin wax. 
Following embedding a section of 5 μm thick was prepared and stained with 
hematoxylin-eosin (HE) and Masson–Trichrome (MT) for photomicroscopic assessment 
(Al-Bayaty, et al., 2010).  
3.11 Alpha smooth muscle actin study 
For alpha smooth muscle actin (α-SMA) studies, the sections were mounted on glass 
slides coated with 0.1% poly-l-lysine. After deparaffination, and subsequent blockage of 
the endogenous peroxidase activity by incubation in 2.5% methanolic hydrogen 
peroxide (30 min), the endogenous biotin was blocked by Biotin Blocking. The sections 
were then washed three times in phosphate-buffered saline (PBS). Mouse monoclonal 
anti-alpha-SMA antibody diluted 1:40 was used as primary antibody. The sections were 
incubated for 1 h at room temperature. After three washings in PBS, the sections were 
incubated for 30 min with the appropriate secondary biotinylated antibody labelled with 
the Avidin-Biotin Complex. The sections were developed with 3-3_ diaminobenzidine 
and finally counterstained with haematoxylin. Negative controls were performed using 
normal mouse antiserum instead of the primary antibody, which uniformly 
demonstrated no reaction. 
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3.12 Evaluation of SOD, CAT and MDA contents in liver homogenate  
Superoxide dismutase (SOD), catalase (CAT) and Malondialdehyde level (MDA) was 
analyzed from liver homogenate sample. The Liver sample was rinsed with saline and 
then homogenized (10 % w/v) in 50 mM cold potassium phosphate buffer (pH 7.4) 
subsequently centrifuged at 3500 rpm for 10 minutes at 4°C. Then the supernatant was 
separated and saved for MDA analysis as per thiobarbituric acid procedure (Yasuda, et 
al., 2003), which is an indicator for lipid peroxidation level. SOD and CAT were 
analyzed using SOD and CAT assay kits from Cayman Chemical Company, USA. 
3.13 Determination of cytokines 
Tumor necrosis factor-α (TNF-α) and Transforming growth factor beta 1 (TGFβ1) were 
analyzed from serum sample whereas, nuclear factor-κB (NF-κB) was analyzed from 
liver homogenate sample. Collected blood samples from the rats were centrifuged at 
3000 rpm for 10 minutes. Then the separated serum samples were used to analyze TNF 
alpha and TG-Fβ1 by using Quantikine’s TNF alpha and TG-Fβ 1 assay kits. Tissue for 
the assay of NFκ-β was minced in very small pieces and then homogenized in 10 ml of 
PBS. The resulting suspensions were exposed to two freeze-thaw cycles to completely 
break the cell membranes. The homogenates were centrifugated for 5 minutes at 
5000×g. Then the supernatant was separated and used to analyze NF-κB by using Uscnk 
assay kit. 
3.14 Fractionation of ethanol crude extracts 
Five grams of the crude ethanol extract of each plant was dissolved in a minimum 
amount of acetone solvent. The concentrated crude solution in acetone was mixed with 
10 grams of silica gel and followed by drying using rotary evaporator to form powder 
sample. Each of the obtained powdered samples was subjected to column 
chromatography (5.0 cm x 30 cm) containing 100 grams silica gel. The amount of silica 
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gel G60, 70 - 230 mesh (Merck, Darmstadt, Germany) was based on the ratio of 1 g of 
crude extract to 20 g of silica gel. The fractionation step was based on gradient elution 
method and the solvent system used was hexane- ethyl acetate eluted stepwise with 
gradient concentrations of 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100 %. The fractions 
were collected in clean tubes every 100 ml of eluent. Based on the similarity of spots on 
thin layer chromatography (TLC), the eluents were pooled to give 10 and 13 major 
fractions of curcuma xanthorrhiza and ipomoea aquatica, respectively. The fractions 
were dried using rotary evaporator, dissolved with minimum amount of acetone and 
were transferred to test tubes. The samples were dried using Centrivap.  
3.15 Hepatoprotective effect of fractions isolated from both plants against TAA 
cytotoxicity 
Hepatoprotective of all fractions isolated from C. xanthorrhiza and I. aquatica crude 
extracts were carried out in cell line. Normal human liver embryo cells (WRL-68) were 
seeded in 200 µl of RPMI containing 10% FBS with density 3000 cells/ well and 
incubated at 37
o
C and 5% CO2 for a day. After 24 hours, using 2.5% DMSO, 10 µg/ml 
media of both plant isolated fractions were prepared. The prepared fractions were added 
to the cells as per the designed experiment (Table 3.3and 3.4) and incubated for 2 hours. 
The cells were then treated with 10 µl of 0.04g/ml TAA. Normal control cells was kept 
with media only, toxin control was kept with 0.04 g.ml TAA only and standard drug 
control (silymarin) was kept with TAA then silymarin at the concentrations 10 µg/ml 
(Sarkar & Sil, 2007). The cells were incubated for 2 hours and the hepatoprotective 
effect of isolated fractions were determined by cell viability using MTT assay as 
described by (Mosmann, 1983; Scudiero, et al., 1988). The assay was carried out in 
three separate experiments.   
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Table 3.3: The design of in vitro hepatoprotective screening of C. xanthorrhiza isolated 
fractions 
Group Name TAA 0.04g/ml  Treatment 10µl/ml 
 
Normal control No TAA (10µl medium) DMSO 10µl 
TAA control 10µl  DMSO 10µl 
Silymarin control 10µl  Silymarin 10µl 
C. xanthorrhiza F1 10µl  Fraction 1 10µl 
C. xanthorrhiza F2 10µl  Fraction 2 10µl 
C. xanthorrhiza F3 10µl  Fraction 3 10µl 
C. xanthorrhiza F4 10µl  Fraction 4 10µl 
C. xanthorrhiza F5 10µl  Fraction 5 10µl 
C. xanthorrhiza F6 10µl  Fraction 6 10µl 
C. xanthorrhiza F7 10µl  Fraction 7 10µl 
C. xanthorrhiza F8 10µl  Fraction 8 10µl 
C. xanthorrhiza F9 10µl  Fraction 9 10µl 
C. xanthorrhiza F10 10µl  Fraction 10 10µl 
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Table 3.4: The design of in vitro hepatoprotective screening of I. aquatica isolated 
fractions  
Group Name TAA 0.04g/ml  Treatment 10µl/ml 
 
Normal control No TAA (10µl medium) DMSO 10µl 
TAA control 10µl  DMSO 10µl 
Silymarin control 10µl  Silymarin 10µl 
I. aquatica F1 10µl  Fraction 1 10µl 
I. aquatica F2 10µl  Fraction 2 10µl 
I. aquatica F3 10µl  Fraction 3 10µl 
I. aquatica F4 10µl  Fraction 4 10µl 
I. aquatica F5 10µl  Fraction 5 10µl 
I. aquatica F6 10µl  Fraction 6 10µl 
I. aquatica F7 10µl  Fraction 7 10µl 
I. aquatica F8 10µl  Fraction 8 10µl 
I. aquatica F9 10µl  Fraction 9 10µl 
I. aquatica F10 10µl  Fraction 10 10µl 
I. aquatica F11 10µl  Fraction 11 10µl 
I. aquatica F12 10µl  Fraction 12 10µl 
I. aquatica F13 10µl  Fraction 13 10µl 
 
3.16 Antioxidants of the cell line treated with the active fractions  
From each plant one isolated fraction which showed best hepatoprotective and 
prevented the oxidative damage were tested for their antioxidant activities. The 
antioxidant activity was measured using the following kits: superoxide dismutase 
(SOD) assay kit (Cayman Chemical Company, USA), catalase (CAT) assay kit 
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(Cayman Chemical Company, USA) and molandialdehyde (MDA) assay kit (Cayman 
Chemical Company according to the manufacturer’s instructions. Briefly, to determine 
the activity of SOD, CAT and lipid peroxidation (MDA), WRL-68 cells were seeded in 
200 µl of RPMI containing 10% FBS with density 3000 cells/ well and incubated at 
37
o
C and 5% CO2 for a day. After 24 hours, using 2.5% DMSO, 10 and 100 µg/ml 
media of fraction which showed the best hepatoprotective results were prepared and 
added to the cells as per the designed experiment (Table 3.5) and incubated for 2 hours. 
The cells were then treated with 10 µl of 0.04g/ml TAA and reincubated for 2 hours. 
Normal control cells was kept with media only, toxin control was kept with 0.04 g/ml 
TAA only and standard drug control (silymarin) was kept with TAA then silymarin at 
the concentrations 10 and 100 µg/ml The cells were then washed three times with PBS 
pH 7.4 and sonicated on ice and the solution was then centrifuged at 13,000 x g for 15 
minutes at 4°C. The obtained supernatants were used to determine intracellular 
antioxidants in a microplate reader at 440 nm for SOD, 540 nm for CAT and 540 nm for 
MAD. The assay was carried out in three separate experiments.   
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Table 3.5: The antioxidant and lipid peroxidation experimental design for cell line 
treated with the active fractions.  
Group Name TAA 0.04g/ml  Treatment 10µl/ml and 
100µl/ml 
Normal control No TAA (10µl medium) DMSO 10µl 
TAA control 10µl  DMSO 10µl 
Silymarin control 10µl  Silymarin 10µl 
Silymarin control 10µl  Silymarin 100µl 
C. xanthorrhiza F5 10µl  Fraction 5 10µl 
C. xanthorrhiza F5 10µl  Fraction 5 100µl 
I. aquatica F11 10µl  Fraction 5 10µl 
I. aquatica F11 10µl  Fraction 5 100µl 
3.17 Active constituents 
The active constituents of the fractions of C. xanthorrhiza and I. aquatica ethanol 
extracts which demonstrated hepatoprotective effects in the cell line experiment were 
identified by using liquid chromatography mass spectrometry (LCMS). The compounds 
from active fractions were identified by comparing with mass spectrometry library. The 
protocol was prepared by the technician at BTS. 
Sample preparation for LC-MS 
Sample concentration used in analysis was 1ug/uL 
For both samples, original sample was dissolved in 100% ACN with 0.1% Formic Acid 
Instrument 
Agilent 1200 Series HPLC system with capillary pump and degasser, micro-well plate 
sampler with thermostat, and Agilent 6520 Accurate-Mass Q-TOF mass spectrometer 
with dual ESI source. 
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LC parameters 
Column Used: Agilent Zorbax SB-C18 (0.5 x 150 mm, 5um). Part no: 5064-8256 
Flow rate: 18uL/min from Agilent 1200 series capillary pump (micro flow) 
Solvents: 0.1% formic acid in water (A); 90% Acetonitrile in water with 0.1% formic 
acid (B) 
Injection volume: 1uL 
Sample analysis: Gradient as shown below, 
 
Time (minutes) B (%) 
Initial 60 
5 60 
30 100 
38 100 
3.18 Selection of xanthorrhizol and violaxanthin for further study 
From the LCMS results of the fractions which showed hepatoprotective, xanthorrhizol 
from fraction 5 of Curcuma xanthorrhiza and violaxanthin from fraction 11 of Ipomoea 
aquatic were selected for further study. The selection of the compounds was based on 
the available information from the previous studies which could be used to infer that 
these compounds may be the main contributor in the hepatoprotective activity of the 
fraction and plant extract as whole. In a recent study violaxanthin isolated from I. 
aquatic has proved to be an excellent free radical scavenger and efficient inhibitor of 
lipid peroxidation. It has shown to be lipid peroxidation inhibitor, particularly in the 
isolated mouse liver cells. In another study, violaxanthin revealed to inhibit activation 
of nuclear factor kappa b (NF-κB).  Nuclear factor kappa b   activation is known to 
trigger the overexpression of proinﬂammatory genes in the nucleus, thereby initiating 
the inﬂammatory processes. On the other hand, xanthorrhizol revealed to have potent 
antioxidant activity and inhibitor of lipid peroxidation. It has also reported that 
xanthorrhizol reduce proinflammatory mediators such as tumor necrosis factor-alpha 
and interleukin-6. Moreover, in a short period study, xanthorrhizol abrogated 
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hepatotoxicity of cisplatin (an anticancer drug which can produce side effects including 
hepatotoxicity).  
3.19 Hepatoprotective effect of xanthorrhizol and violaxanthin against TAA 
cytotoxicity   
The cells were seeded in 200 µl of RPMI containing 10% FBS with density 3000 cells/ 
well and incubated at 37
o
C and 5% CO2 for a day. After 24 hours, using 2.5% DMSO, 
10 µg/ml media of xanthorrhizol and violaxanthin were prepared. The prepared 
compounds were added to the cells as per the designed experiment (Table 3.6) and 
incubated for 2 hours. The cells were then treated with 10 µl of 0.04g/ml TAA. Normal 
control cells was kept with media only, toxin control was kept with 0.04 g.ml TAA only 
and standard drug control (silymarin) was kept with TAA then silymarin at the 
concentrations 10 µg/ml. The cells were incubated for 2 hours and the hepatoprotective 
effects of compounds were determined by cell viability using MTT assay. The assay 
was carried out in three separate experiments.   
 
Table 3.6: The design of in vitro hepatoprotective for cell line treated with xanthorhizol 
and violaxanthin. 
Group Name TAA 0.04g/ml  Treatment 10µl/ml 
 
Normal control No TAA (10µl medium) DMSO 10µl 
TAA control 10µl  DMSO 10µl 
Silymarin control 10µl  Silymarin 10µl 
Xanthorrhizol 10µl  Xanthorrhizol 10µl 
Violaxanthin 10µl  Violaxanthin 10µl 
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3.20 Antioxidant of the cell line treated with xanthorrhizol and violaxanthin 
The antioxidant activity was measured using the following kits: superoxide dismutase 
(SOD) assay kit (Cayman Chemical Company, USA), catalase (CAT) assay kit 
(Cayman Chemical Company, USA) and molandialdehyde (MDA) assay kit (Cayman 
Chemical Company according to the manufacturer’s instructions. Briefly, to determine 
the activity of SOD, CAT and lipid peroxidation (MDA), WRL-68 cells were seeded in 
200 µl of RPMI containing 10% FBS with density 3000 cells/ well and incubated at 
37
o
C and 5% CO2 for a day. After 24 hours, using 2.5% DMSO, 10 and 100 µg/ml 
media of xanthorrhizol and violaxanthin added to the cells as per the designed 
experiment (Table 3.7) and incubated for 2 hours. The cells were then treated with 10 µl 
of 0.04g/ml TAA and reincubated for 2 hours. Normal control cells was kept with 
media only, toxin control was kept with 0.04 g.ml TAA only and standard drug control 
(silymarin) was kept with TAA then silymarin at the concentrations 10 and 100 µg/ml 
The cells were then washed three times with PBS pH 7.4 and sonicated on ice and the 
solution was then centrifuged at 13,000 x g for 15 minutes at 4°C. The obtained 
supernatants were used to determine intracellular antioxidants in a microplate reader at 
440 nm for SOD, 540 nm for CAT and 540 nm for MAD. The assay was carried out in 
three separate experiments.   
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Table 3.7: The antioxidant and lipid peroxidation experimental design for cell line 
treated with xanthorhizol and violaxanthin. 
 
Group Name TAA 0.04g/ml  Treatment 10µl/ml and 
100µl/ml 
Normal control No TAA (10µl medium) DMSO 10µl 
TAA control 10µl  DMSO 10µl 
Silymarin control 10µl  Silymarin 10µl 
Silymarin control 10µl  Silymarin 100µl 
Xanthorrhizol 10µl  Xanthorrhizol 10µl 
Xanthorrhizol 10µl  Xanthorrhizol 100µl 
Violaxanthin 10µl  Violaxanthin 10µl 
Violaxanthin 10µl  Violaxanthin 100µl 
 
3.21 Statistical analysis 
All of the values are reported as mean ± S.E.M. The statistical significance of variations 
between groups was analyzed employing one-way ANOVA pursued by Tukey’s Post-
Hoc test analysis using SPSS version 18 (SPSS Inc. Chicago, IL, USA) with a value of 
p< 0.05 was regarded significant when compared to the control group. 
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CHEPTER IV 
RESULTS 
4.1 DPPH and ABTS radical scavenging capacity of C. xanthorrhiza and I. aquatica 
extracts 
Free radical scavenging efficacy of I. aquatica, C. xanthorrhiza ethanolic extracts and 
the reference standard drug used in the experiment were evaluated by DPPH and ABTS 
assays and the results are presented in the Figure 4.1 and 4.2. As shown in the Figure 
4.1 and 4.2, all the samples exhibited marked free radical scavenging activity expressed 
in terms percentage. In both the assays, Ascorbic acid exhibited highest radical 
scavenging capacity value followed by C. xanthorrhiza extract, BHT, silymarin and I. 
aquatica extract. The DPPH radical scavenging capacity of Ascorbic acid was 
approximately 4 and 1.4 times higher than I. aquatica and C. xanthorrhiza extracts, 
respectively. Similarly, the ABTS radical scavenging capacity of Ascorbic acid was 3 
and 1.2 times higher than I. aquatica and C. xanthorrhiza extracts, respectively. 
However, the DPPH radical scavenging activity of C. xanthorrhiza extract was about 2 
times higher than silymarin the reference standard drug used in liver cirrhosis 
experiment. Similarly, the ABTS radical scavenging capacity of C. xanthorrhiza extract 
is higher than silymarin. 
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Figure 4.1: DPPH radical scavenging activity of C. xanthorrhiza and I. aqatica extracts 
and standards diluted in 25 and 6.25 μg/ml. 
 
 
Figure 4.2: ABTS radical scavenging activity of C. xanthorrhiza and I. aqatica extracts 
and standards diluted in 100 and 25 μg/ml. 
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4.2 Selection of TAA dose for hepatotoxicity induction in WRL-68 cells 
In order to preselect the suitable concentration of thioacetamide for the hepatotoxicity 
induction, cytotoxicity assays of thoiacetamide on WRL-68 cells was carried out. A 
range of TAA concentrations (0.01, 0.02, 0.04, 0.06, 08 and 0.10 g/ml) were tested for 
WRL-68 cells growth inhibition of approximately fifty percent. Cell growth inhibition 
quantified by MTT assay was found to be in dose dependent manner. A concentration of 
0.04 g/ml was found to inhibit 47.6 percent of WRL-68 cells growth and thus it was 
selected for the in vitro hepatoprotective experiment.  
 
 
Figure 4.3: Effects TAA on WRL-68 cell viability treated with a range of TAA 
concentrations.  
 
4.3 In vitro hepatoprotective of crude extracts  
The result of in vitro hepatoprotective experiment showed that C. xanthorrhiza and  I. 
aquatica  crude extracts have the ability to inhibit WRL-68 cell death which induced by 
cytotoxicity effects of TAA. Thioacetamide induced 47 percent death in TAA control as 
compared to normal control. Ethanol crude extract of C. xanthorrhiza at the dose of 10 
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ug/ml significantly increased the cell viability to 81 percent. On the other hand, I. 
aquatica ethanol crude extract showed almost the same results as C. xanthorrhiza. I. 
aquatica ethanol crude extract at the dose of 10 ug/ml significantly increased the cell 
viability to 80 percent. These results show that C. xanthorrhiza and I. aquatica ethanol 
crude extracts at the dose of 10 ug/ml significantly decreased cell death that induced by 
TAA oxidative stress.  
 
 
Figure 4.4: Effect of C. xanthorrhiza and I. aquatica crude extracts on WRL-68 cell 
viability treated with TAA. Data represent mean ± SEM. *p<0.05, significant compared 
to TAA control, **p<0.05, significant compared to normal control. 
 
4.4 Antioxidant of WRL-68 cell treated with crude extracts  
Antioxidant activities of C. xanthorrhiza and I. aquatica crude extracts were studeid in 
WRL-68 normal cell line. The oxidative stress was induced by exposing cells to 
0.04g/ml of TAA. The antioxidant activities of C. xanthorrhiza and I. aquatica crude 
extracts were found to have a positive correlation with the improvement of the cell 
viability. It is apparent that TAA bring about the generation of ROS, which reduced the 
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antioxidant enzymes. Treatment with C. xanthorrhiza and I. aquatica crude extracts 
reduced the free radical and improved the antioxidant enzymes levels. The obtained 
results show that TAA significantly reduced SOD and CAT levels. Treatment with C. 
xanthorrhiza and I. aquatica crude extracts significantly improved the levels of these 
two antioxidant enzymes. At the same time, lipid peroxidation level, determined as 
MDA generation, significantly increased in TAA control group as compared to normal 
control group. Treatment with C. xanthorrhiza and I. aquatica crude extracts 
significantly prevented lipid peroxidation hence low levels of MDA.   
Table 4.1: Effect of C. xanthorrhiza and I. aquatica crude extracts on SOD, CAT and 
MDA on WRL-68 cell treated with TAA. 
 
Group Name SOD U/ml CAT nmol/min/ml MDA nmol/ml 
Normal control 14.34 ± 0.43 6.03 ± 0.41 13.26 ± 1.03 
TAA control 8.048 ± 0.78 ** 2.72 ± 0.23 ** 35.83 ± 1.72 ** 
Silymarin control 10 12.39 ± 0.15 * 4.81 ± 0.20 * 18.00 ± 1.00 * 
Silymarin control 100 13.80 ± 0.70 * 5.34 ± 0.26 * 16.00 ± 1.15 * 
C. xanthorrhiza crude 10 11.91 ± 0.41 * 4.59 ± 0.15 * 23.30 ± 2.12 * 
C. xanthorrhiza crude 100 12.23 ± 0.57 * 4.76 ± 0.10. * 20.03 ± 1.76 * 
I. aquatica crude 10 12.31 ± 0.42 * 4.42 ± 0.19 * 25.43 ± 0.69 * 
I. aquatica crude 100 12.60 ± 0.48 * 4.56 ± 0.20 * 23.40 ± 1.62 * 
 
Data represent mean ± SEM. *p<0.05, significant compared to TAA control, **p<0.05, 
significant compared to normal control. 
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4.5 Acute toxicity study 
In the present study, acute oral toxicity of C. xanthorrhiza and I. aquatica ethanolic 
extracts were evaluated in male as well as female Sprague-Dawley rats for 14 days. 
Each group of animal was orally administered with C. xanthorrhiza and I. aquatica at 
doses of 2 and 5 g/kg, and were kept under observations for 14 days. The animals did 
not manifest any significant signs of toxicity and there were no mortality was at any 
time during the experiment. Histological examination of the kidney and liver tissues 
showed no difference between extracts treated and control groups (Figure 4.5).  
Moreover, serum biochemistry data did not reveal any significant differences between 
extracts treated and control groups (Table 4.2- 4.9). 
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Figure 4.5: Represent acute toxicity histological sections of liver and kidney of different 
groups. Histological section (4.5A and 4.5B) represent control group (vehicle). 
Histological section (4.5C and 4.5D) represent animal group received 5g/kg of C. 
xanthorrhiza extract. Histological section (4.5E and 4.5F) represent animal group 
received 5g/kg of I. aquatica extract (H & E stain 20x).
4.5 A 4.5B 
4.5C 4.5D 
4.5E 4.5F 
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Table 4.2: The results of renal function test of male rats in acute toxicity study of C. xanthorrhiza extract. 
 
 
 
 
 
 
 
Values are expressed as mean ± S.E.M (n=6 rats/group) significant at p<0.05. There are no differences between treated groups and control 
group. CXLD: C. xanthorrhiza low dose, CXHD: C. xanthorrhiza high dose 
 
 
 
 
 
Dose Sodium 
(mmol/l) 
Potassium 
(mmol/l) 
Chloride (mmol/l) Urea (mmol/l) Creatinine 
(µmol/l) 
Vehicle (5 ml/kg) 138.80 ± 2.26 4.41 ± 0.20 101.90 ± 2.61 4.61 ± 0.34 50.81 ± 4.61 
CXLD      (2 g/kg) 137.00 ± 2.69 4.10 ± 0.22 102.36 ± 2.12 4.48 ± 0.33 46.55 ± 5.27 
CXHD      (5 g/kg) 135.95 ± 3.56 4.23 ± 0.25 104.10 ± 1.91 4.53 ± 0.38 49.46 ± 4.33 
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Table 4.3: The results of liver function test of male rats in acute toxicity study of C. xanthorrhiza extract. 
 
 
 
 
 
 
 
 
 
Values are expressed as mean ± S.E.M (n=6 rats/group) significant at p<0.05. There are no differences between treated groups and control 
group. CXLD: C. xanthorrhiza low dose, CXHD: C. xanthorrhiza high dose. TB: total protein, AP: alkaline phosphatase, ALT: alanine 
aminotransferase and AST: aspartate aminotransferase. 
 
 
 
 
 
 
 
 
Dose Total protein 
(g/L) 
Albumin (g/L) TB (mg/dl) AP (IU/L) ALT (IU/L) AST (IU/L) 
Vehicle (5 ml/kg) 69.75 ± 2.97 
 
27.06 ± 1.91 1.39 ± 0.08 77.85 ± 6.85 43.20 ± 3.77 66.11 ± 3.13 
CXLD (2 g/kg) 
 
71.36 ± 3.04 28.33 ± 1.81 1.35 ± 0.09 74.31 ± 5.56 42.50 ± 4.04 68.98 ± 4.91 
CXHD (5 g/kg) 
 
68.05 ± 2.96 26.66 ± 1.63 1.25 ± 0.06 79.65 ± 8.63 45.00 ± 3.67 64.83 ± 6.26 
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Table 4.4: The results of renal function test of female rats in acute toxicity study of C. xanthorrhiza extract. 
 
. 
 
 
 
 
 
Values are expressed as mean ± S.E.M (n=6 rats/group) significant at p<0.05 There are no differences between treated groups and control group. 
CXLD: C. xanthorrhiza low dose, CXHD: C. xanthorrhiza high dose 
 
 
 
 
 
 
 
Dose Sodium 
(mmol/l) 
Potassium 
(mmol/l) 
Chloride (mmol/l) Urea (mmol/l) Creatinine 
(µmol/l) 
Vehicle(5 ml/kg) 136.38 ± 1.70 4.46 ± 0.62 101.56 ± 3.65 4.55 ± 0.44 45.58 ± 5.42 
CXLD (2 g/kg) 137.05 ± 2.59 4.73 ± 0.50 104.31 ± 3.53  4.25 ± 0.45 49.81 ± 4.16 
CXHD (5 g/kg) 134.63 ± 2.32 4.30 ± 0.58 102.10 ± 2.20 4.66 ± 0.50 47.03 ± 3.22 
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Table 4.5: The results of liver function test of female rats in acute toxicity study of C. xanthorrhiza extract 
 
 
 
 
 
 
 
 
 
Values are expressed as mean ± S.E.M (n=6 rats/group) significant at p<0.05. There are no differences between treated groups and control 
group. CXLD: C. xanthorrhiza low dose, CXHD: C. xanthorrhiza high dose.  TB: total protein, AP: alkaline phosphatase, ALT: alanine 
aminotransferase and AST: aspartate aminotransferase. 
 
 
 
 
 
 
 
Dose Total protein 
(g/L) 
Albumin (g/L) TB (mg/dl) AP (IU/L) ALT (IU/L) AST (IU/L) 
Vehicle(5 ml/kg) 
 
68.91 ± 6.16 22.71 ± 2.59 1.81 ± 0.17 68.26 ± 5.40 39.25 ± 3.72 60.85 ± 4.25 
CXLD (2 g/kg) 
 
64.38 ± 5.37 24.86 ± 3.00 1.66 ± 0.29 63.51 ± 8.34 37.78 ± 4.30 59.65 ± 6.13 
CXHD (5 g/kg) 
 
69.08 ± 4.78 21.18 ± 2.26 1.55 ± 0.20 70.23 ± 4.87 35.26 ± 4.90 65.33 ± 6.52 
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Table 4.6: The results of renal function test of male rats in acute toxicity study of I. aquatica extract. 
 
 
 
 
 
 
 
 
 
Values are expressed as mean ± S.E.M (n=6 rats/group) significant at p<0.05 There are no differences between treated groups and control group. 
IALD: I. aquatica low dose, IAHD: I. aquatica high dose 
 
 
 
 
 
 
 
Dose Sodium 
(mmol/l) 
Potassium 
(mmol/l) 
Chloride (mmol/l) Urea (mmol/l) Creatinine 
(µmol/l) 
Vehicle (5 ml/kg) 138.53 ±  2.66  4.30 ± 0.20 102.48 ± 2.92 4.63 ± 0.31 48.08 ± 2.93 
IALD (2 g/kg) 137.33 ±  3.28 4.18 ± 0.21 101.43 ± 2.19 4.53 ± 0.28 47.81 ± 4.35 
IAHD (5 g/kg) 139.66 ±  315 4.40 ± 0.17 104.16 ± 1.95 4.41 ± 0.29 49.66 ± 3.83 
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Table 4.7: The results of liver function test of male rats in acute toxicity study of I. aquatica extract 
 
 
 
 
 
 
 
 
 
Values are expressed as mean ± S.E.M (n=6 rats/group) significant at p<0.05. There are no differences between treated groups and control 
group. IALD: I. aquatica low dose, IAHD: I. aquatica high dose. TB: total protein, AP: alkaline phosphatase, ALT: alanine aminotransferase 
and AST: aspartate aminotransferase. 
 
 
 
 
 
 
 
 
 
Dose Total protein 
(g/L) 
Albumin (g/L) TB (mg/dl) AP (IU/L) ALT (IU/L) AST (IU/L) 
Vehicle (5 ml/kg) 69.45 ± 2.22 25.26 ±1.09 1.33 ± 0.07 73.15 ±6.88 42.13 ±2.95 64.63 ± 3.38 
IALD (2 g/kg) 71.01 ± 3.26 26.16 ±1.32 1.29 ± 0.06 74.03 ±4.42 41.73 ±3.63 65.46 ± 4.86 
IAHD (5 g/kg) 68.05 ± 2.65 24.26 ±1.01 1.32 ± 0.05 76.30 ±4.81 43.35 ±3.34 62.33 ± 7.45 
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Table 4.8: The results of renal function test of female rats in acute toxicity study of I. aquatica extract 
 
 
 
 
 
 
 
 
 
Values are expressed as mean ± S.E.M (n=6 rats/group) significant at p<0.05. There are no differences between treated groups and control 
group. IALD: I. aquatica low dose, IAHD: I. aquatica high dose.  
 
 
 
 
 
 
Dose Sodium 
(mmol/l) 
Potassium 
(mmol/l) 
Chloride (mmol/l) Urea (mmol/l) Creatinine 
(µmol/l) 
Vehicle(5 ml/kg) 137.31± 2.58 4.28 ±0.21 101.28 ±2.14 4.61 ± 0.39 47.01 ± 3.53 
IALD (2 g/kg) 135.48± 2.33 4.20±0.26 102.70±1.18 4.25 ± 0.38 46.66 ± 4.53 
IAHD (5 g/kg) 138.33± 2.29 3.98±0.23 103.05±2.16 4.48 ± 0.42 48.11 ± 5.21 
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Table 4.9: The results of liver function test of female rats in acute toxicity study of I. aquatica extract 
 
 
 
 
 
 
 
 
 
Values are expressed as mean ± S.E.M (n=6 rats/group) significant at p<0.05. There are no differences between treated groups and control 
group. IALD: I. aquatica low dose, IAHD: I. aquatica high dose. TB: total protein, AP: alkaline phosphatase, ALT: alanine aminotransferase 
and AST: aspartate aminotransferase. 
 
 
 
 
 
Dose Total protein 
(g/L) 
Albumin (g/L) TB (mg/dl) AP (IU/L) ALT (IU/L) AST (IU/L) 
Vehicle (5 ml/kg) 
 
69.31 ± 2.77 25.25 ± 1.33 1.25 ± 0.04 75.43 ± 5.32 39.35 ± 3.54 65.63 ± 3.58 
IALD (2 g/kg) 
 
70.73 ± 2.43 24.28 ± 1.32 1.20 ± 0.05 74.38 ± 4.83 38.45 ± 2.69 63.73 ± 4.04 
IAHD (5 g/kg) 
 
68.68 ± 3.11 23.43 ± 1.02 1.19 ± 0.05 77.01 ± 3.89 41.13 ± 3.84 62.26 ± 6.08 
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4.6 Hepatoprotective study of the crude extracts  
4.6.1 Liver index measurement 
Normal growth of the experimental animal was evaluated by measuring the initial and 
final body weight, which was also useful to determine liver index [Liver weight 
(LW)/body weight (BW) %]. Initially prior to experiment, animal weighed between 
195 to 215 g of the average body weight. After eight weeks of treatment the body 
weight of C. xanthorrhiza extract low dose group, high dose group, silymarin group 
and normal control group increased to reach 274, 281, 288 and 321, respectively 
(Table 4.10). As shown in Table 4.11, the body weight of I. aquatica extract low dose 
group, high dose group, silymarin group and normal control group increased to reach 
276, 282, 287 and 308, respectively. However, the cirrhosis control groups showed 
significantly retardation in the body weight growth (Table 4.10 and 4.11). Liver 
weight in proportion to the body weight was estimated by calculating the liver index 
[Liver weight (LW)/body weight (BW) %]. Liver index showed significant 
differences (p<0.05) between the drug treated groups compared to cirrhosis control 
groups (Table 4.10 and 4.11). TAA induced toxicity altered the normal growth patten 
(body weight and liver weight) of the animals. Where as, C. xanthorrhiza and I. 
aquatica extracts and silymarin treatments improved the the normal animal growth 
patten. 
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Table 4.10: Effect of C. xanthorrhiza extract on the liver index of experimental rats.  
 
Group 
Body weight   
 (gm) 
Liver weight   
 (gm) 
Liver index  
(LW/BW %) 
Normal control                  
(10% Tween 20) 
321 ± 22.17 8.53 ± 0.41 2.68 ± 0.13 
Cirrhosis control (TAA) 196 ± 15.12** 9.43 ± 0.15 4.95 ± 0.41** 
Silymarin control (50 mg/kg)  288 ± 17.47* 8.44 ± 0.59 2.93 ± 0.14* 
C. xanthorrhiza (250 mg/kg) 274 ± 16.54* 9.01 ± 0.48 3.31 ± 0.18* 
 C. xanthorrhiza (500 mg/kg) 281 ± 19.23* 8.66 ± 0.49 3.12 ± 0.20* 
 
Data represent mean ± SEM. *p<0.05, significant compared to cirrhosis control 
group, **p<0.05, significant compared to normal control group. 
 
 
Table 4.11: Effect of I. aquatica extract on the liver index of experimental rats. 
 
 Group 
Body weight   
 (gram) 
Liver weight   
 (gram) 
Liver index  
(LW/BW %) 
Normal control  (Distilled 
water) 
308 ± 21.76 7.85 ± 0.58 2.55 ± 0.11 
Cirrhosis control (TAA) 201 ± 16.48** 10.19 ± 0.98 5.04 ± 0.20** 
Silymarin control (50 mg/kg)  287 ± 15.85* 8.98 ± 0.64 3.12 ± 0.14* 
I. aquatica (250 mg/kg) 276 ± 17.55* 9.83 ± 0.87 3.53 ± 0.15* 
 I. aquatica (500 mg/kg) 282 ± 17.31* 8.56 ± 0.65 3.02 ± 0.12* 
 
Data represent mean ± SEM. *p<0.05, significant compared to cirrhosis control 
group, **p<0.05, significant compared to normal control group. 
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4.6.2 Results of serum biochemical parameters of the liver 
The effects of ethanolic extracts of C. xanthorrhiza and I. aquatica on TAA induced 
liver cirrhosis in rats was determined by measuring serum levels of specific liver 
biochemical parameters (Figure 4.6- 4.11). There were significant (p< 0.05) increase 
in serum ALP, AST and ALT in TAA treated rats, which were 3-4 times higher 
compared to normal control and silymarin and also C. xanthorrhiza and I. aquatica 
treatments (Figure 4.6 and 4.7). The observed a significant increase in serum ALP, 
AST and ALT due to the intoxication by TAA was restored by treatment with C. 
xanthorrhiza as well I. aquatica in a dose-dependent manner. As shown in Figure 4.4 
and 4.5, C. xanthorrhiza and I. aquatica extracts at higher dose of 500 mg/kg restored 
serum levels of ALP, AST and ALT, which were comparable to silymarin control 
groups (50 mg/kg). Also, the exhibited result was better than their respective lower 
dose (250 mg/kg).  
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Figure 4.6: Effect of C. xanthorrhiza extract on serum liver enzymes of experimental 
rats. Data represent mean ± SEM. *p<0.05, significant compared to cirrhosis control 
group, **p<0.05, significant compared to normal control group. 
ALP alkaline phosphatase; AST aspartate transferase; ALT alanine transferase. 
 
 
 
Figure 4.7: Effect of I. aquatica extract on serum liver enzymes of experimental rats. 
Data represent mean ± SEM. *p<0.05, significant compared to cirrhosis control 
group, **p<0.05, significant compared to normal control group. 
ALP alkaline phosphatase; AST aspartate transferase; ALT alanine transferase. 
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As shown in Figure 4.8 and 4.9, long-term administration of TAA (cirrhosis control 
group) significantly decreased the total protein and albumin level compared to normal 
control group, indicating the occurrence of acute liver damage. However, treatment of 
animals with silymarin, C. xanthorrhiza and I. aquatica extracts increased the levels 
of total protein and albumin toward normal control group. Both these plant extracts at 
a dose of 500 mg/kg significantly restored the altered liver parameters and the effect 
was more resemble to that of standard drug silymarin.  
 
 
Figure 4.8: Effect of C. xanthorrhiza extract on serum liver biomarkers of 
experimental rats.  Data represent mean ± SEM. *p<0.05, significant compared to 
cirrhosis control group, **p<0.05, significant compared to normal control group. 
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Figure 4.9: Effect of I. aquatica extract on serum liver biomarkers of experimental 
rats.  Data represent mean ± SEM. *p<0.05, significant compared to cirrhosis control 
group, **p<0.05, significant compared to normal control group. 
 
 
Figure 4.10 and 4.11 represents the effect of silymarin, C. xanthorrhiza and I. 
aquatica extracts on bilirubin levels in TAA induced liver damage. It is evident from 
Figure 4.10 and 4.11 that the elevated levels of bilirubin due TAA intoxication were 
significantly reduced in the animal groups treated with silymarin, C. xanthorrhiza and 
I. aquatica extracts. Both extracts exhibited dose dependent decrease in the bilirubin 
level with I. aquatica extract showing superior effect in comparison with C. 
xanthorrhiza extract and was as effective as the silymarin.  
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Figure 4.10: Effect of C. xanthorrhiza extract on serum total bilirubin of experimental 
rats.  Data represent mean ± SEM. *p<0.05, significant compared to cirrhosis control 
group, **p<0.05, significant compared to normal control group. 
 
 
 
Figure 4.11: Effect of I. aquatica extract on serum total bilirubin of experimental rats.   
Data represent mean ± SEM. *p<0.05, significant compared to cirrhosis control 
group, **p<0.05, significant compared to normal control group. 
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4.6.3 Gross morphology 
Macroscopic appearance of rat livers representing different groups of experimental rat 
model of TAA-induced cirrhosis is presented Figure 4.12 and 4.13. Normal control 
group (4.12A and 4.13A) shows normal smooth surfaces liver and without any 
irregularities.  The liver of the cirrhosis control group as a result of long-term 
administration of TAA develops irregular shape and occupied by uniform formations 
of micronodules and macronodules (4.12B and 4.13B). This kind of nodular 
transformations is typical signature of the TAA induced liver cirrhosis in the rat which 
is also seen in human nodular cirrhosis. The treatment of both doses of C. 
xanthorrhiza and I. aquatica extract (250 mg/kg and 500 mg/kg) particularly 500 
mg/kg (4.12E and 4.13E) and silymarin (4.12C and 4.13C) preserved the  anatomical 
shape and appearance of the liver nearly to normal and prevented the formation of 
macro- and micronodules.  
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Figure 4.12: Macroscopic appearance of rat livers representing different groups of an 
experimental model of TAA-induced cirrhosis. The liver of normal control group 
(4.12A) shows smooth surface of the liver. The liver of cirrhosis control group 
(4.12B) shows irregular surface and macronodular cirrhosis of the liver. Silymarin 
contol group (4.12C) shows smooth surface of the liver. (4.12D) The liver of the 
group 250 mg/kg of C. xanthorrhiza extract shows to some extent smooth surface of 
the liver. (4.12E) The liver of the group received 500 mg/kg of C. xanthorrhiza 
extract shows smooth surface of the liver. 
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Figure 4.13: Macroscopic appearance of rat livers representing different groups of 
experimental model of TAA-induced cirrhosis. The liver of normal control group 
(4.13A) shows smooth surface of the liver. The liver of cirrhosis control group 
(4.13B) shows irregular surface and macronodular cirrhosis of the liver. Silymarin 
control group (4.13C) shows smooth surface of the liver. (4.13D). The liver of the 
group received 250 mg/kg of I. aquatica extract shows to some extent smooth surface 
of the liver. (4.13E) The liver of the group 500 mg/kg of I. aquatica extract shows 
smooth surface of the liver. 
 
4.6.4 Histopathological and special stain examination  
Histological studies were carried out to determine the TAA induced liver damage and 
to determine the hepatoprotective activity of C. xanthorrhiza and I. aquatica extracts. 
After eight weeks treatment with TAA alone and in combination with silymarin, 
lower and higher dose of C. xanthorrhiza and I. aquatica extracts, liver sections were 
evaluated for the histological examination using H & E as well as Masson’s trichome 
staining methods. Immunohistochemical staining was used for alpha smooth muscle 
actin (α-SMA) to determine the extent of hepatic stellate cells activation.  
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Light micrographs of the rat liver sections representing different groups of 
experimental rat model of TAA-induced cirrhosis are presented in Figure 14 and 15. 
The liver section representing normal control group (4.14A and 4.15A) appeared 
regular with normal cellular architecture and totally free of any kind of pathology. 
The polygonal hepatic cells display intact cytoplasm, sinusoidal spaces, visible 
nucleus, nucleolus and central vein. The section of cirrhosis control group (4.14B and 
4.15B) confirms liver damage as demonstrated by the presence of inflammation and 
necrosis. The normal architecture of the liver parenchyma is totally damage with 
collagen bridges between hepatic triads and the formation of regenerative nodules of 
hepatocytes or necrosis and fibrotic septa between the nodules. The liver tissue 
section of silymarin control group (4.14C and 4.15C) shows lesser pathology as 
compared to the extensive liver damage found in the cirrhosis control group and 
therefore protected hepatocyte and architecture with smaller section of mild necrosis. 
(4.14C and 15D) The tissue section of the liver of the group received 250 mg/kg of C. 
xanthorrhiza and I. aquatica extract shows partly protected architecture and 
hepatocyte with smaller section of necrosis and fibrotic septa (4.14E and 15E). The 
tissue section of the liver of the group received 500 mg/kg of C. xanthorrhiza and I. 
aquatica extract shows considerably less pathology when compared with the 
extensive liver damage found in the cirrhosis control group and therefore protected 
architecture and hepatocyte with smaller section of mild necrosis (hematoxylin and 
eosin stain magnification 20x). 
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Figure 4.14: Light micrographs of the rat liver sections representing different groups 
of an experimental model of TAA-induced cirrhosis. The liver tissue section of 
normal control group (4.14A) shows central vein with cords of normal liver cells 
radiating from it. The liver tissue section of cirrhosis control group (4.14B) shows 
severe damage, fibrous bands and nodular liver. The liver tissue section of silymarin 
control group (4.14C) shows shows partly protected architecture and hepatocyte with 
smaller section of mild necrosis. (4.14D) The tissue section of the liver of the group 
received 250 mg/kg of C. xanthorrhiza extract shows partly protected architecture and 
hepatocyte with smaller section of necrosis and fibrotic septa (4.14E). The tissue 
section of the liver of the group received 500 mg/kg of C. xanthorrhiza extract shows 
partly protected architecture and hepatocyte with smaller section of mild necrosis 
(hematoxylin and eosin stain magnification 20x). 
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Figure 4.15: Light micrographs of the rat liver sections representing different groups 
of an experimental model of TAA-induced cirrhosis. The liver tissue section of 
normal control group (4.15A) shows central vein with cords of normal liver cells 
radiating from it. The liver tissue section of cirrhosis control group (4.15B) shows 
severe damage, fibrous bands and nodular liver. The liver tissue section of silymarin 
control group (4.15C) shows partly protected architecture and hepatocyte with smaller 
section of mild necrosis. (4.15D) The tissue section of the liver of the group received 
250 mg/kg of I. aquatica extract shows partly protected architecture and hepatocyte 
with smaller section of necrosis and fibrotic septa . (4.15E). The tissue section of the 
liver of the group treated with 500 mg/kg of I. aquatica extract shows partly protected 
architecture and hepatocyte with smaller section of mild necrosis (hematoxylin and 
eosin stain magnification 20x). 
 
 
Masson’s trichome staining of liver sections was employed to evaluate the deposition 
of collagen induced by TAA treatment. This staining method normally detects the 
collagen distribution in the fibrous liver. Figure 4.16 and 4.17 represents the influence 
of silymarin, lower and higher dose of C. xanthorrhiza and I. aquatica extracts. Liver 
sections of normal control group show normal hepatocytes without any collagen 
deposition (4.16A and 4.17A). Liver section of rats intoxicated with TAA shown 
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4.15D 4.15E 
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severe liver damage with the apparent collagen fibrous band deposition (4.16B and 
4.17B). The hepatohistological changes induced by TAA were dramatically 
ameliorated by treatment with silymarin, C. xanthorrhiza and I. aquatica extracts (500 
mg/kg) which shown mild collagen deposition. However, plant extracts at the lower 
dose of 250 mg/kg displayed moderate collagen deposition in the liver Masson’s 
trichome staining method. 
 
   
 
  
 
Figure 4.16: Light micrographs of the rat liver sections representing masson’s 
trichrome staining of collagen deposition from different groups of an experimental 
model of TAA-induced cirrhosis. The liver tissue section of normal control group 
(4.16A) shows normal hepatocyte and architecture of the liver without any collagen 
deposition. The liver tissue section of cirrhosis control group (4.16B) shows severe 
damage and green blue collagen fibrous bands. The liver tissue section of silymarin 
control group (4.16C) shows mild collagen fibrotic septa deposition. (4.16D) The 
tissue section of the liver of the group treated with 250 mg/kg of C. xanthorrhiza 
extract shows moderate collagen fibrotic septa. (4.16E) The tissue section of the liver 
of the group received 500 mg/kg of C. xanthorrhiza extract shows mild collagen 
fibrotic septa deposition (Masson’s trichrome stain magnification 20x). 
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Figure 4.17: Light micrographs of the rat liver sections representing masson’s 
trichrome staining of collagen deposition from different groups of an experimental 
model of TAA-induced cirrhosis. The liver tissue section of normal control group 
(4.17A) shows normal hepatocyte and architecture of the liver without any collagen 
deposition. The liver tissue section of cirrhosis control group (4.17B) shows severe 
damage and green blue collagen fibrous bands. The liver tissue section of silymarin 
control group (4.17C) shows mild collagen fibrotic septa deposition. (4.17D) The 
tissue section of the liver of the group received 250 mg/kg of I. aquatica extract 
shows moderate collagen fibrotic septa. (4.17E) The tissue section of the liver of the 
group received 500 mg/kg of I. aquatica extract shows mild collagen fibrotic septa 
deposition (Masson’s trichrome stain magnification 20x). 
 
 
To evaluate the effectiveness of C. xanthorrhiza and I. aquatica on hepatic stellate 
cell (HSC) indirectly activation, liver tissues of the animals were subjected for 
immunofluorescence staining (Figure 4.18 and 4.19). Alpha smooth muscle actin (α-
SMA) is considered as a marker of activated HSC. As can be seen in Figure 4.16A 
and 4.17A, the normal control group shows negative staining of α-SMA. Whereas the 
number of positively stained α-SMA cells was increased around fibrotic septa in the 
liver sections of cirrhosis control (Figure 4.18 B and 4.19 B). This reveals that TAA 
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intoxication stimulates the HSC in the liver of the rat models. Concurrent treatments 
with a lower dose (250 mg/kg) of C. xanthorrhiza and I. aquatica for eight weeks 
displayed moderate number of positive stains for α-SMA (Figure 4.18D and 4.19D). 
The number of positively α-SMA cells was dramatically reduced in the liver tissues of 
the animals treated with silymarin (4.18C and 4.19C), C. xanthorrhiza and I. aquatic 
in a dose dependent manner, possibly by improving antioxidant status and suppressing 
proinflammatory mediators therefore reduce the number of activated HSC. 
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Figure 4.18:  Light micrographs of the rat liver sections representing 
immunohistochemical staining of α-SMA from different groups of an experimental 
model of TAA-induced cirrhosis. The liver tissue section of normal control group 
(4.18A) shows negative staining of α-SMA.  The liver tissue section of cirrhosis 
control group (4.18B) shows strong positivity for α-SMA. The liver tissue section of 
silymarin control group (4.18C) shows mild positive stain for α-SMA. (4.18D) The 
tissue section of the liver of the group received 250 mg/kg of C. xanthorrhiza extract 
shows moderate positivity for α-smooth muscle actin.  (4.18E) The tissue section of 
the liver of the group received 500 mg/kg of C. xanthorrhiza extract shows mild 
positive stain for α-SMA (α-SMA stain magnification 100x).  
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Figure 4.19:  Light micrographs of the rat liver sections representing 
immunohistochemical staining of α-SMA from different groups of an experimental 
model of TAA-induced cirrhosis. The liver tissue section of normal control group 
(4.19A) shows negative staining of α-SMA.  The liver tissue section of cirrhosis 
control group (4.19B) shows strong positivity for α-smooth muscle actin. The liver 
tissue section of silymarin control group (4.19C) shows mild positive stain for α-
SMA.  (4.19D) The tissue section of the liver of the group received 250 mg/kg of I. 
aquatica extract shows moderate positivity for α-SMA.  (4.19E) The tissue section of 
the liver of the group received 500 mg/kg of I. aquatica extract shows mild positive 
stain for α-SMA (α-SMA stain magnification 100x).  
 
4.7 SOD, CAT and MDA contents in liver homogenates   
Antioxidant enzyme status and oxidative stress induced by the TAA in the liver of 
experimental rats were determined by measuring the amount of superoxide dismutase 
(SOD), catalase (CAT) and also malondialdehyde (MDA). Table 4.12 and 4.13 clearly 
reveals the influence of C. xanthorrhiza and I. aquatica extracts on SOD, CAT and 
MDA contents in liver homogenates of experimental rats, respectively. In the liver 
tissues of cirrhosis control group, the antioxidant enzymes SOD and CAT were 
significantly (p<0.05) reduced in comparison with the normal control group. 
Conversely, SOD and CAT were increased significantly (p<0.05) in the liver tissues 
of animals treated with C. xanthorrhiza, I. aquatica extract and silymarin when 
4.19A 4.19B 4.19C 
4.19D 4.19E 
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compared with cirrhosis control group (Table 4.12 and 4.13). At the tested doses (250 
and 500 mg/kg. p.o), C. xanthorrhiza and I. aquatica extracts exhibited the dose 
dependent increase in the antioxidant enzyme level toward normal control group.  
 
Table 4.12: Effect of C. xanthorrhiza extract on SOD, CAT and MDA contents in 
liver homogenates of experimental rats.  
 
    Group SOD 
U/mg protein 
CAT 
U/mg protein 
MDA 
nmol/mg 
protein 
Normal control  19.07 ± 1.24 39.89 ± 3.35 1.32 ± 0.10 
Cirrhosis control 7.17 ± 0.44** 17.55 ± 0.91** 4.64 ± 0.32** 
Silymarin control 14.66 ± 0.48* 35.45 ± 2.67* 1.62 ± 0.15* 
C. xanthorrhiza (250 mg/kg) 13.62 ± 1.02* 26.89 ± 2.07* 2.41 ± 0.27* 
 C. xanthorrhiza (500 mg/kg) 15.79 ± 1.20* 37.20 ± 3.18* 1.70 ± 0.16* 
 
Data represent mean ± SEM. *p<0.05, significant compared to cirrhosis control 
group, **p<0.05, significant compared to normal control group. 
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Table 4.13: Effect of I. aquatica extract on SOD, CAT and MDA contents in liver 
homogenates of experimental rats.  
 
    Group SOD 
U/mg protein 
CAT 
U/mg protein 
MDA 
nmol/mg 
protein 
Normal control  18.03 ± 0.24 38.76 ± 0.32 1.19 ± 0.04 
Cirrhosis control  8.63 ± 0.32** 18.73 ± 0.32** 4.80 ± 0.06** 
Silymarin control   14.68 ± 0.21* 37.13 ± 0.40* 1.7 ± 0.04* 
I. aquatica (250 mg/kg) 12.41 ± 0.27* 26.46 ± 0.64* 2.33 ± 0.0* 
 I. aquatica (500 mg/kg) 14.56 ± 0.29* 37.95 ± 0.24* 1.40 ± 0.09* 
 
Data represent mean ± SEM. *p<0.05, significant compared to cirrhosis control 
group, **p<0.05, significant compared to normal control group. 
 
4.8 Effect of the plant extracts on TNF-α, TG-Fβ1 and NF-κB 
Table 4.14 and 4.15 represents the effect of C. xanthorrhiza and I. aquatica extracts 
on the inflammatory cytokines such as TNF-α, TG-Fβ1 and NF-κB. As shown in 
Table 4.14 and 4.15, animals treated with TAA exhibited a significant increase of the 
amount of TNF -α, TG-Fβ1 and NF-κB and these values were almost 2, 4 and 3 times 
higher than the normal control groups, respectively. However, the amount of TNF-α, 
TG-Fβ1 and NF-κB was significantly decreased in the livers of the TAA and extracts 
cotreated animals. The treatment of C. xanthorrhiza and I. aquatica at the dose of 500 
mg/kg reduced the TNF-α, TG-Fβ1 and NF-κB to the levels similar to that of the 
silymarin control group which represents that these plant extracts have the ability to 
inhibit the expression of cytokines biomarkers in TAA induced liver cirrhosis. 
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Table 4.14: Effect of C. xanthorrhiza extract on serum level of TNF alpha, TG-Fβ1 
and  liver tissue (homogenate) NF-κB of experintal rats.  
 
Group TNF α pg/ml TGFβ1 ng/ml NF-κB ng/ml 
Normal control 16.23 ± 0.68 0.97 ± 0.05 1.23 ± 0.11 
Cirrhosis control  30.73 ± 1.85** 4.31 ± 0.30** 3.23 ± 0.23** 
Silymarin control  17.35 ± 1.49* 1.52 ± 0.13* 1.37 ± 0.17* 
C. xanthorrhiza (250 mg/kg) 23.34 ± 2.42* 1.75 ± 0.16* 1.73 ± 0.14* 
C. xanthorrhiza (500 mg/kg) 18.48 ± 1.78* 1.33 ± 0.14* 1.50 ± 0.15* 
 
Data represent mean ± SEM. *p<0.05, significant compared to cirrhosis control 
group, **p<0.05, significant compared to normal control group. 
 
 
Table 4.15: Effect of I. aquatica extract on serum level of TNF alpha, TG-Fβ1 and  
liver tissue (homogenate) NF-κB of experintal rats. 
 
Group TNF α pg/ml 
 
TGFβ1 ng/ml 
 
NF-kB ng/ml 
Normal control 15.64 ± 0.66 1.11 ± 0.07 1.16 ± 0.10 
Cirrhosis control  32.42± 2.18** 4.05 ± 0.47** 3.06 ± 0.19** 
Silymarin control  16.85± 1.10* 1.62 ± 0.10* 1.33 ± 0.09* 
I.aquatica (250 mg/kg) 19.67± 1.37* 1.81 ± 0.14* 1.59 ± 0.11* 
 I. aquatica (500 mg/kg) 17.27± 1.17* 1.53 ± 0.17* 1.32 ± 0.13* 
 
Data represent mean ± SEM. *p<0.05, significant compared to cirrhosis control 
group, **p<0.05, significant compared to normal control group. 
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4.9 In vitro hepatoprotective of isolated fractions 
The result of in vitro hepatoprotective screening showed that the fractions isolated 
from C. xanthorrhiza and  I. aquatic, to different degree,  have the ability to inhibit 
WRL-68 cell death which induced by cytotoxicity effects of TAA. Thioacetamide 
induced 47 percent death in TAA control as compared to normal control. The results 
of the 10 fractions of C. xanthorrhiza showed that fraction number 5 (C. xanthorrhiza 
F5) was the most effective fraction which at the dose of 10 ug/ml significantly 
increased the cell viability to 85 percent. On the other hand, isolated fractions from I. 
aquatica showed almost the same results as the ones isolated from C. xanthorrhiza. 
Among the 13 fractions of I. aquatica, fraction number 11 (. I. aquatica F11) was the 
most effective which at the dose of 10 ug/ml significantly increased the cell viability 
to 86.7 percent. These results show that fraction number 5 from C. xanthorrhiza and 
fraction number 11 from I. aquatica were more effective than the crudes in preventing 
TAA oxidative stress and therefore cell death.   
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Figure 4.20: Effect of C. xanthorrhiza isolated fractions (F1 – F10) on WRL-68 cell 
viability treated with TAA. Data represent mean ± SEM. *p<0.05, significant 
compared to TAA control, **p<0.05, significant compared to normal control. 
 
 
Figure 4.21: Effect of I. aquatica isolated fractions (F1-13) on WRL-68 cell viability 
treated with TAA. Data represent mean ± SEM. *p<0.05, significant compared to 
TAA control, **p<0.05, significant compared to normal control. 
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4.10 Antioxidant of WRL-68 cell treated with active fractions 
Antioxidant results of isolated fractions from C. xanthorrhiza and I. aquatica crude 
extracts which showed best hepatoprotective and prevented cell death in WRL-68 
cell. The oxidative stress was induced by exposing cells to 0.04g/ml of TAA. The 
antioxidant activities of fraction 5 and 11 from C. xanthorrhiza and I. aquatic, 
respectively, were found to have a positive correlation with the improvement of the 
cell viability. It is apparent that TAA bring about the generation of ROS, which 
reduced the antioxidant enzymes. Treatment with these fractions reduced the free 
radical and improved the antioxidant enzymes levels. The obtained results show that 
TAA significantly reduced SOD and CAT levels. Treatment with active fractions 
significantly improved the levels of these two antioxidant enzymes. At the same time, 
lipid peroxidation level, determined as MDA generation, significantly increased in 
TAA control group as compared to normal control group. Treatment with active 
fractions significantly prevented lipid peroxidation hence low levels of MDA.   
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Table 4.16: Effect of C. xanthorrhiza isolated fraction 5 (F5) and  I. aquatica isolated 
fraction 11 (11) on SOD, CAT and MDA on WRL-68 cell treated with TAA. 
 
Group Name SOD U/ml CAT nmol/min/ml MDA nmol/ml 
Normal control 14.34 ± 0.43 6.03 ± 0.41 13.26 ± 1.03 
TAA control 8.048 ± 0.78 ** 2.72 ± 0.23 ** 35.83 ± 1.72 ** 
Silymarin control 10 12.39 ± 0.15 * 4.81 ± 0.20 * 18.00 ± 1.00 * 
Silymarin control 100 13.80 ± 0.70 * 5.34 ± 0.26 * 16.00 ± 1.15 * 
C. xanthorrhiza F5 10 11.97 ± 0.26 * 4.76 ± 0.15 * 21.00 ± 1.32 * 
C. xanthorrhiza F5 100 12.73 ± 0.84 * 4.99 ± 0.16 * 18.00 ± 0.75 * 
I. aquatica F11 10 12.35 ± 0 39 * 4.75 ± 0.18 * 19.43 ± 2.05 * 
I. aquatica F11 100 
 
13.16 ± 0.63 * 5.13 ± 0.34 * 17.66 ± 1.01 * 
 
Data represent mean ± SEM. *p<0.05, significant compared to TAA control, 
**p<0.05, significant compared to normal control. 
4.11 LCMS for the identification of active constituents of the active fractions 
In order to identify the active constituents of the Curcuma xanthorrhiza fraction 5 
(F5) and Ipomoea aquatica fraction 11 (F11), LCMS was applied using negative and 
positive mode ionization. All identified peaks are presented in negative and positive 
mode ionization in Figure 4.22 to 4.25.  Table 4.17 to 4.20 present tentative 
compounds of the identified peaks detected with their retention time, observed m/z, 
mass and formula. Among the active constituents are xanthorrhizol from Curcuma 
xanthorrhiza fraction 5 and violaxanthin from the Ipomoea aquatica fraction 11. In 
the LCMS positive mode peak 7 (cpd 7) represents xanthorrhizol of the Curcuma 
xanthorrhiza fraction 5 (Figure 4.23). Whereas the LCMS negative mode peak 3 (cpd 
3) represents violaxanthin of the Ipomoea aquatica fraction 11 (Figure 4.24).  
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Figure 4.23: LCMS of Curcuma xanthorrhiza fraction 5 (F5) peaks in negative mode ionization. The details of the identified compounds are 
presented in Table 4.17.  cpd: Compound 
 
Cpd 1 
Cpd 2,3,4 
Cpd 5,6 
Cpd 7,8 
Cpd 9 
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 Table 4.17: Present the result of negative mode ionization LCMS of Curcuma xanthorrhiza fraction 5 (F5).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peak  Label Formula Score Mass m/z RT 
cpd 1 Loxoprofen Metabolite (Benzeneacetic acid, 4-[(2-
hydroxycyclopentyl)methyl]-a-methyl-, [1S-[1a(R*),2 
C15 H20 O3 97.46 248.14 249.15 2.26 
cpd 2 Loxoprofen Metabolite (Benzeneacetic acid, 4-[(2-
hydroxycyclopentyl)methyl]-a-methyl-, [1S-[1a(R*),2 
C15 H20 O3 94.44 248.14 249.15 3.46 
cpd 3 Loxoprofen C15 H18 O3 98.41 246.13 247.13 3.47 
cpd 4 3alpha-Hydroxy-4,4-Bisnor-8,11,13-Podocarpatriene C15 H20 O 92.95 216.15 217.16 3.73 
cpd 5 Punctaporin B C15 H24 O3 99.17 252.17 253.18 5.24 
cpd 6 Helenine C15 H20 O2 99.81 232.15 233.15 5.38 
cpd 7 Nabumetone C15 H16 O2 99.97 228.12 229.12 6.46 
cpd 8 helenine C15 H20 O2 99.15 232.15 233.15 6.52 
cpd 9 Trichodiene C15 H24 99.99 204.19 205.2 10.63 
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Figure 4.24: LCMS of Curcuma xanthorrhiza fraction 5 (F5) peaks in positive mode ionization. The details of the identified compounds are 
presented in Table 4.18.  cpd: Compound 
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Table 4.18: Present the result of positive mode ionization LCMS of Curcuma xanthorrhiza fraction 5 (F5).   
  
 
Compound 
 
Label Formula Score Mass m/z RT 
cpd 1 Gemfibrozil C15 H22 O3 98.56 250.16 249.15 3.38 
cpd 2 Lactone of PGF-MUM C16 H24 O5 97.35 296.16 295.16 3.41 
cpd 3 Cucurbitacin S C30 H42 O6 99.36 498.3 497.29 3.52 
cpd 4 2,4-Pentadienoic acid, 3-methyl-5-(2,6,6-trimethyl-3-oxo-1-
cyclohexen-1-yl)- 
C15 H20 O3 99.7 248.14 247.13 3.55 
cpd 5 Helenine C15 H20 O2 99.77 232.15 231.14 3.65 
cpd 6 Artemether C16 H26 O5 99.68 298.18 297.17 3.83 
cpd 7 Xanthorizol C15 H22 O 99.54 218.17 217.16 13.56 
cpd 8 20-Dihydrodexamethasone C22 H31 F O5 98.35 394.22 393.21 21.79 
cpd 9 Milbemycin A3 C31 H44 O7 38.34 528.31 527.3 23.04 
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Figure 4.25: LCMS of Ipomoea aquatica fraction 11 (F11) peaks in negative mode ionization. The details of the identified compounds are 
presented in Table 4.19.  cpd: Compound 
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Table 4.19: Present the result of negative mode ionization LCMS of Ipomoea aquatica fraction 11 (F11). 
 
Compound Label Formula Score Mass m/z RT 
cpd 1 Umbelliferone C9 H6 O3 97.14 162.03 163.04 1.49 
cpd 2 Methyl jasmonate C13 H20 O3 96.68 224.14 225.15 1.51 
cpd 3  Violaxanthin C40H56O4 92.62 600.85 601.4 2.64 
cpd 4 Tetranor Iloprost C18 H26 O4 99.8 306.18 307.19 2.68 
cpd 5 9-deoxy-9-methylene-PGE2 C21 H34 O4 99.2 350.25 351.25 3.52 
cpd 6 gamma-Linolenic acid C18 H30 O2 99.97 278.22 279.23 8.3 
cpd 7 13(S)-HOTrE(gamma) C18 H30 O3 99.72 294.22 295.23 9.86 
cpd 8 3alpha-Hydroxy-4,4-Bisnor-8,11,13-
Podocarpatriene 
C15 H20 O 98.94 216.15 217.16 10.62 
cpd 9 1-hexadecanoyl-sn-glycerol C19 H38 O4 99.95 330.28 331.28 21.88 
cpd 10 Harderoporphyrin C35 H36 N4 O6 99.41 608.26 609.27 22.23 
cpd 11 Oleamide C18 H35 N O 99.89 281.27 282.28 24.47 
cpd 12 1-octadecanoyl-rac-glycerol C21 H42 O4 99.67 358.31 359.32 28.41 
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Figure 4.26: LCMS of Ipomoea aquatica fraction 11 (F11) peaks in positive mode ionization. The details of the identified compounds are 
presented in Table 4.20.  cpd: Compound 
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Table 4.20: Present the result of positive mode ionization LCMS of Ipomoea aquatica fraction 11 (F11). 
 
Compound Label Formula Score Mass m/z RT 
cpd 1 Isoquinoline N-oxide C9 H7 N O 99.85 145.05 144.05 1.61 
cpd 2 Traumatic acid C12 H20 O4 99.9 228.14 227.13 1.73 
cpd 3 8,13-dihydroxy-9,11-octadecadienoic acid C18 H32 O4 99.61 312.23 311.22 2.78 
cpd 4 13S-hydroxy-9E,11Z-octadecadienoic acid C18 H32 O3 97.05 296.24 295.23 8.51 
cpd 5 12-oxo-9-octadecynoic acid C18 H30 O3 99.24 294.22 293.21 10.16 
cpd 6 12-oxo-9-octadecynoic acid C18 H30 O3 99.51 294.22 293.21 11.35 
cpd 7 13(S)-HOTrE(gamma) C18 H30 O3 99.72 294.22 295.23 9.86 
cpd 8 2-acetoxy-butanedioic acid bis-(2-ethyl-hexyl) ester C22 H40 O6 49.83 400.28 399.28 18.95 
cpd 9 Unknown C22 H44 O7 49.73 420.31 419.3 19.73 
cpd 10 D-Glucopyranoside C20 H40 O6 49.52 376.28 375.28 22.15 
cpd 11 7-palmitoleic acid C16 H30 O2 99.96 254.22 253.22 24.56 
cpd 12 Sorbitan monooleate C22 H44 O6 49.59 404.31 403.31 28.76 
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4.12 In vitro hepatoprotective of xanthorrhizol and violaxanthin 
The result of in vitro hepatoprotective experiment showed that xanthorrhizol and 
violaxanthin have the ability to inhibit WRL-68 cell death which induced by 
cytotoxicity effects of TAA. Thioacetamide induced nearly 50 percent death in TAA 
control as compared to normal control. Xanthorrhizol and violaxanthin at the dose of 10 
ug/ml significantly increased the cell viability to 89 and 91 percent, respectively.  
 
 
Figure 4.27: Effect of xanthorrhizol and violaxanthin on WRL-68 cell viability treated 
with TAA. Data represent mean ± SEM. *p<0.05, significant compared to TAA control, 
**p<0.05, significant compared to normal control. 
4.13 Antioxidant of WRL-68 cell treated with xanthorrhizol and violaxanthin 
Antioxidant activities of xanthorrhizol and violaxanthin were found to have a positive 
correlation with the improvement of the cell viability in WRL-68 cell. It is apparent that 
TAA bring about the generation of ROS, which reduced the antioxidant enzymes. 
Treatment with xanthorrhizol and violaxanthin reduced the free radical and improved 
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the antioxidant enzymes levels. The obtained results show that TAA significantly 
reduced SOD and CAT levels. Treatment with xanthorrhizol and violaxanthin 
significantly improved the levels of these two antioxidant enzymes. At the same time, 
lipid peroxidation level, determined as MDA generation, significantly increased in TAA 
control group as compared to normal control group. Treatment with xanthorrhizol and 
violaxanthin significantly prevented lipid peroxidation hence low levels of MDA.   
 
Table 4.21: Effect of xanthorrhizol and violaxanthin on SOD, CAT and MDA on WRL-
68 cell treated with TAA. 
 
Group Name SOD U/ml CAT nmol/min/ml MDA nmol/ml 
Normal control 14.34 ± 0.43 6.03 ± 0.41 13.26 ± 1.03 
TAA control 8.048 ± 0.78 ** 2.72 ± 0.23 ** 35.83 ± 1.72 ** 
Silymarin control 10 12.39 ± 0.15 * 4.81 ± 0.20 * 18.00 ± 1.00 * 
Silymarin control 100 13.80 ± 0.70 * 5.34 ± 0.26 * 16.00 ± 1.15 * 
Xanthorrhizol 10 12.52 ± 0.36 * 4.90 ± 0.13 * 18.94 ± 1.00 * 
Xanthorrhizol 100 13.31 ± 0.582 * 5.02 ± 0.170 * 17.28 ± 1.45 * 
Violaxanthin 10 13.34 ± 0.34 * 5.10 ± 0.12 * 17.63 ± 1.15 * 
Violaxanthin 100 13.91 ± 0.18 * 5.30 ± 0.19  * 16.20 ± 0.98 *  
 
Data represent mean ± SEM. *p<0.05, significant compared to TAA control, **p<0.05, 
significant compared to normal control. 
 
 
 
 
 
 
 
 
 
 
115 
 
CHAPTER V 
DISCUSION AND CONCLUSION 
5.1 Mechanism of liver cirrhosis and the potential of medicinal plants on 
hepatoprotective  
Liver cirrhosis regarded as the ending stage of chronic liver disease in which chronic 
fibrosis leads to the accumulation of scar tissue and therefore structural and functional 
alteration. Fibrosis is a reversible wound healing process which takes place virtually in 
all chronic liver damage. Despite the fact that the wound healing response generally 
starts with damage to the hepatocyte, the total response extends far beyond this event 
(Baldo, et al., 2008). Liver is the critical organ of the body for maintaining overall 
health and detoxification and therefore more than all other organ is exposed to toxic 
injury. Drug-induced liver injury as a result of widely used has grown to be a really 
serious health issue. Thereby studies on the mechanism of drug-induced liver damage 
can be very useful in prevention of drug-induced liver injury and therapy (Xu & Qu, 
2008). The damage to the liver generates a cascade of events (Holstege, et al., 2005; 
Svegliati Baroni, et al., 2003). Molecular and cellular mechanisms of hepatic fibrotic 
degradation as a result of chronic hepatic tissue damage have been described. Fibrosis is 
a physiologic mechanism, which happens to be beneficial in the beginning, but then 
develops into pathological in the event that chronic hepatic injury persist (Jarnagin, et 
al., 1994; Meyer, et al., 2005; Minagawa, et al., 2004). Fibrosis process triggered upon 
hepatic tissue damage, followed by inflammatory response with activation of 
macrophage of the liver, Kupffer cells, and the effector cells, stellate cells, which in turn 
bringing about increased expression of pro-fibrotic and pro-inflammatory cytokines. 
The HSC’s generally activated by cytokines that includes tumor necrosis factor alpha 
(TNFα),  tumor growth factor beta (TGFβ) and platelet derived growth factor (PDGF) 
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as well as excessive alterations in composition and arrangement of ECM components 
and  products of oxidative stress. Once activated, stellate cells recruit and activate 
fibroblast which is responsible for increased production of ECM proteins (Flier, et al., 
1993). In addition to the increase in the production of ECM, activated HSCs also 
increase release of tissue inhibitors of metalloproteinases (TIMPs) which prevent matrix 
metaloproteinases (MMPs) to degrade excessive matrix collagen. The process is driven 
by signalling pathways mediated by proinflammatory cytokines including TNFα and 
also transforming growth factor TGFβ1 (Wang, et al., 2006). The most accumulated 
ECM involved in fibrosis are the interstitial collagens, types I, and III (Schuppan, 
1990). In all different chronic liver disease, the progression of fibrosis is a step by step 
and gradually process starting from minimal fibrosis limited to in and within the portal 
tracts causing periportal stellate fibrous accumulates and extension (periportal or zone 
one fibrosis)(Marcellin, et al., 2006). As the process gets progressively worse over time, 
fibrous tissues increase to the nearby mesenchymal arrangements with the development 
of fibrous septa. Then it progressively grows into the lobules towards the central veins 
(zone three) with septa development. Finally, when almost all of the central veins or 
portal tracts interconnected, bridge fibrosis generated, and annular fibrosis surrounding 
nodules of the liver cells, cirrhosis occur (Z.D. Goodman & K.G. Ishak, 1995; Scheuer, 
et al., 2005).  
At the same time, enhanced oxidative stress and significant decrease of antioxidant 
defence have been reported in all types of liver damage (Loguercio & Federico, 2003). 
Reactive oxygen species (ROS) appear to have a key role in the induction and in the 
progression of liver disease (Choi & Ou, 2006). ROS are well-recognized to have 
important role in establishment and maintaining of liver fibrosis in viral hepatitis 
infection, alcohol intoxication and metabolic disorders. Excessive production of reactive 
oxygen species and depletion of antioxidant enzymes such as catalase (CAT) and 
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superoxide dismutase (SOD) play an important role in lipid peroxidation leading to 
hepatic tissue damage and necrosis. To a large extent oxidative stress is the result of a 
necrotic activity, but nevertheless, ROS generated by activated macrophages (Kupffer 
cells) in addition to reactive aldehydes resulting from membrane lipid peroxidation can 
certainly stimulate the expansion of collagen accumulation in the inflamed tissue. It is 
well established that ROS may well be underlying cause and also the results of the 
cellular injury. Several hepato-toxins, as an example, result in increased levels of ROS 
which overcome the normal antioxidant system of the cells (Marí, et al., 2001). 
Increased ROS levels lead to lipid peroxidation resulting in increased in highly reactive 
aldehydic end products. Consequently, alteration of signal transduction, regulation of 
gene expression, rearrangement of the redox condition which include deficit of 
glutathione concentrations, and promotion of apoptosis and necrosis (Dalton, et al., 
1999).  
In accordance with molecular and cellular mechanisms of hepatic fibrogenesis, a 
number of strategies may be applied for hepatoprotective. These strategies may include 
controlling oxidative stress by scavenging of free radicals or enhancing cellular 
antioxidant system, reducing inflammation and cell dying, and promoting excess ECM 
breaking down. These strategies should indirectly down regulate the activation of HSC 
which is responsible for the increased production of ECM, however, a strategy of 
reducing HSC can be directly by stimulating apoptosis. There are already good 
candidatures of hepatoprotective agents which are known to reduce oxidative stress, and 
blocking HSC activation. A good example of agent that reduces oxidative stress is 
silymarin, which was used as a reference drug in this our study (Li & Friedman, 2002).  
In view of absence effective therapy in the modern medicine, and serious side effects as 
a results of synthetic agents, a good number of medicinal plants increasingly used to 
treat liver disorders (Dhiman, et al., 2012). These recommended medicinal plants for the 
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treatment of liver disorder have been in use for long time and claimed to produce 
significant results (Sanmugapriya & Venkataraman, 2006). Some of traditional 
medicinal plants which have been scientifically studied for various liver disorders have 
exhibited promising results. For example, Silymarin, a well known hepatoprotective 
agent with antioxidant and antinflammatory, derived from Silybum marianum has 
demonstrated potential in the prevention of cirrhosis (Stickel & Schuppan, 2007). There 
is a number of other medicinal plants that have proved to have hepatoprotective 
properties including Camellia sinensis, Glycyrrhiza glabra and Curcuma longa (Luper, 
1999). Therefore it is obviously beneficial to conduct studies in medicinal plants 
searching for safe and reliable liver-protective therapy. Hepatoprotective studies, 
particularly, of the medicinal plants possess antioxidants and antinflammatory 
properties may lead to a discovery of new drug, which can prevent or even treat the 
cirrhosis by blocking the progression of fibrosis process.  
5.2 Antioxidant activities of Curcuma xanthorrhiza and Ipomoea aquatica extracts  
Curcuma xanthorrhiza ethanolic extract exhibited high efficacy in free radical 
scavenging property, whereas its counterpart I. aquatica extract exhibited lesser efficacy 
in free radical scavenging property evaluated by DPPH and ABTS assays. Along with 
C. xanthorrhiza, I. aquatica ethanol extracts and Silymarin the reference standard drug 
used in our liver cirrhosis experiment, all the samples exhibited marked free radical 
scavenging activity expressed in terms percentage. In both the assays, Ascorbic acid 
exhibited highest radical scavenging capacity value followed by C. xanthorrhiza 
extract, BHT, silymarin and I. aquatica extract. The DPPH radical scavenging capacity 
of Ascorbic acid was approximately 4 and 1.4 times higher than I. aquatica and C. 
xanthorrhiza extracts, respectively. Similarly, the ABTS radical scavenging capacity of 
Ascorbic acid was 3 and 1.2 times higher than I. aquatica and C. xanthorrhiza extracts, 
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respectively. However, the DPPH radical scavenging activity of C. xanthorrhiza extract 
was about 2 times higher than silymarin the reference standard drug used in liver 
cirrhosis experiment. Similarly, the ABTS radical scavenging capacity of C. 
xanthorrhiza extract is higher than silymarin. 
In the oral toxicity of C. xanthorrhiza and I. aquatica ethanol extracts at higher dose of 
5 g/kg did not exhibit any mortality, behavioral changes or alter serum chemistry. The 
oral LD50 value of both these extracts was predicted to be higher than 5mg/kg. Hence, 
they were considered to be practically safe in Sprague-Dawley rats. For further animal 
experimental studies, 1/10
th
 and 1/20
th
 of the highest dose of C. xanthorrhiza and I. 
aquatica ethanolic extracts were employed. 
5.3 In vitro hepatoprotective and antioxidant properties of crude extracts  
The usage of cell line as an in vitro hepatic model to screen the effectiveness of crude 
extracts before moving to the animal experiment is the most suitable when considering 
the time involved together with expenses. Normal human embryonic liver cells (WRL 
68 cells) are regarded as the convenient in vitro model for toxicological and 
pharmaceutical studies (Wilkening, Stahl & Bader, 2003). For the hepatoprotective 
studies, liver cell damage is induced by the use of hepatotoxin to which the 
effectiveness of the treatment can be evaluated. The effectiveness of the treatment can 
be evaluated by means of parameters which include cell viability and oxidative stress 
(Bladier, et al., 1997; Huang, et al., 1999).  Hence in vitro hepatoprotective experiment 
was conducted in the normal liver cell line WRL-68 treated with TAA to study the 
effects of C. xanthorrhiza and I. aquatica ethanol extracts and their fractions. TAA 
produces oxidative stress, equally by both increased generation of ROS and also by 
reduction of cellular oxidative defences system. It is well established that mitochondria 
has an essential role in the apoptotic response, therefore functional alteration in 
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mitochondrial following TAA treatment lead to cell death through necrosis or apoptosis 
(Hoek & Pastorino, 2002). Studies have also revealed that liver cells intoxicated with 
TAA tend to be more susceptible to the cytotoxic effects of TNF-α along with other 
cytokines. 
It has been established that TAA induce damage in the cell line by suppressing 
antioxidant defence system. Antioxidant defence system which include SOD and 
catalase act together to eliminate ROS and therefore play key role in the prevention of 
cellular lipids, proteins and DNA from oxidative damage. Reduction in antioxidant 
defence system result in the release of ROS from the mitochondrial matrix into the 
cytosol. Study in the cell line treated with TAA has also revealed the correlation 
between ROS production and increased lipid peroxidation. Imbalance between the 
production of ROS and the level on antioxidant defence system result in oxidative stress 
damage and therefore cell death. 
Curcuma xanthorrhiza and Ipomoea aquatica crude extracts were screened for their in 
vitro hepatoprotective activity against TAA-induced damage in WRL-68 cell. In this 
study, C. xanthorrhiza and I. aquatica crude extracts inhibited WRL-68 cell death 
which induced by TAA oxidative stress. Both plant crude extracts prevented TAA 
oxidative stress damage and enhanced the WRL-68 cell viability. In the antioxidant 
study of the WRL-68 induced-TAA oxidative stress, the results supported the 
hepatoprotective findings in terms of improving antioxidant defence system which 
prevent cell death from TAA-induced oxidative stress. C. xanthorrhiza and I. aquatica 
crude extracts significantly increased the cellular SOD and CAT as compare to the TAA 
control group. The levels of MDA which represent the lipid peroxidation was also 
significantly reduced by the treatment with  C. xanthorrhiza and I. aquatica crude 
extracts. This reprodiuceble  in vitro hepatoprotective results justified the in vivo 
experiment. 
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5.4 In vivo hepatoprotective, antioxidant and antinflammatory properties of 
Curcuma xanthorrhiza and Ipomoea aquatica crude extracts 
Thioacetamide is a selective hepatotoxin and widely used to induce acute and chronic 
liver injury in rats and other experimental animals depending on the dose and duration 
of administration (Hung, et al., 2005; Wang, et al., 2004). TAA induces rat liver 
cirrhosis with biochemical and morphological observations, resemble that of human 
liver cirrhosis and therefore serves as a suitable animal model for studying human liver 
fibrosis and cirrhosis (Fan & Weng, 2005).Oxidative stress and inflammation have been 
reported to contribute to the pathogenesis of TAA liver damage in animal model (Lin, et 
al., 2009). The appropriate dose of TAA to induce liver damage in experimetal animals 
through intraperitoneal route of administration is reported to be 200 mg/kg (Chen, et al., 
2012). Its long-term administration induces hepatic fibrosis in rats, and causes the 
development of cirrhosis associated with an increased extent of lipid peroxidation 
(Kadir, et al., 2011). Following administration, TAA is metabolised by the mixed 
function of oxidase system to acetamide and TAA-S-oxide ((Ahmed, et al., 2008; 
Bastway Ahmed, et al., 2010). Then TAA-S-oxide is metabolised, at least in part, by 
cytochrome P-450 monoxygenases to, a very highly reactive compound, TAA-S-
dioxide (Wang, et al., 2006). The binding of TAA-S-dioxide to tissue macromolecules 
induce hepatic necrosis and oxidative stress (Túnez, et al., 2005). Besides, TAA 
produces oxidative stress, equally by both increased generation of ROS and also by 
reduction of cellular oxidative defences system. Studies have also revealed that liver 
cells intoxicated with TAA tend to be more susceptible to the cytotoxic effects of TNF-
α along with other cytokines. It is well established that mitochondria has an essential 
role in the apoptotic response, therefore functional alteration in mitochondrial following 
TAA treatment lead to cell death through necrosis or apoptosis (Hoek & Pastorino, 
2002). 
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TAA treatment (cirrhosis control) resulted in significant (p<0.05) body weight 
reduction as the animals suffered growth retardation and increase in liver weight and 
therefore significantly increased liver index. The increased liver index might be 
attributed to swelling of the liver by the TAA induced chronic inflammatory response. 
In accordance with our study, a study has also reported the decrease in the body weight 
and larger liver size in Sprague-Dawley rats treated with TAA in comparison with the 
untreated rats (Ljubuncic, et al., 2005). Eight weeks treatment with ethanolic extracts of 
C. xanthorrhiza, I. aquatica extract and silymarin allowed natural growth pettern ( body 
weight gain and liver index) towords normal.  
Liver function biomarkers such as aspartate amino transferase (AST) and alanine 
aminotransferae (ALT) are cytosolic enzymes present in liver cells. TAA treatment 
causes the hepatocellular membrane damages through lipid peroxidation which leads to 
the alteration of the membrane permeability and leakage of liver enzymes in to the 
circulation system (Poli, 2000; Rees & Spector, 1961; Túnez, et al., 2005). The elevated 
level of AST and ALT indicates the cellular leakage, loss of functional integrity of 
hepatic cell membrane and thus hepatotoxicity. (Drotman & Lawhorn, 1978; Fontana, et 
al., 1996). Hence, in the present study experimental animals treated with TAA exhibited 
significant increase in the serum levels of AST and ALT (Figure 4.4 and 4.5), which 
ensure hepatotoxic effect of TAA. Treatment with C. xanthorrhiza and I. aquatica 
extracts at doses of 250 and 500 mg/kg, attenuated the elevated AST and ALT and 
brought them toward the level of normal control group and these results were in 
comparable with the standard drug silymarin. These results suggest that ethanolic 
extracts of C. xanthorrhiza and I. aquatica might protect the hepatocellular membrane 
structural integrity or enhance the regeneration of damaged hepatocytes.  
Increased biliary pressure during the liver damage increases the alkaline phosphatase 
(ALP) and bilirubin synthesis and thus the increased serum level of them (Muriel, et al., 
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1992). In the present study TAA induced the elevation of serum level of ALP and 
bilirubin which were reduced toward normal control level with the treatment of C. 
xanthorrhiza and I. aquatica extracts. These results suggest the ability of the selected 
plant extracts for the stability of biliary dysfunction in rats with TAA induced liver 
damage.  
It is well known that following the hepatocellular damage the capacity of liver cells to 
synthesize proteins is reduced and as the extent of damage increases, the levels of these 
proteins in the plasma will tend to decrease. Figure 4.6 and 4.7 shows the similar 
observations in our studies, where the total protein and albumin levels were decreased 
markedly. However, silymarin as well C. xanthorrhiza and I. aquatica extract treated 
groups restored these levels of protein toward normal.  
Mammalian cells contain various endogenous antioxidant enzymes such as superoxide 
dismutase(SOD), catalase (CAT), glutathione peroxidase and reduced glutathione which 
scavenge the reactive oxygen species (ROS) generated and maintains the balance 
(Saeed, et al., 2005). These enzymes serve as biomarkers of hepatocellular injury as 
they easily inactivated by lipid peroxides or ROS formed by the use of alcohol and drug 
(Chattopadhyay & Bandyopadhyay, 2005; Recknagel, et al., 1989). However, during 
the pathological conditions an imbalance occur between the endogenous antioxidative 
system and ROS leading to oxidative stress (Karan, et al., 1999; Khan & Sultana, 2009). 
SOD is clinically important endogenous antioxidative enzymes that scavenge the highly 
reactive and potentially toxic superoxide anion to form hydrogen peroxide. Decrease in 
the level of this enzyme activity is considered as a sensitive index of liver cell damage 
(Curtis, et al., 1972; Reiter, et al., 2000). Catalase is another endogenous antioxidative 
enzyme which widely distributed in all animal tissues but highest activity is found the 
red blood cells and liver. CAT helps in eliminating highly reactive hydrogen peroxide 
radical and protects the tissue from the oxidative injury. Hence, reduction in the activity 
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of SOD and CAT may results in a number of deleterious effects due to accumulation of 
highly reactive superoxide anion and hydrogen peroxide radicals.   
Lipid peroxidation refers to the oxidative degradation of lipids, is a multifarious and 
natural harmful process (Tribble, et al., 2005). Malondialdehyde is a major breakdown 
output of lipid peroxidation and useful indicative for lipid peroxidation and free radical 
activity (Kurata, et al., 1993). Increase in the lipid peroxidation causes changes in the 
hepatocellular metabolism which leads to cell deformity and death (Halliwell, et al., 
1992). Thiobarbituric acid reactive substances of liver are increased during lipid 
peroxidation which was measured to estimate the amount of Malondialdehyde.  
Results of the present study revealed that TAA intoxication caused the imbalance 
between free radical production and the antioxidant defence which resulted in oxidative 
stress in the liver with significant reduction in the SOD and CAT and marked increase 
in the MDA. This suggests that TAA induce the hepatocellular damage through the 
oxidative stress. However, pretreatment with silymarin, C. xanthorrhiza and I. aquatica 
ethanolic extracts significantly accelerated the return of altered activities of SOD and 
CAT to the values of normal control and markedly reduced the amount of MDA. These 
evidences suggest that both C. xanthorrhiza and I. aquatica particularly at higher dose 
(500 mg/kg) exhibit hepatoprotective activity, at least in part, by improving endogenous  
antioxidant enzymes status and therefore inhibiting  lipid peroxidation.  
Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine found in the fibrous 
liver tissues. Kupffer cells are the main source of TNF-α and are produced in higher 
amount when these cells are exposed to lipopolysaccaride, viruses, alcohol or to TAA 
(Reeves & Friedman, 2002; Schultze, et al., 1999). Even HSC and sinusoidal 
endothelial cells upon activation secrete this inflammatory cytokine (Kurosaka, et al., 
2001). Elevated level of TNF-α is responsible for the inflammation of the liver and also 
for the necrosis as well as fat accumulation. Results of the present study shown that, 
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TAA significantly elevated the level of TNF-α in the serum of the cirrhotic control 
animal group as compared to the corresponding normal control animal group. This 
increase in TNF-α level might be due to the liver cirrhosis induced by TAA (Marinos, et 
al., 1995). However, treatment with silymarin, C. xanthorrhiza and I. aquatica 
significantly reduced the serum level of TNF-α toward the level of normal control in 
dose dependent manner. Possessing antinflammatory properties, both plants, at least in 
part, might have inhibited fibrosis progression through the down regulation of 
proinflammatory cytokines in which TNF-α is the most important.  
Transforming growth factor beta 1 (TGFβ1) is the most potent fibrogenic cytokine 
produced by the nonparenchymal cells such as Kupffer cells, HSC and endothelial cells 
during the tissue damage and oxidative stress (Bissell, et al., 2003). Once TGFβ1 
expressed in higher level it activates the HSC which in turn releases higher amount of 
platelet derived growth factors, collagen and also TGFβ1 (Freedman, et al., 1992). This 
leads to the increased extracellular matrix production and finally ends up with the liver 
fibrosis (Kimura, et al., 1999). The abnormal expression of TGFβ1 serves as a useful 
serologic marker in detecting the hepatocellular carcinoma. Since TGFβ1 have a low 
molecular weight it is released easily into the blood and leads to the presence of higher 
concentration (Song, et al., 2001). Hence, the down regulation of TGFβ1 is very 
important in the effective treatment of liver fibrosis (Prosser, et al., 2006).  
In our study, animal’s intoxicatied with TAA exhibited significant amount level of 
serum TGFβ1 compared to normal control group. Concurrent administration of C. 
xanthorrhiza and I. aquatica extracts as well as silymarin dramatically reduced the 
increased levels of TGFβ1. Hence, antinflammatory property of these plant extracts 
through inhibition of inflammation (which include inactivation of kupffer cell) might 
have indirectly reduced the expression of TGFβ1 from liver cells.  
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Nuclear factor-κB (NF-κB) is a transcriptional factor which is normally retained in the 
cytoplasm in an inactive form and play a pivotal role in the regulation of inflammation 
(Inoue, et al., 1995). NF-κB is activated by several factors including interleukin-1, 
lipopolysccharide, TNF-α and oxidative stress. NF-κB  normally induces the expression 
of genes involved in the proliferation, apoptosis and carcinogenesis of cells (Akira & 
Kishimoto, 1997). Once it is activated it induces the acute and chronic liver injury. 
Results obtained from this study reveals that treatment of experimental animals with 
TAA induced the elevation of NF-κB in a significant amount in comparison with the 
normal control group. In contrast, eight weeks treatment with C. xanthorrhiza and I. 
aquatica extracts significantly reduced the amount of NF-κB toword the level of normal 
control group. Hence, these plant samples might show their hepatoprotective effect by 
suppressing inflammation and fibrogenesis through  NF-κB which regulate 
inflammatory in which TNF-α is the most impotent. 
The hepatoprotective effect of C. xanthorriza and I. aquatica extract was confirmed by 
the histopathological findings. TAA administration leads to severe damage, congested 
central veins, sinusoid and multifocal area of necrosis, fatty changes and inflammatory 
cell with granular swelling in cirrhosis control group. Treatment C. Xanthorriza, I. 
aquatic extract and silymarin to some extent prevented the liver from these effects and 
preserved the liver architecture nearly to normal control group.  Small necrosed area and 
also decrease in the infiltration of the inflammatory cells in the liver lobules confirm the 
efficacy of C. xanthorriza and I. aquatic in hepatoprotective. In addition, the Masson’s 
trichome stain clearly demonstrated that fiber extension and collagen accumulation in 
cirrhosis control group. The deposition of collagen was markedly reduced in dose 
dependent manner by C. xanthorriza and I. aquatic extract and silymarin treatment. 
Alpha smooth muscle actin (α-SMA) staining has been widely employed to detetct the 
extent of hepatic stellate cell (HSC) activation as the activation of HSCs leads to the 
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generation of α-SMA. The expession of α-SMA widely used as marker of activated  
HSC and also considered to be responsible for the liver fibrosis (Magness, et al., 2004; 
Mann & Smart, 2002). Since HSC is activated by increased expression of TGFβ1 and  
TNF-α, down regulation of these cytokines by the plant extracts and silymarin might 
have reduced the activation of HSC and therefore expression of α-SMA.  
5.5 In vitro hepatoprotective and antioxidant properties of isolated active fractions, 
xanthorrhizol and violaxanthin  
In addition to time and expense, there are other benefits in in vitro hepatoprotective 
studies using human liver cells model in comparison with standard animal model. 
Particularly, one importent benefit is the fact that the cell line will not needed large 
quantity of the examined sample as in the case of animal model study and therefore 
suits the study of isolated fraction or compound, which generally yeiled in small 
amount.  Furthermore usefulness of working with human cell models is to eliminate the 
issue of extrapolating animal data to humans (Olivares, et al., 1997).  
To find out the most effective fraction of Curcuma xanthorrhiza and Ipomoea aquatica 
crude extracts, all isolated fractions from both extracts were screened for their in vitro 
hepatoprotective activity against TAA-induced damage in WRL-68 cell. The results 
showed that isolated fractions number 5 from C. xanthorrhiza and fraction number 11 
from I. aquatic are the most. Both fractions produced the best results in term of 
normalization of the oxidative stress generated by TAA induction and therefore 
improving WRL-68 cell viability. All other fractions were less effective than their crude 
extracts. In the antioxidant study of the WRL-68 induced-TAA oxidative stress, the 
results supported the hepatoprotective findings in terms of improving antioxidant 
defence system which prevent cell death from TAA-induced oxidative stress. Similarly 
and even better than their crude extracts, fractions 5 from C. xanthorrhiza and fraction 
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11 from I. aquatica exhibited strong overall antioxidant properties by increasing SOD 
and CAT levels, and reducing MDA levels.    
The LCMS results showed about 15 compounds in the fraction 5 of C. xanthorrhiza and 
about 19 compounds in the fraction 11 of I. aquatic. Among the compound found in 
these active fractions were xanthorrhizol and violaxanthin from C. xanthorrhiza and I. 
aquatic, respectively. Xanthorrhizol and violaxanthin were selected for further study 
based on the available information from the previous studies which could be used to 
infer that these compounds may be the main contributor in the hepatoprotective activity 
of the fraction and plant extract as whole. In a recent study violaxanthin isolated from I. 
aquatic has proved to be an excellent free radical scavenger and efficient inhibitor of 
lipid peroxidation (Fu, et al., 2011). It has shown to be lipid peroxidation inhibitor, 
particularly in the isolated mouse liver cells. In another study, violaxanthin revealed to 
inhibit activation of nuclear factor kappa b (NF-κB). Nuclear factor kappa b activation 
is known to trigger the overexpression of proinﬂammatory genes in the nucleus, thereby 
initiating the inﬂammatory processes (Soontornchaiboon, et al., 2012). On the other 
hand, xanthorrhizol revealed to have potent antioxidant activity and inhibitor of lipid 
peroxidation (Lim, et al., 2005). It has also been reported that xanthorrhizol reduce 
proinflammatory mediators such as tumor necrosis factor-alpha (TNFα) and interleukin-
6 (IL-6). Moreover, in a short period study, xanthorrhizol abrogated hepatotoxicity of 
cisplatin (an anticancer drug which can produce side effects including hepatotoxicity) 
(Hwan Kim, et al., 2004). 
The results of our in vitro study exhibited that both violaxanthin and xanthorrhizol are 
highly hepatoprotective against thioacetamide induced cell damage in WRL-68 normal 
liver cell line. Both compounds were more efficient than crude extracts and fractions in 
preventing TAA oxidative stress damage and enhancing the WRL-68 cell viability. It is 
probably that the efficiency of these compounds in preventing TAA oxidative stress 
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damage and enhancing the WRL-68 cell viability is antioxidant activity which was 
found to be stronger in of improving antioxidant defense system than that found in 
fraction of crude extracts. Violaxanthin and xanthorrhizol significantly increased the 
cellular SOD and CAT and reduced lipid peroxidation levels in the cell line. In fact, 
violaxanthin, the compound from Ipomoea aquatic, was more effective in 
hepatoprotective and improving antioxidant status than the silymarin, the standard drug 
used as control in this study.   
5.6 Conclusion   
The results obtained from this study demonstrated that ethanol crude extracts of 
Curcuma xanthorrhiza and Ipomoea aquatica possess hepatoprotective activities in vivo 
against thioacetamide-induced liver cirrhosis in rats which was proven in biochemical 
and histopathological findings. In the preliminary in vitro screening of free radical 
scavenging of both plants, Curcuma xanthorrhiza showed higher free radical 
scavenging activity than silymarin, however, the free radical scavenging of Ipomoea 
aquatica was moderate and less than silymarin. Nevertheless, both plant extracts 
significantly improved the overall oxidant status by increasing antioxidant enzymes and 
reducing lipid peroxidation. These evidences suggest that both Curcuma xanthorrhiza 
and Ipomoea aquatic particularly at higher dose (500 mg/kg) exhibit hepatoprotective 
activity, at least in part, by improving endogenous antioxidant enzymes status and 
therefore inhibiting lipid peroxidation. In addition to that, both plant extracts exhibited 
antinflammatory properties to which, at least in part, might have inhibited fibrosis 
progression through the down regulation of proinflammatory and profibrotic cytokines 
which lead to the decrease in hepatic stellate cell activation and therefore less 
extracellular matrix deposition. This was proven by liver tissue immunohistochemical 
staining of α-SMA and Masson’s trichome staining. 
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The hepatoprotective activities of both plant crude extracts were confirmed in vitro 
against thioacetamide induced cell damage in WRL-68 normal liver cell line. 
Furthermore, in hepatoprotective screening study of the fractions from both plant 
extracts, separated fraction 5 from Curcuma xanthorrhiza and fraction 11 from Ipomoea 
aquatica exhibited the highest hepatoprotective activities against thioacetamide induced 
cell damage in WRL-68 normal liver cell line. From the LCMS results of the fractions 
which exhibited best hepatoprotective results, violaxanthin from Ipomoea aquatica and 
xanthorrhizol from Curcuma xanthorrhiza were selected for further study. The selection 
of these compounds was based on the available information from the previous studies 
which could be used to infer that these compounds may be the main contributor in the 
hepatoprotective activity of the fraction and plant extract as whole. Both compounds 
were highly hepatoprotective against thioacetamide induced cell damage in WRL-68 
normal liver cell line. Similar to the animal study, both crude extracts, their fractions 
and compounds improved antioxidant enzymes, inhibited lipid peroxidation. Both 
compounds were more effective than their crude extracts in protecting cell damage, 
improving antioxidant status. In fact, violaxanthin, the compound from Ipomoea 
aquatic, was more effective than the silymarin, the standard drug used as control in this 
study. These results propose that the possible mechanism of action of both plant extracts 
in hepatoprotective is likely to be through improving antioxidant enzymes, inhibiting 
lipid peroxidation and decreasing proinflammatory and profibrotic cytokines. Moreover, 
in addition to the fact that they are known to have antinflammatory activities, the extent 
of effectiveness of violaxanthin and xanthorrhiza in preventing cell death, improving 
antioxidant levels and inhibiting lipid peroxidation, suggest that they are likely to be the 
active compounds for the hepatoprotective activities of their plant extracts.  
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5.7 Future work 
Violaxanthin and xanthorrhizol are quite expensive, however, they worth attention. 
Further studies are needed on pharmacological evaluation of these compounds in animal 
experiment in order to determine their pharmacodynamics, bioavailability and 
pharmacokinetics.  
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APPENDIX A Preparation of reagents  
A1. Reagent of hematoxylin 
1. Pot or aluminium alum 6 gm 
2. Mercuric oxide 1.25 gm 
3. Hematoxylin 1.5 gm 
4. Absolute alcohol 25 ml 
5. Glacial Acetic acid 1 ml 
Hematoxylin was dissolved in absolute alcohol, pot or aluminum alum was heated in 
500 ml of distilled water until dissolved. Hematoxylin was added to mixture until 
boiled, then removed from heater and mercuric oxide was added. After it cooled, glacial 
acetic acid was added then filtered before use. 
A2. Reagent of ethyl eosin 
1.       Ethyl eosin                                 1 gm 
2. Absolute alcohol    95 ml 
3. Acetic acid 2 ml 
4. Distilled water 5 ml 
Mixed well and filtered before use. 
A3. Reagent of Masson’s Trichromes stain 
1. Lugol's Iodine 
1. Iodine  1 g 
2. Potassium iodide 2 g 
3. Distilled water 100 ml 
2. 5% Sodium thiosulphate 
20 g of sodium thiosulphate were dissolved in 400 ml distilled water 
3. Weigert iron hematoxylin 
A. 10 g hematoxylin dissolved in 100 ml Alcohol 
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B. 15 g Ferric chloride dissolved in 100 ml distilled water 
C. i) 10 ml from stock A mixed in 90 ml 95% alcohol 
ii) 4 ml from stock B mixed in 95 ml distilled water and 1 ml HCl Equal part of solution 
(i) and (ii) were taken at time of use. 
4. 1% acid alcohol 
                    99 ml 70% OH mixed with 1 ml HC1 pure 
5. 1% Ponceau fuschin 
                4 g Ponceau fuschin dissolved in 400 ml of 1% acetic acid 
6. 1% Phosphomolybdic acid 
              4 g phosphomolybdic acid dissolved in 400 ml distilled water 
7. 2% Light green 
               8 g Light green dissolved in 400 ml 2% acetic acid 
8. 1% Acetic acid 
              1 ml acetic acid dissolved in 99 ml distilled water 
A4. Preparation of thioacetamide 
Thioacetamide stock solution of 5 mg L
-1
 was prepared by diluting the pure thioacetamide 
which is in the crystal form with distilled water and stirred well until all the crystals were 
dissolved. 
E. Preparation of 10% Tween 20 
100 ml of the stock solution was prepared by dissolving 10ml of 10% Tween-20 in 90 
ml of distilled water. 
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A5. Preparation of 0.9% normal saline 
9 g of NaCl was added to 1 L of distilled water. 
A6. Preparation of phosphate buffer saline (PBS) PH 7.3+ 0.2 
1 Liter PBS was prepared as follows: sodium chloride 8.0 g L
-1
, potassium chloride 0.2 
g L
-1
, di-sodium phosphate 1.15 g L
-1
 and potassium di-hydrogen phosphate 0.2 g L
-1 
were dissolved in distilled water at 25°C. 
A7. Preparation of 10% fresh formalin (Buffered formalin) 
1 L of fresh formalin was prepared by dissolving 6.5 g di-sodium hydrogen phosphate 
with 4 g sodium di-hydrogen phosphate monohydrate and 100 ml concentrated formalin 
(38 - 40%) in 900 ml of phosphate buffer saline (PBS). 
APPENDIX B Procedures and kits instructions  
B1 Techniques for processing the tissues 
Fixation 
The tissue processing started with fixation by using 10% buffered formalin. The 
purpose of fixation is to preserve tissues permanently in life - like state as possible after 
removal of the tissues. The tissues were excised into small pieces of about 1 cm in size 
and then put in cassettes containing fresh formalin of 10:1 ratio of fixative to tissue for 
48 hr. 
a) Tissue processing  
The technique of getting fixed tissue into paraffin is called tissue processing. The main 
steps in this process were: 
i) Dehydration 
Water from the tissues was removed by a procedure called dehydration in series of 
alcohol. 
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ii) Clearing 
The removal of dehydrant was done with toluene that is miscible with the embedding 
medium, paraffin. Toluene is more tolerant of small amounts of water left in the tissues 
and less toxic than xylene. 
iii) Infiltration and impregnation 
Finally, the tissues were infiltrated with embedding agent, usually with the paraffin in 
oven less than 60 °C.  
All the above processes were done by using automatic tissue processor, which performed 
fixation, dehydration, clearing and paraffin impregnation of tissues in a programmed 
sequence. The protocols are provided in appendixes section. 
iv) Tissue embedding 
After the above processes, the tissues were manually transferred from the cassettes and 
put into the blocks with molten paraffin over them, with proper orientation of tissue in 
the block of paraffin. 
c) Sectioning 
Once the melted paraffin was cooled and hardened, the blocks were trimmed into an 
appropriately sized block and put into freezer under -4°C for 1 hr before sectioning.  
Each block was then mounted in a specially designed slicing machine, a microtome. 
They were cut with steel knife into sections of 5 µm thickness. These sections were 
floated in a 40 °C warm water bath to avoid wrinkling, then they were picked up on a 
labeled glass microscopic slides. All these slides were then dried under 50 °C 
temperature. 
b) Staining 
Before staining, all the slides were deparaffinized by running them through xylenes I, II 
for 5 min each, in order to remove the paraffin wax out of the tissues and allow water 
soluble dyes to penetrate the sections. 
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The stains which were used in our experiment were H and E and special stains and 
Masson's Trichrome stain for detecting of collagen and elastic fibrous tissues. 
 
 
i) Staining technique of hematoxylin and eosin 
Thick paraffin sections (5 µm) of liver were de-waxed in xylene, dehydrated in series of 
alcohol to water then immersed in hematoxylin for 15 min. Sections were then 
differentiated with 1% acid alcohol and washed in tap water, followed by staining with 
eosin for 5 min. Finally, sections were dehydrated in series of alcohol, cleared in 
xylene, mounted with DPX. 
ii) Staining technique of Masson's Trichrome 
Sections were brought to water, stained with lugol's iodine for 5 min, then decolorized 
with 5% sodium thiosulphate and washed with tap water until clear and before staining 
with weigert's iron hematoxylin for 20 min. Section were decolorized with 1% acid 
alcohol and tap water, then stained with 1% ponceau- fuchsin for 5 min, mordant in 1% 
phosphomolybdic acid for 5 min and stained with 2% light green, then differentiated 
with 1% acetic acid. Finally, sections were dehydrated in series of alcohol, cleared in 
xylene, mounted with DPX . 
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B2 Catalase assay kit (Cayman) 
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B3 Superoxide dismultase assay kit (Cayman) 
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B4 TBARS (MDA) assay kit (Cayman) 
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B5 TNF-α assay kit (Quantikine) 
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B6 TFGB assay kit (Quantikine) 
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B7 NFKB assay kit (Uscn) 
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APENDIX C Standard curves and cytotoxicity 
C1. DPPH and ABTS standard curves 
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C2. Cytotoxicity 
Screening crudes and compounds for cytotoxicity after 24 hrs 
Sample Conc. Rep 1 Rep 2 Mean 
Inhibition 
% SD SEM 
DMSO 5% 0.919 0.842 0.881 0 0.054 0.031 
Siimarin  1 µg 0.629 0.792 0.711 19.307 0.115 0.066 
Siimarin  1 µg 1.244 1.308 1.276 -44.918 0.045 0.026 
Siimarin  10 µg 1.305 1.398 1.352 -53.492 0.066 0.038 
C. xanthorrhiza 1 µg 0.967 0.999 0.983 -11.641 0.023 0.013 
C. xanthorrhiza 10 µg 1.001 1.004 1.003 -13.856 0.002 0.001 
C. xanthorrhiza 100 µg 0.929 1.027 0.978 -11.073 0.069 0.040 
I. aquatica 1 µg 0.895 0.943 0.919 -4.373 0.034 0.020 
I. aquatica 10 µg 1.106 1.091 1.099 -24.759 0.011 0.006 
I. aquatica 100 µg 0.987 1.023 1.005 -14.140 0.025 0.015 
Xanthorrhizol 1 µg 1.277 1.482 1.380 -56.672 0.145 0.084 
Xanthorrhizol 10 µg 1.372 1.381 1.377 -56.332 0.006 0.004 
Xanthorrhizol 100 µg 1.304 1.44 1.372 -55.821 0.096 0.055 
Violaxathin  1 µg 1.437 1.569 1.503 -70.698 0.093 0.054 
Violaxathin 10 µg 1.439 1.554 1.532 -73.992 0.081 0.047 
Violaxathin 100 µg 1.343 1.565 1.52 -72.629 0.157 0.090 
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